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Precise copper balance is essential for normal growth, differentiation, and function of 
human cells. Loss of copper homeostasis is associated with heart hypertrophy, liver 
failure, neuronal de-myelination and other pathologies. The copper-transporting ATPases 
ATP7A and ATP7B maintain cellular copper homeostasis. In response to copper 
elevation, they traffic from the trans-Golgi network (TGN) to vesicles where they 
sequester excess copper for further export. The mechanisms regulating activity and 
trafficking of ATP7A/7B are not well understood. Our studies focused on determining 
the role of kinase-mediated phosphorylation in copper induced trafficking of ATP7B, and 
identifying and characterizing novel regulators of ATP7A. We have shown that Ser-
340/341 region of ATP7B plays an important role in interactions between the N-terminus 
and the nucleotide-binding domain and that mutations in these residues result in vesicular 
localization of the protein independent of the intracellular copper levels. We have 
determined that structural changes that alter the inter-domain interactions initiate exit of 
ATP7B from the TGN and that the role of copper-induced kinase-mediated 
hyperphosphorylation might be to maintain an open interface between the domains of 
ATP7B. In a separate study, seven proteins were identified, which upon knockdown 
result in increased intracellular copper levels. We performed an initial characterization of 
the knock-downs and obtained intriguing results indicating that these proteins regulate 
ATP7A protein levels, post-translational modifications, and copper-dependent 
trafficking.  None of these proteins has been previously linked to copper homeostasis. 
Our studies have pointed to novel kinase inhibitors (IBTK and CAMK2N2), a novel 
relationship between copper transport and organic anion/bile acid transport (ABCC3), a 
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likely mechanism of ATP7A regulation through changes in glycosylation levels, and 
identified an adaptor protein (ankyrin repeat domain protein 9 (ANKRD9)) that might be 
involved in stabilizing the Golgi structure. ANKRD9 depletion led to increase of 
intracellular copper levels, Golgi fragmentation, and defects in protein glycosylation. 
Additionally, the mRNA and protein levels of the human copper uptake protein Ctr1 were 
increased significantly despite high copper levels in the cells. We are facing challenging 
questions related to Golgi fragmentation and copper homeostasis. Further 
characterization of the above-mentioned novel regulatory modes will greatly expand our 
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I. Copper auto regulates its cytoplasmic levels by modulating the amounts of high 
affinity transporter CTR1 at the plasma membrane.   
 
1.1. Acute regulation of CTR1 through binding and signaling.   
Copper enters human cells through at least two independent pathways.  The high affinity 
copper transporter hCTR1 is responsible for the 60-70% of total copper influx, while the 
remaining uptake is mediated through a low affinity transport mechanism (Lee et al., 
2002).  The identity of the low affinity transporter(s) remains unknown. Several 
candidates have been proposed (Arredondo et al., 2003; Zimnicka et al., 2011); the role 
of divalent metal transporter DMT1 in copper acquisition in the brain has recently been 
questioned (Zheng et al., 2012).  Human CTR1, hCTR1, is a homotrimer with a relatively 
long His/Met-rich N-terminal tail exposed at the extracellular side, three transmembrane 
(TM) segments, and a very short cytosolic C-terminus containing the His-Cys-His motif 
(Kaplan and Lutsenko, 2009; Puig et al., 2007).  In the vast majority of cells, hCTR1 is 
responsible for acquisition of copper from the blood; in intestine, it plays an essential role 
in a dietary copper absorption (Nose et al., 2006).  Copper uptake by hCTR1 is tightly 
controlled: the short-term regulation is mediated via copper dependent changes in the 
abundance of hCTR1 at the plasma membrane (PM).  Copper depletion increases the 
amount of hCTR1 at the PM through the recruitment from the intracellular pools (Kuo et 
al., 2006), whereas elevated copper induces rapid endocytosis of the transporter from the 
PM to vesicles (Guo et al., 2004) (Fig. 1-1).  
 
The mechanisms through which copper triggers hCTR1 internalization and, reciprocally, 
the loss of copper initiates the return of hCTR1 to the PM, are unclear.  Biochemical and 
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molecular modeling experiments revealed the presence of copper binding sites at both the 
extracellular and cytosolic portions of hCTR1 (De Feo et al., 2009; Haas et al., 2011; 
Tsigelny et al., 2012). Mutations to Ala of residues at the entrance of the transmembrane 
copper translocation pathway (Met150 and Met154 in the TM2) eliminate copper uptake.  
In contrast, mutations/deletions of Met, His, or Cys residues in the N-terminal or C-
terminal tails of hCTR1, respectively, change the rates of transport (Du et al., 2012), but 
do not fully abolish the transport activity, pointing to the regulatory functions for the N-
terminal and C-terminal copper-binding sites. The binding of copper to one or more of 
such regulatory sites and subsequent conformational changes in the protein (Eisses and 
Kaplan, 2002) are likely to be the first steps towards hCTR1 internalization. Further steps 
involve a clathrin-dependent pathway, as suggested by a co-localization of hCTR1 with 
the transferrin receptor and the inhibition of hCTR1 endocytosis by chlorpromazine and 
methyl-β-cyclodextrin (Petris et al., 2003).  
 
1.2. Does low or high copper serve as a physiologically relevant signal for CTR1 
trafficking?  
 It should be noted that most of the current evidence for hCTR1 internalization and 
recycling has been obtained using the recombinant over-expressed protein.  There is little 
doubt that the recombinant hCTR1 traffics to the intracellular compartments upon 
exposure to copper, whereas treatment with the copper chelator (or cisplatin) stabilizes 
protein levels at the plasma membrane (Guo et al., 2004). Given these observations, it 
might be worth considering why the results of early experiments on the endogenous 
hCTR1 are distinctly different from those with the overexpressed protein.  In cells of 
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various origin, the location of the endogenous hCTR1 was found to be predominantly 
intracellular.  In addition to vesicles, the plasma membrane location was observed in 
HEK293 cells (Eisses et al., 2005), Caco-2 cells  (Klomp et al., 2002)and in polarized 
Jeg-3 cells (Hardman et al., 2006).  High copper did not affect the plasma membrane 
localization of CTR1 in any of these cells, and no obvious internalization was observed. 
More recently, endocytosis of recombinant and endogenous hCTR1 was examined using 
surface biotinylation (Molloy and Kaplan, 2009).  In these experiments, partial 
endocytosis (20-60%) was detected for both the recombinant and endogenous hCTR1 in 
some, but not all cell types.  Internalization of endogenous CTR1 was seen in polarized 
MDCK cells and in HepG2 cells; no significant internalization of hCTR1 in response to 
extracellular copper was detected in HeLa and T47D cells (Molloy and Kaplan, 2009). 
 
In mouse tissues, mCTR1 is also predominantly intracellular (with a notable exception of 
the liver where it was immuno-detected at the plasma membrane (Hardman et al., 2006; 
Kuo et al., 2006; Ralle et al., 2010).  In copper deficient tissues, there is a distinct 
upregulation and recruitment of mCTR1 to the plasma membrane, especially in the 
intestine (Kuo et al., 2006).  High copper has an opposite effect on protein localization, 
but not under all circumstances.  The decreased levels of mCTR1 at the PM were 
observed in the liver tissue with a prolonged (20 weeks) intracellular accumulation of 
copper (Ralle et al., 2010), whereas high dietary copper did not seem to have such an 
effect (Araya et al., 2012).  Altogether, these observations raise an interesting possibility 
that under physiologically relevant conditions the distribution of CTR1 between the 
intracellular and PM pools is controlled by the metabolic demands of a cell (i.e. by the 
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need for copper for biosynthetic purposes) rather than by extracellular copper.   This 
hypothesis would be consisted with a repeatedly observed increase in the CTR1 levels 
(total and at the PM) in response to copper deprivation.  (Hardman et al., 2006) have also 
found decreased intracellular staining of CTR1 in the insulin treated Jeg-3 cells and 
proposed that insulin influenced the recruitment of hCTR1 to the PM through the 
mechanism resembling that of the glucose transporter GLUT4. 
 
1.3.  Copper sensors sites in CTR1 are probably cytosolic.   
How copper levels are sensed by hCTR1 and then transferred into a signal for 
redistribution between cellular compartments is an interesting unresolved problem.  The 
fact that the endogenous hCTR1 in HEK293 cells does not traffic in response to 
extracellular additions of copper, whereas a stably transfected hCTR1 does, suggests that 
the rate of copper entry and accumulation in the cytosol (which is higher in cells 
overexpressing hCTR1) may play an important role in triggering the internalization of the 
transporter.  Consistent with this hypothesis, the recombinant CTR1, which lost its 
transport activity due to mutations of critical Met150 and Met154 (see above), does not 
traffic from the plasma membrane to vesicles despite the presence of the extracellular 
copper binding sites at the N-terminal tail (Guo et al., 2004).  Finally, since hCTR1 
internalization is a reversible process (i.e. copper depletion triggers the return of CTR1 to 
the PM) it seems that a “copper sensing” site is present at the cytosolic face of the 
molecule, where copper can be easily exchanged. Consistent with this idea, exposure of 
cells to higher copper delays the return of internalized hCTR1 to the PM (Molloy and 
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Kaplan, 2009), although this phenomenon could also be due to time needed to clear extra 
copper by the efflux systems.    
 
1.4. Regulation of copper uptake by modulation of total levels of CTR1  
The long-term regulation of hCTR1 is achieved through transcriptional/translational 
changes.  The basal levels of CTR1 are influenced by the HIF2α transcription factor 
(Pourvali et al., 2012), however which proteins directly control expression of hCTR1 in 
response to changing copper levels or other metabolic needs is not entirely clear.  
Furthermore, similar to studies on CTR1 trafficking, there is some discrepancy in the 
literature on whether an elevated copper influences levels of CTR1 mRNA.  Recent 
studies demonstrating that regulation of the CTR1 abundance could be affected by 
various metabolic factors offer potential explanation for such inconsistencies between the 
reports. For example, incubation of HepG2 cells in high copper results in decreased 
amounts of CTR1 mRNA and protein, whereas treatment with estradiol alleviates this 
copper effect (Arredondo et al., 2010). It is also interesting that overexpression of the 
exogenous CTR1 is associated with down-regulation of the endogenous CTR1 mRNA 
indicating a tight homeostatic control of the total hCTR1 levels (Liang et al., 2012). 
 
The role of glutathione in regulating copper transport machinery is another intriguing 
finding. Overexpression of recombinant γ- GCSht0090, a rate-limiting enzyme in the 
biosynthesis of glutathione, in human lung cancer cell line is associated with a 2-3 fold 
increase in cellular levels of glutathione (Yamane et al., 1998).  This, in turn, coincides 
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with an increase in the CTR1 mRNA and protein level as well as increased copper uptake 
(Chen et al., 2008).  In another set of experiments, the expression of CTR1 was shown to 
be up-regulated upon copper depletion and down-regulated under replete conditions. 
These changes in CTR1 paralleled changes in the levels of the transcription factor 
Specificity protein 1 (Sp1) leading to the suggestion that Sp1 oscillations in response to 
copper availability regulate hCTR1 expression (Liang et al., 2012; Song et al., 2008).    
 
Increases in the hCTR1 mRNA and protein have also been observed in a cell model of 
inflammation. Treatment of BV-2 microglial cells with γ-interferon resulted in a two-fold 
increase of the CTR1 mRNA levels, increased rates of copper uptake, and higher copper 
accumulation (Zheng et al., 2010).  Very similar phenomena, i.e. an increase in the CTR1 
mRNA along with higher copper accumulation was observed in RAW264.7 cells exposed 
to hypoxic conditions (4% oxygen) (White et al., 2009b).  The mechanisms behind these 
interesting and potentially important regulatory events remain largely unexplored; 
however, the role of a kinase-mediated signaling appears increasingly likely. Recent 
study revealed an unexpected requirement for the CTR1-mediated copper uptake in 
signaling via the Ras/mitogen-activated protein (MAP) kinase pathway (Turski et al., 
2012). In these studies, genetic inactivation of CTR1 in flies and in mouse cells as well as 
copper deficiency induced by metal chelation were shown to reduce the ability of the 
MAP kinase kinase Mek1 to phosphorylate the MAP kinase Extracellular signal regular 
Kinases ERK1/2, whereas Akt kinase remained unaffected (Turski et al., 2012).  
Surprisingly, silver (which would be expected to mimic the effects of copper) had effect 
similar to copper chelation, i.e. it decreased cells response to insulin, as evidenced by the 
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diminished ERK1/2 phosphorylation.  An important finding in this set of experiments 
was the observation that the addition of copper to the CTR1+/+ cells did not potentiate 
insulin signaling, whereas the same treatment of the copper-deficient CTR1-/- cells 
partially restores the ability of insulin to signal via the ERK1/2 phosphorylation pathway.  
These results seem to imply that the CTR1 function in insulin signaling is to maintain 
normal cell metabolism, rather than directly deliver copper to a copper dependent 
kinase(s), although there is a convincing evidence for the direct Cu
2+
 binding to Mek1 
kinase in vitro (Turski et al., 2012). 
 
II. Regulation of copper export via protein trafficking and kinase-mediated 
phosphorylation 
 
2.1. ATP7A and ATP7B are copper-transporting ATPases important for maintaining 
cellular copper homeostasis. 
Human cells express two homologous copper-exporting ATPases, ATP7A and ATP7B, 
that transport copper across a membrane bilayer by using the energy derived from ATP 
hydrolysis. Both ATP7A and ATP7B belong to the P-type ATPases family, i.e. during 
their catalytic cycle they form a transient phosphorylated intermediate (catalytic 
phosphorylation) that is stimulated by binding of the exported ion, copper.  ATP7A/B 
contains eight TM domains and several cytosolic domains (Fig. 1-2).  The cytosolic N-
terminal domain is composed of six metal binding domains (MBDs) that are connected 
by flexible loops. Each MBD binds one copper (Lutsenko et al., 1997); the binding 
induces conformational changes within the domain (DiDonato et al., 2000) that are 
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accompanied by the rearrangements of loops connecting MBD’s (Bartee et al., 2009).  
The nucleotide binding domain (NBD), the phosphorylation (P) domain and the actuator 
(A) domain are central for the P-type ATPase function. The NBD and the P-domain are 
involved in ATP binding and hydrolysis, whereas the A-domain is required for 
conformational changes during ATP hydrolysis. Both the N-terminal domain and C-
terminal tails of ATP7A/B are important for proper targeting of the protein. The 1-63 





is involved in trans-Golgi network (TGN) retention/apical targeting (Braiterman et al., 
2009), whereas the C-terminal tail contains domains/motifs important for endocytosis 
(Cater et al., 2006; Francis et al., 1999; Stephenson et al., 2005) and copper-responsive 
trafficking to apical membrane (Braiterman et al., 2011). 
 
2.2. Localization of human copper efflux transporters is regulated.   
ATP7A and ATP7B have two main localizations within cells.  One compartment is the 
TGN where these copper-ATPases supply the copper cofactor to cuproenzymes; the other 
compartment is vesicles-PM, to which copper-ATPases traffic in order to remove excess 
copper out of the cells (Gupta and Lutsenko, 2009).  Copper regulates the distribution of 
ATP7A and ATP7B between these two locations.  In basal or low copper, the TGN is the 
primary site for the localization and function of copper-ATPases; in high copper the 
transporters exit the TGN and relocate to vesicles, which eventually fuse with the PM.  
This copper regulated trafficking of ATP7A/7B is important for maintaining a cellular 
copper homeostasis. Despite its central role, the exact mechanism of ATP7A/7B 
trafficking between cellular compartments remains only partially characterized. It has 
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been established that both ATP7A/7B undergo kinase-mediated phosphorylation and the 
level of phosphorylation is copper-dependent and reversible. Therefore, the kinase-
mediated phosphorylation of ATP7A/7B is likely an important regulatory step for 
trafficking of ATP7A/7B and/or for modulation of their copper-transport function.  
 
2.3. Both copper-ATPases are phosphorylated on multiple sites.  
Biochemical and mass-spectrometry (MS) experiments suggest that both ATP7A and 
ATP7B are phosphorylated by kinases on serine residues (Vanderwerf et al., 2001; 
Vanderwerf and Lutsenko, 2002; Voskoboinik et al., 2003).  The level of kinase-
mediated phosphorylation is linked to the intracellular localization of copper-ATPases. 
Under basal conditions, while in TGN, ATP7A/B are basally phosphorylated. Upon 
copper elevation, the kinase mediated phosphorylation increases, and this coincides with 
the trafficking of ATP7A/B to vesicles. Return to the basal media or copper depletion 
with chelators triggers trafficking back to the TGN.  In parallel, the regulatory 
phosphorylation of ATP7A/7B reverts to its basal levels; suggesting that copper-
dependent phosphorylation might be required for either exit from the TGN or retention in 
vesicles (Vanderwerf et al., 2001; Voskoboinik et al., 2003). 
 
The identification of phosphorylation sites is necessary for determining the precise 
physiological role of ATP7A/7B phosphorylation. The in-cell and in vitro studies indicate 
that more than one residue is phosphorylated in either ATP7A or ATP7B (Pilankatta et 
al., 2009; Vanderwerf et al., 2001; Voskoboinik et al., 2003).  For ATP7B, it has been 
shown that the copper-responsive phosphorylation occurs at different site(s) than the 
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basal phosphorylation site(s) and different regions of the protein are involved in these 
events (Vanderwerf et al., 2001).  The C-terminal tail and the N-terminal domain of 
ATP7B are not required for basal phosphorylation, indicating that at least some of the 
basal phosphorylation site(s) are located in the Ser 796-Tyr 1384 region of ATP7B. On 
the other hand, the copper-induced phosphorylation requires the presence of the N-
terminal domain (Vanderwerf et al., 2001), which is a target of phosphorylation both in 
vitro and in cells.  MS analysis of the in vitro phosphorylated N-terminal domain of 
ATP7B pointed to the loop connecting MBD3-MBD4 as a site for the kinase mediated 
phosphorylation (Bartee et al., 2009).  Other putative copper-responsive phosphorylation 
sites were identified by MS analysis of the full-length ATP7B expressed in mammalian 
cells (Table 1-1):  these sites are located in the N-terminal domain (Ser 478 and Ser 481), 
the nucleotide-binding domain (Ser 1121) and the C-terminal tail (Ser 1453) (Pilankatta 
et al., 2009; Pilankatta et al., 2011).  
 
Similar to ATP7B, ATP7A has multiple phosphorylation sites. Residues associated with 
basal and copper-induced phosphorylation have been mapped to the N-terminal domain 
and the C-terminal tail of ATP7A (Veldhuis et al., 2009).  Several other 
phosphosites/phosphopeptides have been identified by the MS analysis and the results are 
summarized in Table 1-2 (Fedjaev et al., 2012; Huttlin et al., 2010; Lundby et al., 2012; 
Monetti et al., 2011). Despite these important advances, it remains unclear which, if any, 
of these sites represent primary targets of phosphorylation, and how stoichiometry of 
phosphorylation is regulated in response to changing copper levels. Mutation of two 







, have different intracellular localization, indicating that 
phosphorylation may have different consequences even when residues are located in the 
same domain (Veldhuis et al., 2009).  At the same time, different signaling events may 
yield phosphorylation of the same region/sites triggering trafficking response similar to 
that induced by copper.  For example, treatment of placental Jeg-3 cells with insulin 
stimulates ATP7A exit from the TGN and, interestingly, down-regulates the ATP7B 
protein levels resulting in lower copper levels in cells (Hardman et al., 2006).  In those 
earlier studies, the mechanism of insulin action was not explored.  However, more recent 
studies using the large-scale mass-spectrometry identified numerous liver proteins 
phosphorylated following insulin signaling, including ATP7A and ATP7B.  The residues 
phosphorylated in response to insulin were found in regions that were also known to be 
phosphorylated in response to changing copper level (Tables 1-1 and 1-2).  How different 
signaling pathways intersect and interact with each other is a complex and fascinating 
question for further studies.  
 
Several studies have been done to identify the kinases involved in the phosphorylation of 
ATP7A and ATP7B.  Protein kinase D (PKD) (Pilankatta et al., 2011) and casein kinase 
II (Vanderwerf et al., 2001) were suggested to be involved in kinase mediated 
phosphorylation of ATP7B.  In contrast, PKD does not seem to affect ATP7A, whereas 
Protein Kinase A and Rho GTPase Cdc 42 were implicated in ATP7A anterograde 




2.4. Copper-induced trafficking of ATP7B depends on the conformational state of the 
transporter.  
The cytosolic copper chaperone Atox1 was shown to transfer copper to the regulatory 
metal binding domains (MBDs) of the Cu-ATPases and regulate their occupancy (Walker 
et al., 2004).  Current data indicate that copper binding to N-terminal domain of both 
ATP7A and ATP7B is necessary for their copper-responsive phosphorylation 
(Vanderwerf et al., 2001; Veldhuis et al., 2009; Voskoboinik et al., 2003). Upon binding, 
copper induces rearrangements of the loops connecting MBDs in the N-terminal domain 
of ATP7B and also facilitates phosphorylation by a kinase; suggesting that 
conformational changes due to copper binding might be important in the exposure of 
additional phosphorylation sites (Bartee et al., 2009).  An ATP7A mutant which can not 
bind copper (due to mutation of CxxC in MBDs to SxxS) (Strausak et al., 1999) has a 
basal level of phosphorylation, but shows no increase in phosphorylation upon copper 
treatment and no trafficking (Voskoboinik et al., 2003). 
 
The Wilson disease causing mutant ATP7B
G591D
 is mislocalized to the endoplasmic 
reticulum (ER) under basal conditions (de Bie et al., 2007) and has a basal level of 
phosphorylation but no copper-induced phosphorylation (Vanderwerf et al., 2001). 
Similarly, the ATP7B
R875
 variant is also localized in ER under basal/copper-depleted 
conditions and is basally phosphorylated (Hasan et al., 2012).  These findings indicate 
that the basal phosphorylation of ATP7B occurs early in the secretory pathway 







binds copper and under elevated copper conditions traffics to vesicles, which 
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is also coupled with the increase in the kinase mediated phosphorylation (Hasan et al., 
2012).  
 
2.5. The sequence of events associated with the TGN exit/trafficking of copper-ATPases  
It is not yet clear how hyperphosphorylation and trafficking are linked, or which occurs 
first. Copper binding to the regulatory N-terminal domain of ATP7A/7B might expose 
additional phosphorylation sites and the addition of a negative charge 
(hyperphosphorylation) may induce further structural changes necessary for the exit from 
the TGN.  Alternatively, copper binding to the ATPase and the subsequent structural 
changes may enable protein sorting within the TGN/interaction with the trafficking 
machinery, whereas hyperphosphorylation may be a result of the relocalization of 
ATP7A/7B to the correct compartment in which kinase(s) might be present. 
 
Several sets of data support the important role of copper induced structural changes in the 
initiation of ATP7B exit from the TGN.  Copper binding not only influences the 
rearrangement of the N-terminal domain of ATP7B, but also alters the domain-domain 
interactions within the entire ATP7B molecule. Relative to the copper-free form, copper-
bound N-terminal domain interacts poorly with the NBD (Tsivkovskii et al., 2001), but 
strongly with the A-domain (Gupta et al., 2011).  Since copper binding to the N-terminus 
of ATP7B alters the inter-domain contacts, the increased phosphorylation might be a 




An alternative model is that the stabilization of ATP7B in a distinct conformational state 
is sufficient to cause its trafficking from TGN to vesicles. This model is supported by the 
observation that mutating residues that are not directly involved in copper binding may 





which is catalytically inactive,  is found in vesicles under basal copper conditions (Cater 
et al., 2007).  This targeting is associated with the stabilization of this mutant protein in 
the so-called E2 conformational state, as was demonstrated by the high level of catalytic 
phosphorylation (whether this hyperphosphorylation caused by the loss of phosphatase 
activity by the mutant is also coupled to the increase in regulatory kinase-mediated 
phosphorylation has not been explored). Mutating the six N-terminal MBDs and/or the 
TM Cys-Proc-Cys(CPC) motif individually results in a non-trafficking ATP7B; however, 
simultaneous mutation of all sites produces protein targeted to vesicles even in basal 
conditions (Cater et al., 2007). The fact that the conformation acquired by ATP7B
TGE>AAA
 
was sufficient to trigger its trafficking to vesicles suggests that trafficking is driven by 
structural changes in ATP7B, rather than interactions with other copper-binding proteins 
or phosphorylation by copper-dependent kinases.  
 
Similar results were obtained by mutating S340/341 residues of the N-terminal domain of 
ATP7B.  The ATP7B mutants with S340/341 mutations are found in vesicles under basal 
conditions. Metabolic labeling in cells with inorganic phosphate directly demonstrated 
that mutation of S340/341 residues significantly decreased the level of ATP7B 
phosphorylation, indicating that these residues were important for ATP7B modification 





protein was not due to mutation-induced hyperphosphorylation of 
some other residues, but rather due to conformational changes in ATP7B.  Further studies 
revealed weakened interactions between the N-terminal and NBD domains in 
ATP7B
S340/341A  
compared to the control ATP7B (Hasan et al., 2012). Thus, the role of 
kinase mediated phosphorylation might be to keep the N-terminal and NBD domains 
apart and stabilize the protein in a particular confirmation that can be recognized by the 
trafficking machinery, rather than acting as a recognition sequence for such machinery 




 and S340/341 residues are located in different 
domains of ATP7B, the mutation of these sites may have similar effects on the overall 
conformation of ATP7B and thus produce similar trafficking response.  
 
2.6. Copper binding to the regulatory N-terminal sites and catalytically important 
trans-membrane (TM) sites has different effect on the kinase mediated phosphorylation of 
ATP7B.  
Mutating the N-terminal copper-binding site in MBD6 (ATP7B
C575/578A
) interferes with a 
kinase mediated phosphorylation, whereas mutating the intramembrane TM6 copper-
binding site (ATP7B
C983/985A
) does not have such an effect.  Thus, copper binding to the 
MBD6 of N-terminal domain might be important for inducing the conformational 
changes within the domain so the phosphorylation sites can be accessed by the kinase. 
Neither mutant traffics in response to copper, i.e. the kinase-mediated phosphorylation of 
ATP7B
C983/985A 
is not sufficient for triggering its relocalization. At the same time, the 
ATP7B
C983/985A 
mutant has a lower phosphorylation level (or possibly a slower rate of 
phosphorylation) compared to the wildtype (WT) ATP7B, suggesting that the extent of 
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phosphorylation might be important for ATP7B exit from the TGN or that this mutation 
indirectly altered other sites (Pilankatta et al., 2011). 
 
2.7. The catalytic and kinase mediated phosphorylation occur through different 
mechanisms and are independent events.  
Both catalytic and kinase mediated phosphorylation are stimulated by copper, but through 
different mechanisms (Pilankatta et al., 2011). Supporting the model that both 
phosphorylations are independent events, inhibition of the kinase mediated 
phosphorylation using a kinase inhibitor does not affect the formation of catalytic 





 mutants are phosphorylated indicating that the 
catalytic transfer of phosphate from ATP to D1027 is not necessary for their kinase 
mediated phosphorylation (Bartee et al., 2009; Pilankatta et al., 2011). The same 
phenomenon was observed for the ATP7B
C983/985A 
mutant, which had no catalytic 
phosphorylation, but showed kinase mediated phosphorylation (Pilankatta et al., 2011).  




mutants the kinase mediated 
phosphorylation level was lower (or the phosphorylation rate was slower compared to the 
WT), suggesting that the overall phosphorylation level of ATP7B might be altered as a 
result of catalytic impairment (Pilankatta et al., 2011).  
 
In summary, both ATP7A and ATP7B undergo kinase mediated phosphorylation, which 
is a regulatory post-translational modification coupled to the intracellular localization of 
the protein. Copper binding to the N-terminal domain and/or trafficking to the post-Golgi 
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) the conformational state attained by the protein 
determines its localization irrespective of copper binding. Several putative 
phosphorylation sites have been identified, however it remains unclear whether the 
stoichiometry of phosphorylation or phosphorylation of distinct residues are important for 
the copper-responsive trafficking of ATP7A/B.   
 
III. Redox control of copper uptake and efflux from human cells.   
As described in section I, copper deficiency is associated with the increase of cellular 
glutathione levels, which in turn stimulate production of hCTR1 (Tennant et al., 2002).  
Recent studies indicate that the cellular glutathione status and the intracellular redox 
potential may also have a significant effect on the copper export activity of ATP7A and 
ATP7B. It has been suggested that under basal conditions, the copper ATPases can be 
glutathionylated, presumably at their metal-binding sites, and that the glutathionylation of 
ATP7A/7B and their interaction with glutaredoxin 1 are affected by changes in copper 
levels (Singleton et al., 2010).  The down-regulation of glutaredoxins by small interfering 
RNA (siRNA) resulted in increased intracellular copper accumulation (Singleton et al., 
2010), which was interpreted as evidence for direct regulation of copper export by 
glutaredoxin 1.  While the data are compelling, it remains to be established more firmly 
whether the diminished copper export is due to a direct oxidation of copper-ATPases or 
due to effect on cellular redox environment and interference with the copper delivery 
system. Recent data suggest that copper export can be controlled at the stage of copper 
transfer to copper-ATPases. 
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The copper ATPases receive copper from a copper chaperone Atox1.  This small 
cytosolic protein has a characteristic copper-binding site CxxC, which is maintained in 
the reduced state by glutathione (Hatori et al., 2012).  Decrease in the cellular ratio of 
reduced to oxidized glutathione (GSH:GSSG) results in Atox1 oxidation and a 
diminished delivery of copper to the secretory pathway, as evidenced by decreased levels 
of secreted holo-ceruloplasmin (Hatori et al., 2012). The redox potential of Atox1 is 
estimated at approximately -220 mV and, in resting cells, Atox1 is expected to be fully 
reduced.  However, upon cell proliferation and differentiation, the intracellular 
environment changes significantly (Dong-Yun et al., 2003; Markovic et al., 2009; Ranjan 
et al., 2006).  In Caco-2 cells, where both ATP7A and ATP7B are expressed, the redox 
state of cellular GSH/GSSG pair changes towards a 40-mV oxidation when cells progress 
from proliferation to contact inhibition and differentiation (Nkabyo et al., 2002).  This 
shift would be sufficient to produce partial oxidation of Atox1 and presumably influence 
copper excretion.  The direct testing of these predictions would greatly expand our 
understanding between copper transport and cellular redox balance. 
 
Overall, the current results suggest that copper transport in and out of cells is likely to 
fluctuate depending on cellular metabolic status, the stage of cell division, or 
differentiation. An example of significant changes in the routes of copper distribution is 
provided by the effects of hypoxia in macrophages (White et al., 2009a). Oxygen 
limitation in RAW264.7 macrophage cells stimulates copper uptake likely due to 
increased expression of hCTR1.  Under these conditions, copper transfer to the secretory 
pathway is also enhanced, as evidenced by the trafficking of ATP7A to vesicles.  At the 
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same time, the activities of cytosolic superoxide dismutase and mitochondria cytochrome 
c oxidase are reduced in response to hypoxia (White et al., 2009a).  Thus, under hypoxic 
conditions copper delivery to the secretory pathway becomes the primary pathway of 
copper distribution, presumably to facilitate copper incorporation into ceruloplasmin. 
 
In conclusion, the human copper transporters are subject of a complex multi-layer 
regulation by various metabolic signals.  Recent success in understanding the structure 
and biochemistry of these transporters provide strong foundation for trying to link the 








Figure 1-1. Main regulation modes of copper transporters in human cells. The high affinity copper 
transporter hCTR1 is located at the PM, where it facilitates copper entry into the cell. It is currently 
unknown whether hCTR1 is functional in the intracellular compartments. The cycling between two 
compartments may be constitutive and involves the clathrin-dependent pathway (CCV, clathrin-coated 
vesicles). Copper binding to “sensor” sites favors the redistribution of hCTR1 toward intracellular vesicles, 
whereas copper depletion facilitates the delivery of hCTR1 to the PM. Copper-transporting ATPases 7A 
and 7B are located in the TGN under basal conditions where they have basal level of phosphorylation 
(indicated by a star). In response to copper elevation and hormonal signaling, the Cu-ATPases become 
hyperphosphorylated and traffic to vesicles, where they sequester excess copper. The return to the TGN is 
linked to the decrease in copper levels and return to a basal level of phosphorylation. Changes in 
glutathione (GSH) levels and/or alterations of the cellular redox balance GSH:GSSG influence the levels 





Figure 1-2. The location of phosphorylated sites in ATP7A and ATP7B. (A, C) Schematic presentation 
of the domain organization of ATP7A (A) and ATP7B (C). Filled circles represent the N-terminal MBDs 
and are numbered 1–6. TM domains are numbered 1–8. The other domains are as follows: A: actuator 





) important for TGN retention/apical targeting (Braiterman et al., 2009b). The positions 
of identified phosphosites are shown. Underlined residues are putative copper-responsive phosphosites; the 
star (*) labels the putative phosphosites identified in other species and aligned with human ATP7A or 
ATP7B. (B,D) Sequence alignment of ATP7A (B) and ATP7B (D) orthologs in the regions with identified 
phosphosites. Sites for basal/constitutive phosphorylation identified by MS are in gray background. 




Table 1-1. Predicted Phosphorylation Sites in ATP7B. Species: m-mouse; r-rat; h-human; N-N-terminal; 
C-C-terminal; ND: not determined. *The identified phosphopeptide has different phosphorylated residue 
combinations identified by MS, and different phospho-occupancy. 
Phosphosites/ Phosphopeptides Type of 
phosphorylation 
Effect of mutation Ref. 
[Ser 478 (N-terminal), Ser 481(N-terminal),  




mutant is not 
trafficking in 
response to copper. 
(Pilankatta et al., 
2009; Pilankatta et al., 
2011) 
[340 SSSSHSPGSPPR] N, h 
 
Basal/constitutive S340/341 mutants 
are localized in 
vesicles. 
(Bartee et al., 2009)  
[270 SCVLNIEENIGQLLGVQSIQVSLENK] N, h 
[352 NQVQGTCSTTL] N, h  
[407 VISPEELR] N, h 
[415 AIEDMGFEASVVSESCSTNP 
LGNHSAGN] N, h 
[439 HSAGNSMVQTTDGTPTSVQEV 
APHTGR] N, h 
[444 SMVQTTDGTPTSVQEVAPHTGR] N, h 
[496 GMTCASCVSNIER] N, h  
[512 EAGVLSVLVALMAGK] N, h 
[589 TNGITYASVALATSK] N, h 
[595 ASVALATSK] N, h 
Basal/constitutive ND (Bartee et al., 2009) 
[140 AAS142WPSR] N, m Basal/constitutive  ND (Huttlin et al., 2010) 
[1389 MKPLS1393AS1395QVS1398VHIGMDDR] *, C, m   Basal/constitutive  ND (Huttlin et al., 2010) 
[1389 MKPLSAS1395QVSVHI] C, m Insulin dependent ND (putative 
kinase motif: 
NEK6) 
(Monetti et al., 2011) 
[458 GLLTHQGPGYLSDSPPS474PGGTASQ] N, r Insulin dependent ND (Fedjaev et al., 2012) 
[128 AAS130WPSR] N, r  
 
Basal/constitutive  ND (Lundby et al., 2012) 
[323 VS324LPDGLEK] N, r Basal/constitutive  ND (Lundby et al., 2012) 
[431 VSSGNSVPQAVGDS444PGS447VQNMA 
SDTR] *, N, r 
Basal/constitutive  ND (Lundby et al., 2012) 
[457 GLLTHQGPGYLS468DS470PPS473PGGT477ASQ] *, N, r Basal/constitutive  ND (Lundby et al., 2012) 
[1381 PLS1383AS1385QVS1388VHVGMDDR]  *, C, r Basal/constitutive  ND (Lundby et al., 2012) 











Table 1-2. Predicted Phosphorylation Sites in ATP7A. Species: m-mouse; r-rat; h-human; N-N-terminal; 
C-C-terminal; ND: not determined. *The identified phosphopeptide has different phosphorylated residue 
combinations identified by MS, and different phospho-occupancy. 











ND (Veldhuis et al., 2009) 
[270 S270PS272YTNDSTATFIID] *, N, h Basal/constitutive  ND (Veldhuis et al., 2009) 
[321 YNASSVT327PESLR] N, h Copper-
responsive 
ND (Veldhuis et al., 2009) 
[334 AIEAVS339PGLYR] N, h Basal/constitutive  ND (Veldhuis et al., 2009) 
[345 VS346ITS349EVEST354S355NS357P 
SSSS362LQK] *, N, h   
Basal/constitutive  ND (Veldhuis et al., 2009) 
[1430 SPS1432EISVHVGIDDTSR] C, h 
 
Basal/constitutive  S1432A is 
mislocalized 
(vesicles in high 
Cu, proximal to 
basolateral PM) 
(Veldhuis et al., 2009) 
[1456 IVNYS1460RAS1463INS1466LL 





(vesicles in high 
Cu, but no PM 
localization) 
(Veldhuis et al., 2009) 










(Veldhuis et al., 2009) 
[345 VSIASEVESTAS356S357PS359SS 
S362LQK] *, N, m 
Basal/constitutive  ND (Huttlin et al., 2010) 
[1421 SPS1423EIS1426VHVGIDDT1434 
S1435RNS1438PR] *,C, m 
 
Basal/constitutive  ND (Huttlin et al., 2010) 
[1447 IVNY1450S1451RAS1454INS1457LL 
S1460DKR] *, C, m 
Basal/constitutive   ND (Huttlin et al., 2010) 
[1464 S1464LNS1467VVT1470S1471EPDKH  
S1477 LLVGDFREDDDTTL] *, C, m 
Basal/constitutive   ND (Huttlin et al., 2010) 
[1446 DRIVNYS1452RAS1455INS1458L 








(Monetti et al., 2011) 
[345 VS346ISSEVES353PTSS357P 
SSSSLQK] *, C, r   
Basal/constitutive ND (Lundby et al., 2012) 
[1454 AS1455INS1458LLSDK] *, C, r   Basal/constitutive   ND (Lundby et al., 2012) 
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Copper homeostasis plays an important role in human physiology. Copper is both a 
catalytic and a structural cofactor for a variety of enzymes essential for human cellular 
metabolism (cytochrome c oxidase, superoxide dismutase, dopamine-β-hydroxylase, etc).  
Under physiologic conditions, copper cycles between two oxidation states, Cu(I) and 
Cu(II); and copper levels must be tightly regulated to avoid participation in unwanted 
reactions affecting an intracellular redox status (Gupta and Lutsenko, 2009). Copper 
homeostasis is primarily maintained by the copper-transporting ATPases ATP7A and 
ATP7B.  Both ATP7A and ATP7B are P-type ATPases that use the energy of ATP 
hydrolysis to transport copper across membranes; mutations in these proteins result either 
in copper accumulation in the body (Wilson’s disease) or copper deficiency (Menkes 
disease) (Bull et al., 1993; La Fontaine et al., 1998; Payne et al., 1998; Tanzi et al., 1993; 
Voskoboinik et al., 1998; Vulpe et al., 1993).  
  
ATP7B is highly expressed in the liver and has a dual function in hepatocytes. Under 
basal conditions, it transports copper into the TGN, where copper is incorporated into 
cuproenzymes.  Elevation of intracellular copper triggers ATP7B trafficking from the 
TGN to vesicles, which accumulate copper and then fuse with the apical plasma 
membrane to excrete copper out of the cell. Thus, ATP7B trafficking is essential for 
regulation of cellular copper levels. Mechanistic link between copper sensing by ATP7B 
and recognition of ATP7B by trafficking machinery is not yet understood, although 
involvement of such proteins as COMMD1, dynactin, clusterin and glutaredoxin have 
been proposed (Bartee and Lutsenko, 2007; Guo et al., 2005; Hung et al., 1997; Lim et 
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al., 2006a; Lim et al., 2006b; Materia et al., 2012; Roelofsen et al., 2000; Tao et al., 
2003).  
 
In addition to regulating ATP7B localization, copper modulates ATP7B phosphorylation 
by kinases. In low copper, ATP7B has a basal level of phosphorylation. Copper elevation 
results in a hyperphosphorylation of ATP7B, and this event is coupled to trafficking of 
ATP7B from the TGN to vesicles, whereas dephosphorylation is associated with the 
return of ATP7B from vesicles to the TGN (Vanderwerf et al., 2001). The basal and 
copper-induced phosphorylation sites are different and involve different kinases 
(Vanderwerf et al., 2001). Mass-spectrometry studies revealed a large number of 
potential phosphorylation sites (Bartee et al., 2009; Pilankatta et al., 2009); simultaneous 
mutation of four such sites disrupts ATP7B trafficking (Pilankatta et al., 2011).  
However, the cumulative effects of this multi-site mutation on either ATP7B structure, 
activity, or phosphorylation level have not been explored, thus specific reason for the 
disrupted trafficking remains uncertain.   
 
Biochemical and cellular studies also revealed the important role of the cytosolic N-
terminal domain of ATP7B (N-ATP7B) in both copper sensing and kinase-mediated 
phosphorylation. N-ATP7B is composed of six metal binding domains (MBDs) that are 
connected by flexible loops. Each MBD binds one copper (Fig. 2-1a) (Lutsenko et al., 
1997; Lutsenko et al., 2007). Copper binding to all 6 sites induces significant 
conformational changes in N-ATP7B (DiDonato et al., 2000) that are accompanied by the 
rearrangements of the loops connecting MBD’s (Bartee et al., 2009) and decreased 
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interactions with the nucleotide-binding domain, NBD (Tsivkovskii et al., 2001). The 
recombinant N-ATP7B is phosphorylated in vitro and in cells (Bartee et al., 2009), and in 
the full-length ATP7B, deletion of the N-terminal region results in the loss of copper-
dependent phosphorylation (Vanderwerf et al., 2001). Together, these observations 
suggested that copper binding to N-ATP7B induces structural changes favorable for 
kinase mediated phosphorylation and led to the hypothesis that phosphorylation may act 
as a signal for ATP7B exit from the TGN.  
 
However, other reports indicate that ATP7B exit from the TGN can be induced by 
mutation of residues that are not directly involved in either copper binding or 
phosphorylation. The N41S mutation results in a poor TGN retention and mis-targeting to 





>AAA is found in vesicles in either basal or high copper (Cater et al., 
2007). This latter mutant is catalytically inactive and trapped in a hyperphosphorylated 
state (although in this case the increased phosphorylation could be due to increased 
stability of a catalytic acyl-phosphate intermediate (Cater et al., 2007). These 
observations suggest an alternative model according to which stabilization of ATP7B in a 
distinct conformational state is sufficient to cause its traffic from the TGN (Cater et al., 
2007). 
 
To gain insight into the mechanism of ATP7B exit from the TGN, we have focused on 
the Ser-rich region in N-ATP7B, which we previously identified as a region of a kinase-
mediated phosphorylation (Bartee et al., 2009).  We demonstrate that mutating S340/341 
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in this region results in ATP7B acquiring conformation that resembles its copper 
saturated state. Although S340/341 mutant has reduced levels of kinase-mediated 
phosphorylation, it shows poor retention in the TGN and preferential localization to 
vesicles. Our data suggest that exit of ATP7B from the TGN is predominantly governed 
by a conformational state of the protein and requires copper transfer from the cytosol. 
 
Results 
The loop connecting MBD3 and MBD4 of ATP7B has several putative sites for kinase-
mediated phosphorylation.   
To test whether inhibiting phosphorylation would affect the ATP7B exit from the TGN 
we examined the Ser-rich cluster in the loop between MBD3 and MBD4, which we 
previously identified as a region of kinase-mediated phosphotylation (Bartee et al., 2009).  
This cluster is conserved between human ATP7A and ATP7B (Fig. 2-1b), and in ATP7A, 
several Ser residues in this region are phosphorylated (Huttlin et al., 2010). Bioinformatic 
analysis of ATP7B using NetPhos or GPS 2.1 program predicts 4-5 potential sites within 





 region to alanine decreases the in vitro phosphorylation of a recombinant N-ATP7B 
by 25-40%, however none of these mutations completely abolishes phosphorylation (our 
data, not shown).  To determine if any of the serines was more important than the others 
we compared the ATP7B orthologs (Fig. 2-1c). None of the residues was invariant, 
however S340 and S341 showed highest conservation; consequently, we focused our 








>A mutation was introduced into Flag-ATP7B cloned into the pcDNA5/FRT-
TO plasmid to allow for a tet-regulated expression (We have previously observed that 
high expression often leads to ATP7B mis-localization. Consequently, expression of the 
Flag-ATP7B or the S
340/341
A mutant was controlled by doxicycline and only cells with a 
low/medium Flag signal were imaged). As expected, in basal conditions the wild-type 
Flag-ATP7B was localized to TGN (Fig. 2-2a and 2-2b, upper panels). We expected that 
Flag-ATP7B
S340/341A
 would also be targeted to the TGN but might be unable to traffic.  
Instead, the mutant showed predominantly vesicular localization (Fig. 2-2a and 2-2b, 
lower panels). In cell with high expression, the TGN localization was partially retained, 
resulting in both vesicular and TGN staining of Flag-ATP7B
S340/341A
 (Fig.  2-2c). 
 
In hepatocytes, ATP7B traffics from TGN to vesicles in response to 10 µM copper, and 
copper chelation with BCS causes the ATP7B return to TGN. In renal cells and in HEK 
293 cells, ATP7B does not traffic in response to 10 µM copper (Barnes et al., 2009). 
Trafficking can only be seen upon treatment with very high copper (100 µM) and only 
small fraction of protein leaves the TGN under these conditions (data not shown).  
Therefore, finding the S340/341A mutant in vesicles in Hek293TRex cells was 
particularly striking and suggested that this mutation facilitated conversion of ATP7B 
from a “TGN retained” form to a “trafficking-compatible” state.   This phenotype also 






 does not return to the TGN in response to copper depletion.  
One reason for vesicular localization of Flag-ATP7B
S340/341A
 could be an increased 
sensitivity to basal copper levels induced by the mutation.  If this were the case, then 
decreasing intracellular copper using the chelator BCS would induce trafficking of the 
Flag-ATP7B
S340/341A
 back to the TGN. However, after prolonged treatment with 100 µM 
of BCS, the localization of mutant was unchanged, i.e. Flag-ATP7B
S340/341A
 remained in 
vesicles (low expression) (Fig. 2-3a) or in vesicles and TGN (higher expression). We 
generated and observed similar results for single mutants S340A, S340T, and S341A 
(Fig. 2-3c illustrates the results for ATP7B
S340A
. Other single mutants had similar 
vesicular localization).  
 
The differences in the compartmentalization of wt ATP7B, the S340/341A mutant, and 
the S340A mutant were verified by immuno-EM. Gold labeling showed the wt ATP7B to 
be distributed along cisterns and tubular profiles at the trans face of the Golgi, whereas 
little of S340/341A mutant was detected in similar structures (Fig. 2-3b; arrows). Instead, 
the mutant was primarily localized in large vesicles (300 - 1000 nm in size).  
Reciprocally, wt ATP7B was almost completely excluded from such vesicular profiles 




the single mutant GFP-ATP7B
S340A
 
appeared in large “vesicles” (arrowheads) (Fig. 2-3c, right panel).   Thus, the presence of 
serine residues in positions 340/341 is important for ATP7B retention in the TGN, 





Mutation of S340/341 mimics consequences of copper binding.  
The shift in the steady-state distribution of the S340/341A mutant from TGN to vesicles 
in low copper suggested that the mutant acquired a conformation resembling that of 
ATP7B under high copper conditions. To test this hypothesis, we took advantage of a 
naturally occurring ATP7B variant ATP7B
R875
, which has a low apparent affinity to 
copper compared to a common ATP7B
G875
 variant and a very distinct cellular behavior. 
In basal or low copper, ATP7B
R875
 localizes in the endoplasmic reticulum (ER), but it 
traffics to the TGN and then to vesicles when copper is increased in a step-wise fashion 
(Gupta et al., 2011).  Stabilizing the “copper-bound” state for the ATP7B
R875
 variant is 
expected to change its localization from ER to TGN and/or vesicles under basal 
conditions. To test this prediction we mutated S340/341 to A340/341 in ATP7B
R875
 and 
examined the localization of this mutant in Hek293TRex cells. In basal medium, the 
control ATP7B
R875
 showed expected ER localization, and it trafficked to vesicles upon 
copper treatment (Fig. 2-4a). In contrast, the mutant was localized exclusively to vesicles 
mimicking the behavior of ATP7B
R875
 in high copper (Fig. 2-4b).  Copper chelation 
treatment did not alter the localization of ATP7B
R875,S340/341A 
(Fig. 2-4b).  To further 
minimize structural perturbations (side chains of glycine are smaller compared to 




 was also 
localized exclusively to vesicles in both basal and copper depleted conditions (Fig. 2-4c).    
 
To determine whether on its way to vesicles the S340/341 mutant follows a normal 
intracellular route of ATP7B trafficking via the TGN, we utilized the tyrosinase 
activation assay. The assay uses Menkes fibroblasts expressing the copper-dependent 
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enzyme tyrosinase (YSTT cells). The YSTT cells lack active copper ATPases and thus 
produce inactive tyrosinase. Transfection of YSTT cells with a wt ATP7B, which is 
targeted to the TGN, restores copper transport to the TGN lumen and activates tyrosinase 
resulting in a black chromogenic precipitate (Fig. 2-5, left panel) (Gupta et al., 2011). 
The negative control, Flag-ATP7B
R875 
localized in the ER, does not activate tyrosinase 
(Fig. 2-5, middle panel) (Gupta et al., 2011). Expression of Flag-ATP7B
R875,S340/341G
 
induces pigment formation, indicating that the mutant followed the normal trafficking 
itinerary and delivered copper to tyrosinase, presumably when passing through the TGN 




 has a reduced kinase-mediated phosphorylation.  
The exit of wt ATP7B from the TGN is stimulated by high copper, which also stimulates 
ATP7B phosphorylation by a kinase (Vanderwerf et al., 2001). Given our observations 
that the S340/340A mutation mimics behavior of ATP7B in elevated copper, we were 
wondering whether this mutation instead of eliminating phosphorylation induced 
structural changes that exposed sites critical for kinase mediated phosphorylation in high 
copper.   
 





 using in vivo metabolic labeling 
with radioactive orthophosphate. (The ATP7B
R875
 variant was particularly useful for 




 have uniform intracellular 
localization, ER and vesicles, respectively).  In low copper, the mutant had ~30% lower 
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phosphorylation compared to ATP7B
R875
 (Fig. 2-6).  Copper treatment did not affect the 





 became larger when metabolic labeling was carried out  in the 
presence of copper (Fig. 2-6). Thus, Ser340/341 are important for normal 
phosphorylation of ATP7B, particularly in high copper, however the loss of 
phosphorylation caused by mutations is not detrimental for the ability of ATP7B to exit 
the TGN. To reconcile these observations, we hypothesized that in a wild-type ATP7B 
phosphorylation of S340 and/or S341 induces structural changes similar to those induced 
by Ser mutations.  To test this prediction we generated and characterized a phospho-
mimetic mutation S340/341D. This variant behaved indistinguishably from the 
S340/341A i.e. it was targeted to vesicles (Fig. 2-7a).  
 
The effect of Ser340/341 mutations on trafficking is selective.  
We were also curious whether vesicular targeting observed by mutating S340 and/or 
S341 was an effect specific for these sites or manipulating any phosphorylation site(s) in 
ATP7B would induce changes in localization. Consequently, using ATP7B
R875
 as a 
template we mutated to alanine S478, S481 and S1435, which were previously suggested 
as additional sites of phosphorylation in ATP7B (Pilankatta et al., 2009).  No effect on 
localization was observed for all three mutants. Similarly to ATP7B
R875
, these mutants 
were found in the ER in basal condition, were targeted to the TGN in low copper, and 
trafficked to vesicles in response to higher copper (Fig. 2-7b). We concluded that 




The S340/341A mutation does not markedly alter folding of N-ATP7B.  
Our data suggested that the S340/341 substitution induced structural changes in ATP7B, 
which could either be local or transmitted via inter-domain interactions to affect entire 
ATP7B. S340/341 residues are located in the N-terminal domain of ATP7B (N-ATP7B). 
To evaluate potential structural effects, we first mutated S340/341 in a recombinant N-
ATP7B. The folding of N-ATP7B and N-ATP7B
S340/341A
 was compared using limited 
proteolysis with varying concentrations of trypsin at different time intervals.  No 
difference in proteolytic patterns was detected under all tested conditions (Fig. 2-8a). 
Treatment with different protease, papain, yielded similar results (our data, not shown). 
We concluded that the S340/341A substitution did not markedly alter the N-ATP7B fold. 
To verify this conclusion, we examined the effect of Ser mutations on N-ATP7B 
structure in more detail. The recombinant N-ATP7B and N-ATP7B
S340/341A 
were 
metabolically labeled with N15, purified in a non-tagged form, and their folding was 
compared by NMR at equal protein concentrations (Fig. 2-8b). The spectra of wt N-
ATP7B and N-ATP7B
S340/341A 
showed excellent chemical shift dispersion, characteristic 
of the well-folded proteins. The differences in spectra were very minor, demonstrating 
that the S340/341A mutation does not significantly change the fold of N-ATP7B.  
 
Mutation of S340/341 induces conformational changes within ATP7B by reducing 
interactions between N-ATP7B and nucleotide-binding domain.   
The lack of significant effects on N-ATP7B structure suggested that the Ser mutations 
may alter the inter-domain interactions in ATP7B. It was previously shown that N-
ATP7B interacted with the nucleotide-binding domain (NBD) and that copper binding to 
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N-ATP7B decreased this interaction (Tsivkovskii et al., 2001). We hypothesized that the 
S340/341A mutation might mimic this effect and decrease interactions between N-
ATP7B and NBD. To test this hypothesis, we performed a co-purification experiment, 
using cell lysates containing the recombinant maltose fusion N-ATP7B (WT and 
S340/341A) and the intein fusion of NBD. N-ATP7B
S340/341A
 showed a ~50% reduction 
of inter-domain interaction compared to N-ATP7B (Fig. 2-9a). Thus, similarly to copper 
binding, S340/341 mutation decreases interactions between the N-terminal domain and 
NBD. 
 
In the full-length ATP7B, the change of inter-domain interactions is expected to 
influence the kinetics and/or pattern of limited proteolysis. Consistent with this 





. This was evident from 
differences in the relative intensities of proteolytic bands (Fig. 2-9b).  We concluded that 
Ser340/341 influences the interdomain interface and overall conformation of ATP7B.  
 




Copper binds to ATP7B in at least 8 sites (6 in the cytosol and likely 2 sites in the trans-
membrane portion).  Occupation of the cytosolic MBDs with copper and changes in 
interdomain contacts may be sufficient to trigger trafficking of ATP7B to vesicles. 
Alternatively, binding of copper at both the cytosolic and membrane/lumenal sites of the 
transporter might be necessary to initiate ATP7B exit from the TGN. To discriminate 
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between these two possibilities, we generated a catalytically inactive mutant D1027A and 
a triple mutant D1027A,S340/341G (all on the R875 background). The D1027 mutation 
is expected to have no effect on the ability of ATP7B to bind copper at the cytosolic 
MBDs, but it would prevent transfer of copper to the lumenal side due to inability to 
hydrolyze ATP. Analysis of intracellular targeting showed that the control D1027A 
mutant had a mixed ER/TGN targeting; a higher proportion of TGN targeting compared 
to the ER-localized parent ATP7B
R875
 (Fig. 2-10) implied that the mutant might have 
increased protein stability. Significantly, the D1027A mutation completely blocked 
trafficking of the Ser340/341G variant, i.e. the localization of ATP7B
S340/341G,D1027A 
mutant was no longer  
 
shifted towards vesicles (Fig. 2-10). We concluded that both 
domain/domain dissociation and copper transfer into the lumen are necessary for exiting 




In this study, we demonstrate that the N-terminal Ser-rich region of ATP7B is an 
important regulator of protein exit from the TGN. The residues Ser340/341 contribute to 
a regulatory phosphorylation of ATP7B, particularly in high copper, and modulate the 
inter-domain interactions (Fig. 2-6, Fig. 2-9a). Significantly, mutations inhibiting 
phosphorylation (S>A, S>G) and mutation mimicking the phosphorylated state (S>D) all 
facilitate ATP7B trafficking from the TGN. Thus, the structural change that alters inter-
domain contacts in ATP7B is a key trigger of ATP7B trafficking to vesicles. The role of 




N-ATP7B acts as a copper sensor; and copper binding to MBDs alters the conformation 
of the entire N-ATP7B (Barnes et al., 2009; DiDonato et al., 2000).   ATP7B with 
non-functional MBDs (which cannot bind copper) does not traffic in response to copper 
elevation (Cater et al., 2004). Residues S340/341 are located within the long loop 
connecting MBD3 and MBD4 and are not expected to have any effect on copper binding 
capacity of N-ATP7B, although this remains to be experimentally verified.  It is also 
unlikely that S340/341 interact directly with the cellular trafficking machinery; because a 
deletion mutant of ATP7B that lacks the N-terminal residues 63-443 exhibits normal 
TGN localization and copper dependent trafficking (Guo et al., 2005).  Instead, the 
S340/341 region appears to play an important role in interactions between N-ATP7B and 
the nucleotide-binding domain.  This role could be direct because the effect of 
S340/341A mutation on overall structure of N-ATP7B is minimal (Fig.  2-8a, 2-8b), 
whereas the effect on inter-domain interaction is significant (Fig. 2-9a).  
Phosphorylation of other membrane proteins was shown to expose sorting signals 
(Bonifacino and Traub, 2003) or itself serve as a signal for trafficking by facilitating 
interaction with the components of cellular trafficking machinery (Hinners and Tooze, 
2003).  Our data are more consistent with a scenario, where phosphorylation alone is not 
a required factor in the exit of ATP7B from the TGN; rather it stabilizes the ‘trafficking 
ready’ copper bound state of ATP7B. We speculate that in low copper S340/341 are 
protected from a kinase by inter-domain interactions.  Domain dissociation in response to 
copper binding to N-ATP7B exposes S340/341 to phosphorylation by a kinase. The 
phosphorylation would then keep domains apart, thus stabilizing ATP7B is a state that 
has a poor TGN retention (Fig. 2-11).  
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The fact that even a mild mutation such as S340T produces the loss of TGN retention 
indicates that this region of ATP7B is not merely an exposed loop, but a site critical for 
the conformational state of entire ATP7B. From this perspective, it is interesting to 




 also result in the 
loss of TGN retention (Braiterman et al., 2009).  It is tempting to speculate that in a three-
dimensional structure of ATP7B, the two N-terminal regions can be in vicinity to each 
other.  Copper binding and subsequent structural rearrangements that expose S340/341 
for phosphorylation may simultaneously expose the F37-E45 region for interaction with 
the apical trafficking machinery (Braiterman et al., 2009). 
Mass-spectrometry analysis of the recombinant ATP7B demonstrated that S478, S481 
and S1453 can be phosphorylated and that quadruple mutant (S478, 481, 1121, 1453A) 
fails to traffic in response to copper (Pilankatta et al., 2009; Pilankatta et al., 2011). In our 
studies, individual mutations of these residues do not alter trafficking pattern (Fig. 2-7b). 
Difference in the phenotypes could be due to global conformational changes induced by a 
quadruple mutation versus a single mutation. These observations emphasize the role of 
ATP7B structure in its localization.  





>AAA (Cater et al., 2007). This mutant is trapped in a so called E2P 
state (Cater et al., 2007).  Similar E2P state would be stabilized under conditions of 





 and S340/341 residues are located in different domains of ATP7B, 
the mutation of these sites are likely to have similar effects on the overall conformation 
of ATP7B.   
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The following model (Fig. 2-11) is consistent with our results as well as many 
experimental observations reported in the literature.  Under basal conditions, N-ATP7B 
has a partial copper occupancy and ATP7B pumps copper into the lumen of TGN, where 
the released copper is incorporated into available apo-proteins.  In high copper, more 
copper binds to N-ATP7B; the binding relieves the autoinhibitory interaction between N-
ATP7B and the nucleotide-binding domain and activates the pump. Higher transport 
activity would saturate the copper-binding capacity of acceptor proteins and eventually 
inhibit copper release from ATP7B into the lumen.   Altogether, these events would lead 
to ATP7B acquiring a “copper-saturated” conformation, which is a target of a kinase-
mediated phosphorylation.  Phosphorylation of serine residues may stabilize the “TGN-
exit ready” conformation, which is posed to interact with the cellular machinery 
responsible for an anterograde trafficking of ATP7B. The mutations that stabilize this 
specific form would facilitate the TGN exit and result in vesicular localization of ATP7B.  
 
Materials and Methods 
Cell lines: Hek293TRex cells were maintained in MEM supplemented with 10 % FBS, 
1 % pen/strep, 1 % non-essential amino acids, 12.5 μg/mL blasticidin and 100 μg/mL 
zeocin. During experiments media without blasticidin and zeocin was used. YSTT cells 
were maintained in DMEM supplemented with 10 % FBS, 1 % pen/strep, 1 % non 
essential amino acids, 200 µg/ml G418 and 0.5 µg/ml puromycin.  Hek293 cells were 




Site-directed mutagenesis in ATP7B: The previously generated construct of N-terminally 
Flag-tagged ATP7B in pcDNA 5.1 FRT/TO vector was used as a template (Gupta et al., 
2011). The Ser>Ala, Ser>Gly, Ser>Thr, and Ser>Asp mutations were introduced by PCR 
using the Quickchange XL mutagenesis kit (Stratagene).  All primers were obtained from 
Invitrogen and the primer sequences are available upon request. The presence of the 
mutation and the fidelity of the cDNA sequence were verified by DNA sequencing of the 
coding region.  
Tyrosinase activation assay: YSTT cells grown on glass coverslips were transfected with 
either 2 μg of pcTYR (a plasmid encoding apo-tyrosinase) or with 2 μg pcTYR and 2 μg 
Flag-ATP7B plasmids using Turbofect (Fermentas). Positive control (wt GFP-ATP7B, 
known as pYG7 (Guo et al., 2005)) and negative control (only pcTYR) were used to 
ensure the specificity of the assay. 24 h post-transfection, cells were washed with PBS 
and fixed in cold acetone-methanol for 30 sec. The cells were then incubated for 4 h at 
37°C in 0.1 M Na-phosphate buffer (pH 6.8) containing 0.15% (wt/vol) levo-3,4-
dihydroxy-L-phenylalanine (L-DOPA). Coverslips were mounted, and the formation of 
the black DOPA-chrome pigment was detected by phase microscopy. Pigment color 
intensity was quantified using Image J. 
Analysis of kinase-mediated phosphorylation. Hek293TRex cells were grown in 6 cm 





 plasmids using Turbofect (Fermentas). Protein 
expression was induced with 40 ng/ml DOX (Sigma) for 16 h in basal conditions. Cells 
were rinsed with PBS and kept in the phosphate-free DMEM for 3 h. Then, media was 
changed to fresh phosphate-free DMEM (Gibco) containing 0.3 mCi 
32
P (Perkin Elmer). 
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After 3 h, media was removed and cells were treated with 100 µM BCS or 100 µM CuCl2 
(both pre-dissolved in FBS) added to a phosphate-free DMEM for 2 h. Cells were 
harvested, homogenized in a homogenizing buffer (25 mM imidazole, 0.25 M sucrose, 
1 mM AEBSF and protease inhibitor tablets (Roche)) using a Dounce homogenizer with 
40 strokes of a tight-fitting pestle. The lysate was centrifuged at 700 g for 10 min at 4°C 
to pellet cell debri and nuclei. The postnuclear supernatant was centrifuged at 3,000 g for 
10 min at 4°C to pellet mitochondria. The resulting supernatant was then centrifuged at 
20,000 g for 30 min at 4°C to pellet down the microsomal membranes. The pellet was 
resuspended in 100 μl of IP buffer (150 mM NaCl, 10 mM Tris-HCl, 2 mM EDTA (pH 
7.5), 1 % n-Dodecyl β-D-maltoside (DDM) (Sigma), protease inhibitor tablets (Roche)). 
200 μl of blocking buffer (3 % BSA in PBST) was added. After 5 min, 2.5 μl of anti-Flag 
antibody (Sigma) was added and rotated for 1 h at room temperature. 55 μl of pre-
equilibrated protein G resin (Thermo Scientific) was added and rotated for 1 h at RT. The 
resin was washed with 20 column volumes of PBS and the bound protein was eluted 
using 60 μl of elution buffer (0.17 M Tris, pH 6.8, 6.8 % SDS, 2.7 M urea, 1:100 β-
mercaptoethanol). 24 μl of the eluted protein was loaded to a 4-20% TGX gel (Bio-Rad) 
(2 gels were used). One of the gels was dried for determining the phosphorylation level. 
The proteins in the second gel were transferred to PVDF membrane using a 10 mM 
CAPS, pH 11 transfer buffer.  Immunoblotting was done using rat polyclonal anti-N-
ATP7B antibody (1:5000) as primary antibody, and HRP-conjugated goat anti-rat IgG 
(1:10,000) (Santa Cruz) The average intensity of protein bands was determined using 
densitometry (Alpha Imager 2200). The level of phosphorylation was normalized to 
protein levels detected in the immunoblot. 
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Cloning, expression, and purification of N-ATP7B variants: The cDNA fragment 
encoding the N-ATP7B in a pTYB12 vector was used for expression of N-ATP7B-intein 
fusion protein. The Ser>Ala replacement was introduced by PCR using the Quickchange 
XL mutagenesis kit. 1 L of E. coli BL21 (DE3) cells transformed with the appropriate 
plasmids were grown at 37°C to an A600 of 0.7. Protein expression was induced with 
1 mM isopropyl 1-thio-β-D-galactopyranoside (IPTG). Protein was expressed at 25°C for 
4 h. Cells were harvested by centrifugation, disrupted using French press, recombinant 
proteins were purified on chitin beads according to manufacturer’s protocol (NEB) and 
eluted with 50 mM DTT for 36 hours at room temperature. The proteins were 
concentrated using ultracel-30K (Millipore) and the purity of recombinant N-ATP7B was 
verified by SDS-PAGE. 
Limited proteolysis with trypsin: 5 µg of purified N-ATP7B was diluted to 1 µg/µl in 
40 mM Na-phosphate, pH 7.5, containing 400 mM NaCl, 1 mM BCS and mixed with 
0.05 µg TPCK-treated bovine pancreatic trypsin (Sigma) at RT in a total volume of 12 µl.  
The reaction was quenched for 10 min by adding 1.2 µl of 50 mM AEBSF. Proteins were 
precipitated using 1.2 µl of 20 % TCA, and mixed with a loading dye and 1 µl of 1 M 
NaOH. Digestion patterns were determined by using 12 % Tricine gels and staining of 
protein bands with Coomassie blue. 
For limited proteolysis of Flag-ATP7B, confluent Hek293TRex cells in 10 cm dishes 





plasmids using Turbofect. Protein expression was induced with 10 ng/ml DOX for 4 h in 
basal conditions and cells were kept overnight in media containing 50 µM BCS.  Cells 
were harvested, homogenized in a homogenizing buffer (25 mM imidazole, 0.25 M 
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sucrose) and the microsomal fractions were isolated as described above. The pellet 
containing the microsomal membranes was resuspended in 100 μl of trypsin buffer 
containing 40 mM Na- phosphate, pH 7.5, 400 mM NaCl, and 0.25 M sucrose. Equal 
amounts of total protein were loaded (15 µg); when necessary levels of ATP7B were also 
equalized by using membranes from non-transfected cells. The microsomal fractions 
were treated with 0.15 µg TPCK-treated trypsin at 37°C in a total volume of 20 µl.  The 
reaction was quenched by adding 2 µl of 100 mM AEBSF. Proteins were analyzed by 
8 % SDS gel, transferred to PVDF membrane using a 10 mM CAPS transfer buffer, pH 
11 and immunostained using rabbit polyclonal anti-NBD-ATP7B antibody (1:2500) as 
primary antibody, and HRP-conjugated goat anti-rabbit IgG (1:10,000) (Santa Cruz).  
The average intensity of protein bands was determined by densitometry (Alpha Imager 
2200).  
Domain-domain interactions: Nucleotide-binding domain (NBD) cloned in a pTYB12 
vector (Dmitriev et al., 2006) was expressed in E.coli BL21 strain in 500 ml of culture 
medium using 1 mM IPTG.  N-ATP7B (wt and S340/341A) fused with maltose binding 
protein (MBP) (~105kDa) was expressed as previously described (Lutsenko et al., 1997). 
Bacterial cells were harvested by centrifugation at 5000 rpm at 4°C, lysed by French 
press (3 passes) followed by centrifugation at 17,000 rpm at 4°C to remove cell debris 
and collect supernatants. 100 µl of supernatant were analyzed by 10 % SDS PAGE to 
quantitate amount of expressed recombinant proteins by densitometry. Supernatants were 
then mixed to reach an equimolecular ratio of NBD and N-ATP7B and incubated for 1 h 
in a rotator at 4°C. The mixture was applied to amylose beads and incubated for 1 h in the 
rotator at RT. The beads were then washed with 20 column volumes of 50 mM Na-
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phosphate buffer containing 500 mM NaCl (pH 7.0) and complete EDTA free protease 
inhibitor cocktail (Roche). Interacting proteins were eluted with the same buffer 
containing 10 mM maltose. 10 µl of the eluate was ran on a 15% SDS-PAGE, transferred 
to PVDF membrane and the presence of NBD was detected with rabbit polyclonal anti-
NBD antibody. To quantify N-ATP7B, the membrane was stripped with 10X PBS for 1 h 
and re-probed with rat polyclonal anti-N-ATP7B Ab. The bands intensity was quantified 
by densitometry using Alpha Imager 2200. 
NMR analysis of N-ATP7B: The 
15
N-isotopic labeling of N-ATP7B for NMR was 
performed using published protocol (Dmitriev et al., 2006). Following purification by 
chitin affinity chromatography, N-ATP7B was additionally purified by ion-exchange 
chromatography on a Hi Trap Q column (GE Healthcare) using linear concentration 
gradient of NaCl (0-0.5M) for elution, dialyzed to remove salt, and concentrated  by 
membrane filtration. Samples for NMR contained 20-90 μM protein, 50 mM HEPES-Na, 
pH 7.4, 50 mM NaCl, 5 mM tris(2-carboxyethyl)phosphine, 5% (v/v) D2O and 0.5 mM 





TROSY (Pervushin et al., 1997) experiments were recorded on a 900 MHz Varian NMR 
spectrometer  at 298K. 
Immunofluorescence microscopy: Hek293TRex cells on coverslips were transiently 
transfected with the wt or mutant Flag-ATP7B using Turbofect. Protein expression was 
induced with 40 ng/ml DOX for 16 h in basal conditions.  Cells were treated with 
100 µM BCS or 100 µM CuCl2 for 2 h, rinsed with PBS and fixed with in cold acetone-
methanol mixture (1:1) for 30 sec. The cells were blocked in blocking buffer (1 % 
gelatin, 1 % BSA in PBS) and then incubated with appropriate primary and secondary 
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antibodies diluted in blocking buffer. (Primary antibody: mouse anti-Flag antibody 1:250 
(Sigma) and rabbit anti-TGN38 1:100 (Santa Cruz). Secondary antibody: Alexa Fluor 
488 Goat anti mouse antibody 1:500 (Invitrogen) and Alexa Fluor 555 goat anti rabbit 
1:500 (Invitrogen)). Coverslips were mounted onto glass slides using Vectashield 
w/DAPI (Vector Laboratories).  Images were taken using a Zeiss PALM confocal 
microscope and a 100x oil immersion objective. 
Immuno-electron microscopy: HEK293 cells transfected with either wt or mutant Flag-
ATP7B were fixed with a mixture of 4% paraformaldehyde and 0.05% glutaraldehyde, 
labeled with rabbit polyclonal anti-Flag antibody (Sigma) using the gold-enhance 
protocol as described previously (Polishchuk et al., 2003). Then, cells were fixed in 
uranyl acetate and in OsO4, dehydrated through a graded series of ethanol and embedded 
in the epoxy resin (Epon 812). Thin sections were cut with Leica EM UC6 
ultramicrotome (Leica Microsystems, Wetzlar, Germany). Images from sections were 
acquired using a JEM-1011 electron microscope (JEOL, Tokyo, Japan) equipped with an 





















Figure 2-1. (A) Schematic representation of ATP7B, (B) sequence alignment of ATP7B and ATP7A, or 
(C) ATP7B orthologs in the region containing Ser 340 and Ser 341 (A) Filled circles represent the N-
terminal metal binding domains (MBDs) and are numbered 1 to 6. Transmembrane domains are numbered 
TM1 to TM8. The other domains are as follows: A: actuator domain; P: phosphorylation domain; N: 
nucleotide-binding domain. The positions of serine residues mutated in this study are shown. (B) The Ser rich 
cluster (shown in bold) in human ATP7B (S340-S343) is conserved in mammalian ATP7A orthologs. (C) Ser 
residues in ATP7B orthologs that align with human ATP7B Ser340 and Ser341 are shown in bold font.  





Figure 2-2. Mutating S340 and/or S341 shifts the steady-state localization of ATP7B towards vesicles 
in Hek293TRex cells. (A) Hek293TRex cells were transiently transfected with wt Flag-ATP7B or Flag-
ATP7B
S340/341A
. After doxycycline-induced expression in basal conditions, cells were immunostained with 
anti-Flag antibody (left, green) and anti-TGN38 (middle, red) and the patterns were compared (merge, 
right). Scale bar: 5 µm. (B) Magnified images demonstrating good colocalization between wt Flag-ATP7B 
and TGN 38 (upper panel), and vesicular localization of Flag-ATP7B
S340/341A 
and the loss of colocalization 
with TGN38 (lower panel). (C) Random fields of view were chosen and the number of cells having 
different intracellular localizations of transfected ATP7B were counted.  The graph shows the number of 
cells having wt Flag-ATP7B or Flag-ATP7B
S340/341A
 in different localizations within the cells: TGN, 








 do not return to TGN with copper depletion. (A) Copper 
depletion of Hek293TRex cells transiently transfected with wt Flag-ATP7B or Flag-ATP7B
S340/341A 
was done 
using 100 µM BCS for 2 h. Cells were immunostained using anti-Flag antibody (green) and TGN 38 (red). 
Merged image is located at the right panel. Scale bar: 5 µm. (B) Copper depletion treatment was done using 
200 µM BCS for 3 h. Cells were processed for immuno-gold EM with anti-Flag antibody. The wt Flag-ATP7B 
(left panel) was detected over the tubular-vesicular profiles (arrows) at the trans-side of the Golgi stacks 
(asterisks).  Arrowheads indicate large vesicles which were devoid of ATP7B signal. Flag-ATP7B
S340/341A 
(right panel) decorated membrane profiles (arrows) at the trans-side of the Golgi stacks (asterisk) as well as 
large vesicles (arrowheads). (C) Representative confocal image (left panel) of Flag-ATP7B
S340A
 (green) with a 
TGN marker (red)  in copper depleted conditions (100 µM BCS for 2 h). Electron microscopy (right panel) of 
GFP-ATP7B
S340A
 in Hek 293 cells under copper depleted conditions (200 µM BCS for 3 h) is shown. GFP-
ATP7B
S340A
 is localized at the trans-side (arrows) of the Golgi complex (asterisk). In addition the mutant 
appeared also in large “vesicles” (arrowheads) which (in contrast to wt ATP7B) exhibited heavy gold labeling 









mimic a copper saturated form and are localized in 








   
were kept in basal media, copper depleted by treatment with 100 µM BCS for 
2 h or copper treated by treatment with 100 µM CuCl2 for 2 h. Cells were immunostained using Flag antibody 
(green) and TGN 38 (red); shown are merged images. (Scale bar: 5 µm) (A) wt Flag- ATP7B
R875
 is localized in 
ER in basal (left panel) and copper-depleted conditions (middle panel), and moves to vesicles upon copper 
treatment (right panel). (B) ATP7B
R875,S340/341A 
 is localized in vesicles in basal (left panel) and copper-depleted 
(right panel)  conditions. (C) ATP7B
R875,S340/341G 
 is localized in vesicles in basal (left panel)  and copper-






has copper transport activity and pumps copper into the TGN of 
YSTT cells in basal conditions.  Tyrosinase assay shows pigment formation for wt GFP-ATP7B (arrow, 
left panel) and Flag-ATP7B
R875,S340/341G
 (arrow, right panel) 
 
but no pigment formation for wt Flag-
ATP7B
R875








































has a decreased level of kinase mediated phosphorylation. Hek293TRex 




, treated with 100 µM 
BCS or 100 µM CuCl2 for 2 h and in vivo metabolically labeled with radioactive orthophosphate.  The 
kinase mediated phosphorylation of Flag-ATP7B
R875
 (wt) and Flag-ATP7B
R875,S340/341G 
(S>G) was 
compared following immunoprecipitation, gel-separation and densitometry. Error bars indicate S.D. across 






























Figure 2-7. The phospho-mimetic mutant ATP7B
R875,S340/341D 
is localized in vesicles and the effect of 













   
were kept in basal media, copper depleted by treatment with 100 µM BCS for 2 h or 
copper treated by treatment with 100 µM CuCl2 for 2 h. Cells were immunostained using anti-Flag antibody. 
(A) Shown are representative confocal images of Flag-ATP7B
R875,S340/341D 
in basal (upper panel) and copper 
depleted conditions (lower panel). Flag-ATP7B
R875,S340/341D 
is localized in vesicles. (B) Representative confocal 







behave as wild type. They are predominantly found in ER in basal conditions, and 



















Figure 2-8. The Ser340/341A mutation does not disrupt protein folding of N-ATP7B.  (A) Proteolytic 
patterns obtained following treatment of 5 µg purified recombinant N-ATP7B (WT) and N-ATP7B
S340/341A 
(S>A) with 0.05 µg trypsin. Peptides were resolved using 12%  Tricine gel and stained with Coomassie 




N-TROSY spectra of the S340/341A mutant MBD1-6  (left panel), and an 





































Figure 2-9. The Ser340/341A mutation reduces interactions between N-ATP7B and nucleotide-
binding domain (NBD) resulting in an altered conformation of ATP7B.  (A) Cell lysates containing 
maltose-binding fusions of N-ATP7B (WT) or N-ATP7B
S340/341A 
(S>A) were mixed with lysates containing 
recombinant NBD and passed over amylose resins.  NBD co-purified with the N-ATP7B was quantified in 
western blot using anti-NBD antibody (upper panel) and by densitometry (lower panel). Staining with anti-
N-ATP7B antibody shows comparable amount of purified wt and mutant N-ATP7B (middle panel). (B) 
Proteolytic patterns obtained following treatment of 15 µg total membrane (from Flag-ATP7B
R875





transfected cells) with 0.15 µg trypsin for 15 min at 37°C. Peptides were 
resolved using 8% SDS gel and immunoblotted with NBD-ATP7B antibody. The bands were analyzed by 










Figure 2-10. Copper transport activity is necessary for the shift of the intracellular localization of  
ATP7B
R875,S340/341G












D>A). Cells were kept in basal media. Cells were immunostained using Flag antibody and TGN 38. 
Random fields of view were chosen and the number of cells having different intracellular localizations of 
transfected ATP7B were counted.  The graph shows the number of cells having WT, D>A, S>G and S>G, 
































Figure 2-11. The proposed sequence of events that triggers ATP7B trafficking. In basal copper, 
N-ATP7B has a partial copper occupancy and ATP7B pumps copper into the lumen of TGN, where 
released copper is incorporated into available apo-proteins (green beads and brown half-spheres). In high 
copper, MBDs are saturated with copper and N-ATP7B dissociates from the N-domain resulting in pump 
activation. The S340/341 sites situated in the MBD3-MBD4 loop are phosphorylated and that keeps the 
domains apart (dotted red arrow). Due to higher pump activity, the acceptor proteins become saturated, 
copper release is diminished, and ATP7B is stabilized is a conformation favorable for TGN exit. In this 
conformation, ATP7B interacts with the trafficking machinery (green rhomboid). Similar effect on ATP7B 
conformation is achieved by mutating Ser340/341. The domains are denoted as, A: Actuator; N: 
Nucleotide-binding domain; P: Phosphorylation domain. The six metal-binding sites on N-ATP7B are 
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III.  Novel Regulators of Copper Homeostasis 
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wide RNAi ionomics screen reveals new genes and regulation of human trace element 
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Copper is essential for normal growth and development; as being a cofactor for a variety of 
vital metabolic enzymes. However, copper levels must be tightly regulated to avoid oxidative 
stress and changes in intracellular redox status. Loss of copper homeostasis is associated 
with heart hypertrophy, liver failure, neuronal de-myelination and other pathologies.  
ATP7A is a copper ATPase that is involved in maintaining the copper homeostasis. ATP7A is 
localized to the trans-Golgi network (TGN) under basal conditions where it pumps copper to 
cuproenzymes located in the lumen of  the TGN and upon  increase of  intracellular copper 
levels it traffics to vesicles and plasma membrane to export excess copper (Gupta and 
Lutsenko, 2009). Despite its central role, the exact mechanism of ATP7A trafficking between 
cellular compartments remains only partially characterized. 
 
The regulation of copper-ATPases occurs on multiple levels, some of which have not been 
characterized well. AIPP1, p97 VCP and glutaredoxin1 have been shown to interact with 
ATP7A, however their mechanism of action has not been well characterized yet (Lim et al., 
2006; Stephenson et al., 2005; Yi et al., 2012). In addition, ATP7A is modified post-
translationally by glutathionylation and glycosylation, but little is known about the functional 
effects of these modifications (Singleton et al., 2010; Yamaguchi et al., 1996).  ATP7A also 
undergoes kinase mediated phosphorylation on multiple serine residues under basal and 
elevated copper conditions, and the level of phosphorylation is copper-dependent and 
reversible (Voskoboinik et al., 2003). Therefore, the kinase-mediated phosphorylation of 
ATP7A might be involved in regulation of trafficking or copper-transport activity. In addition, 
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copper ATPases traffic in response hormones, such as insulin and estrogen; which again raises 
the possibility of other regulatory proteins involved (Hardman et al., 2007). 
 
A genome-wide high-throughput siRNA/ionomics screen was performed by our collaborators 
to determine novel regulators of trace elements homeostasis, yielding eight proteins as potential 
candidates for regulation of copper homeostasis. Knockdowns of IBTK, CAMK2N2, 
DNAJC5, DNAJC17, ABCC3, ANKRD9, and SLC6A4 resulted in elevation of intracellular 
copper levels (Table 3-1) (Malinouski et al., 2014). To uncover the specific roles of these genes 
in cellular copper balance, we determined the effects of their inactivation on ATP7A, the major 
copper export protein in HeLa cells. Novel mechanisms controlling the copper ionome through 
ATP7A were identified. Out of seven tested targets, down-regulation of five had a significant 
effect on ATP7A. This result emphasizes the primary role of ATPase-mediated copper export 
in balancing cellular copper. 
 
Results 
Characterization of predicted copper regulators reveals new mechanisms controlling the 
copper ionome through ATP7A 
Several candidates not known previously to be involved in the regulation of trace element 
homeostasis were identified (Table 3-1). Knockdowns of two members of the DNAJ 
family (DNAJC5 and DNAJC17), two kinase inhibitor genes (CAMK2N2 and IBTK) 
and two transporters (SLC6A4 and ABCC3) led to increased copper levels (Table 3-1). 
Following down-regulation of the target genes, we characterized ATP7A expression, 
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intracellular targeting, and its ability to undergo copper-dependent trafficking from trans-
Golgi network (TGN) to the plasma membrane (a step required for copper efflux).   
 
Out of seven tested targets, down-regulation of five had a significant effect on ATP7A. 
This result emphasizes the primary role of ATPase-mediated copper export in balancing 
cellular copper. Knockdown of DNAJC5 and SLC6A4 did not influence ATP7A protein 
levels, trafficking or targeting, indicating that these proteins may regulate other 
components of the copper-handling machinery. In contrast, knockdown of a member of 
the HSP40 family DNAJC17 produced a significant reduction in ATP7A amount in cells 
as evidenced by the decreased intensity of ATP7A signal (green) in the TGN compared to 
the marker TGN46 (red) (Fig. 3-1, Fig. 3-2).  The decrease of ATP7A in the TGN was 
due to lower ATP7A protein levels (rather than the loss of TGN targeting) as evidenced 
by Western blotting of cellular lysates (Fig. 3-1). The levels of other tested proteins, such 
as Na,K-ATPase and TGN46, were not affected. Knockdowns of kinase inhibitors IBTK 
and CAMK2N2 had a dual effect: reduction in the ATP7A levels and a shift in the 
ATP7A electrophoretic mobility (Fig. 3-1, Fig. 3-2) that suggested changes in 
posttranslational modification of ATP7A. 
 
A different mode of ATP7A regulation was detected in the case of the ABCC3 
knockdown. Downregulation of this gene did not have a significant effect on ATP7A 
levels (Fig. 3-1) or ATP7A targeting to the TGN (Fig. 3-2a). Instead, in cells with the 
down-regulated ABCC3 the distribution of ATP7A between the TGN and vesicles was 
altered, with less ATP7A leaving the TGN in response to copper treatment (Fig. 3-3 b,c). 
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Perhaps, the most intriguing results were obtained with cells depleted of ANKRD9. 
Down-regulation of this adaptor protein led to an increased cell size, dispersion of the 
TGN and a change in ATP7A electrophoretic mobility (Fig. 3-1b, Fig 3-3d). A shift in 
ATP7A migration on SDS-PAGE gels suggests that the posttranslational modifications of 
ATP7A, which is a glycosylated protein, are affected. Although the ANKRD9 
knockdown affected TGN morphology, it did not disrupt colocalization of ATP7A and 
TGN46 suggesting that the molecular identity of this compartment was preserved (Fig. 3-
2b). We are now facing intriguing mechanistic questions about a link between TGN 
morphology, ATP7A modification, and cellular copper levels. Taken together, these data 
show that essentially all effects of the target gene knockdowns with respect to copper 
elevation can be explained by changes in ATP7A trafficking, modification, and/or 
expression. Cellular machinery that controls ATP7A mRNA and/or protein stability has 
not been previously characterized, and the identification of several new regulatory 
components as a result of the ionomics screen provides exciting opportunities for better 
understanding of copper metabolism in human cells. 
 
Effect of DNAJC17 downregulation is indirect 
Individual siRNA sequences against DNAJC17 were used to confirm the specificity of 
DNAJC17 knockdown.  ATP7A levels were determined by immunoblotting following 
transfection with siRNAs. ATP7A protein levels were decreased significantly with 
DNAJC17 #2 siRNA transfection (Fig. 3-4a). ATP7A and DNAJC17 mRNA levels were 
determined using RT-PCR assays, and although the same level of downregulation of 
DNAJC17 was achieved with   DNAJC17 #2 siRNA and DNAJC17 #1,3,4 siRNAs; only 
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DNAJC17 #2 siRNA resulted in decreased ATP7A mRNA levels (Fig. 3-4b,c), raising 
the possibility that the effect of DNAJC17 downregulation is off-target (i.e. not mediated 
though DNAJC17). In addition, DNAJC17 #2 siRNA transfection resulted in high degree 
of cell death.  
 
Discussion 
In this study, the effect of downregulation of novel regulatory proteins on the copper-
exporting ATPase ATP7A was studied. The novel regulatory proteins (IBTK, 
CAMK2N2, DNAJC5, DNAJC17, ABCC3, ANKRD9, and SLC6A4) were identified 
through a high-throughput ionomics screen (Malinouski et al., 2014) and their 
knockdowns resulted in elevation of intracellular copper. Both IBTK (inhibitor of Bruton 
tyrosine kinase) and CAMK2N2 (calcium/calmodulin-dependent protein kinase II 
inhibitor 2) are kinase inhibitors, and their down-regulation resulted in a significant 
decrease in ATP7A protein levels. Kinase-mediated phosphorylation plays a role in the 
trafficking of ATP7A (Veldhuis et al., 2009; Voskoboinik et al., 2003); however, roles of 
Bruton tyrosine kinase or CAMK2 in ATP7A phosphorylation have not been previously 
known or considered. It is interesting that both kinases participate in major signaling 
pathways involving a nuclear factor-kappaB (NF-κB) (Petro et al., 2000; Scharenberg 
and Kinet, 1998; Singh et al., 2009). These results suggest a link between the stress-
response pathways and a tight regulation of copper homeostasis (Veldhuis et al., 2009; 




The negative effect of ABCC3 (ATP-binding cassette, subfamily C (CFTR/MRP), 
member 3) down-regulation on ATP7A trafficking is an equally novel result. ABCC3 is 
an organic anion and bile acid transporter. Previously, treating hepatocytes (HepG2) with 
copper resulted in an upregulation of ABCC3 (Song and Freedman, 2005). Together, 
these results suggest that the bile acid transport and copper metabolism might be linked.  
The observed increase in copper levels in response to disregulation of lipid metabolism 
further supports idea of copper and lipid homeostasis being interconnected. The 
downregulation of ABCC3 may also be affecting the organic anion/bile acid balance in 
HeLa cells, which might inhibit ATP7A transport activity and copper-responsive 
trafficking, which are also mutually dependent. 
 
Downregulation of ANKRD9 (ankyrin repeat domain-containing protein 9) produces a 
complex phenotype, which includes fragmented TGN and apparent changes in ATP7A 
post-translational modification and protein levels. The function of this protein is not 
known, but it was suggested to play a role in lipid metabolism (Wang et al., 2009). Other 
ankyrin proteins are involved in membrane protein trafficking/stabilization (Devarajan et 
al., 1996; Tamura et al., 2011). Thus, ANKRD9 may bind to ATP7A and stabilize its 
TGN localization. Furthermore, ANKRD9 induced a decrease in ATP7A protein levels 
and a shift in ATP7A migration on SDS-PAGE gels, which could be a secondary effect 
of TGN fragmentation and may alter the ability of ATP7A to efficiently pump excess 
copper out of the cell.  
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It is also possible that the identified proteins are affecting other complements of the 
copper handling machinery within the cells. Further studied will be needed to determine 
the mechanistic role of the identified proteins in maintaining the copper homeostasis.   
 
Materials and Methods 
Cell lines: HeLa cells (obtained from ATCC) were maintained in DMEM supplemented 
with 10 % FBS and 1 % pen/strep at 37 ºC in a 5% CO2 incubator. 
siRNA transfection, western blotting and immunohistochemistry: Modified version of the 
Dharmacon’s Wet Reverse Transfection Protocol was used for the transfection of HeLa 
cells. Dharmafect I reagent (0.4 µl/well) was diluted using Optimem  media 
(24.6 µl/well). Stock siRNA (human siGenome pool siRNA, Dharmafect) was mixed 
with Optimem to a final volume of 10 µl (the final siRNA concentration is 20 nM/well). 
Both Dharmafect I/Optimem  and siRNA/Optimem solutions were mixed and added to 
each well of an 8-well chamber (Millipore). Chambers were incubated for 30 min at RT. 
HeLa cells were trypsinized and resuspended in antibiotic free complete medium. 0.3 x 
10
5
 cells were added to each well in a volume of 170 µl. The chambers were placed at 
37 ºC in a 5% CO2 incubator. 60 h after the transfection 200 µl of in antibiotic free 
complete medium was added to each well. Cells were fixed 72 h after the transfection 
using 3% paraformaldehyde at 37ºC for 12 min. Cells were washed with 1X PBS and 
blocked/permeabilized simultaneously for 12 min using 1% BSA/ 1% saponin in 1X 
PBS. Cells were washed with 1X PBS and then incubated with appropriate primary and 
secondary antibodies diluted in 0.5 % BSA in 1X PBS (Primary antibody: mouse anti-
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ATP7A antibody 1:250 (Santa Cruz) and sheep anti-TGN46 1:300 (Genetex). Secondary 
antibody: Alexa Fluor 488 Goat anti mouse antibody 1:500 (Invitrogen) and Alexa Fluor 
555 donkey anti sheep 1:500 (Invitrogen). The glass slides were mounted using 
Fluoromount G w/DAPI (Electron Microscopy Sciences).  Images were taken using a 
Zeiss LSM 510 confocal microscope and a 40x oil immersion objective. For Western 
blotting, cells were harvested, the pellet was resuspended in 30 µl of Laemmli loading 
buffer, sonicated for 30 sec and centrifuged for 15 min at 3000 g at 4 ºC. The supernatant 
was loaded to 8 % SDS gel. Proteins were transferred to a PVDF membrane using CAPS 
buffer, pH 11.0. The membrane was cut at 130 kDa and probed for Na/K ATPase 
(1:10000, Millipore) and ATP7A (1:3000, Santa Cruz). Goat anti mouse Igg-HRP 
(1:10000, Santa Cruz) was used as a secondary antibody and the membranes were 
developed using a SuperSignal West Pico Substrate (Thermo Scientific). 
RNA isolation and quantitative PCR: HeLa cells were transiently transfected with the 
indicated siRNA or scrRNA control and cells were harvested. RNA was isolated using 
RNeasy Mini Kit (Qiagen) and cDNA was prepared using Transcriptor First Strand 
cDNA Synthesis Kit (Roche).  Real-time PCR was performed using a Power SYBR 
Green master mix (Applied Biosystems) using the following primer sequences:  ATP7A, 






Table 3-1. Ionomic profiles of siRNA gene knockdowns involved in copper metabolism. Knockdown 
of the listed genes results in increase in copper levels specifically. z-scores, represent the number of 
standard deviations from the mean value the listed value is (z-score >3  was defined as the threshold) . 


















copper levels  
 
z-score  
DNAJC5 DnaJ (Hsp40) homolog, subfamily C, member 5 1.3 3.5 
DNAJC17 DnaJ (Hsp40) homolog, subfamily C, member 17 1.3  5.1  
IBTK Inhibitor of Bruton agammaglobulinemia tyrosine 
kinase 
1.4  6.7  
ATP7A ATPase, Cu
+2
 transporting, alpha polypeptide 
(Menkes syndrome)** 
1.6  9.5  
SLC6A4 Neurotransmitter transporter, serotonin, member 4 1.4  3.5  
ANKRD9 Ankyrin repeat domain 9 1.7  7.2  
CAMK2N2 Calcium/calmodulin-dependent protein kinase II 
inhibitor 2 
1.6  6.0  




Figure 3-1. Characterization of targets that affect copper levels in HeLa cells. (a) Effect of targets 
downregulation on ATP7A localization in basal conditions. Following gene-specific siRNA-mediated 
knockdowns, HeLa cells were fixed, stained with the antibodies against ATP7A (green) and the TGN 
marker TGN46 (red) and analysed by confocal microscopy. The merged image is shown in the right panel. 
Scale bar, 25 µm. (b) Effect of target downregulation on ATP7A protein levels and electrophoretic 
mobility. Following gene knockdowns, HeLa cell lysates were analysed by western blotting. The blot was 
cut at 130 kDa; the upper part was immunostained for ATP7A and the lower part was immunostained for 
Na/K-ATPase. A representative blot is shown. (c) Quantification of western blot data by densitometry. The 
ATP7A protein levels were normalized to Na/K-ATPase protein levels and the values were compared with 
the intensity of ATP7A in cells transfected with a non-targeting siRNA (scrRNA). The error bars 
correspond to s.d. values from four independent experiments. Asterisks mark significant changes (the 




Figure 3-2. Characterization of genes that affect copper levels in HeLa cells. Following gene-specific 
knockdowns, HeLa cells were fixed and analyzed by confocal microscopy with antibodies against ATP7A 
(green) and the trans-Golgi network marker TGN46 (red). Scale bar: 25 μm. (b) 100x magnification 
images. ANKRD9 knockdown results in fragmented TGN and fragmented ATP7A staining pattern. Scale 
bar: 10 μm. (c) HeLa cells were transiently transfected with siRNAs, and cell lysates were analyzed by 
western blotting. The blot was cut at 130 kDa and the upper part was immunoblotted for ATP7A and the 




Figure 3-3. ABCC3 and ANKRD9 are new regulators of ATP7A. (a–c) Downregulation of ABCC3 
affects ATP7A trafficking. Following siRNA-mediated knockdown, HeLa cells were kept under basal 
conditions (panel a, scale bar, 25 µm) or treated with 200 µM CuCl2 for 5 h (panel b, scale bar, 25 µm), and 
then fixed, immmunostained with antibodies against ATP7A (green) and TGN46 (red) and analysed by 
confocal microscopy. (c) Percentage of cells with ATP7A in the TGN following the copper treatment (left 
panel). Intensity of ATP7A signal in the TGN was quantified using Image J (right panel). (d) ANKRD9 
knockdown results in fragmented TGN and fragmented ATP7A staining pattern. Following siRNA-
mediated knockdown, HeLa cells in basal conditions were fixed, stained with antibodies against ATP7A 




Figure 3-4. Effect of DNAJC17 downregulation is indirect. (a) HeLa cells were transiently transfected 
with siRNAs, and cell lysates were analyzed by western blotting. The blot was cut at 130 kDa and the 
upper part was immunoblotted for ATP7A and the lower part was immunoblotted for Na/K ATPase.  A 
representative blot is shown.  (b) ATP7A mRNA levels in transiently-transfected cells were analyzed by 
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Ankyrins comprise a family of intracellular adaptor proteins that link integral membrane 
proteins to the intracellular spectrin-actin cytoskeleton.  In complexes with their binding 
partners, ankyrins organize distinct membrane domains. Ankyrins were shown to interact 
with diverse proteins: ion channels (voltage-gated Na
+
 channels, voltage-gated potassium 









ATPase, cell adhesion molecules (L1-CAMs, 
CD44, E-cadherin, dystroglycan), cellular trafficking proteins (tubulin, clathrin)). 
Ankyrin proteins consist of three domains: membrane protein binding domain containing 
ankyrin repeats (24 ankyrin repeats in major isoforms), spectrin binding domain, 
regulatory domain, and so-called “death” domain. Ankyrins and their isoforms are 
expressed in many tissues including cardiomyocytes, neurons, skeletal muscle cells and 
epithelial cells. Dysfunction of ankyrins results in defective membrane expression of the 
ankyrin-binding partners and leads to diseases such as such as haemolytic anaemia, 
cardiac arrhythmia and neurological disorders (Bennett and Healy, 2009; Cunha and 
Mohler, 2009).  
 
Ankyrins are involved in trafficking of channels/ion-exchangers/transporting ATPases 
(Bennett and Healy, 2009). One of the most studied ankyrin proteins, Ankyrin G, binds to 
a variety of channels/pumps and cell adhesion molecules via its ankyrin repeats and links 
these membrane proteins to the actin cytoskeleton (Bennett and Healy, 2009). In neuronal 
cells, Ankyrin G acts as an adaptor and binds KIF5/kinesin-1 to transport Nav channels 











 exchanger 1, and InsP3 
receptor in cardiomycoytes to regulate cytosolic Ca
2+
 levels (Mohler et al., 2005). 
Ankyrin B associates with the cardiac KATP channel via Kir6.2 and downregulation of 
Ankyrin B decreases the plasma membrane expression of both Kir6.2 and KATP channel 
(Li et al., 2010). 
 
In addition to ankyrins, cells express a large spectrum of proteins containing ankyrin 
(ANK) repeats. ANK repeats are 33 amino acid motifs found in viral, bacterial and 
archaeal proteins, and most commonly in eukaryotic proteins.  Presently, 19,276 ankyrin 
repeat sequences have been identified in 3608 non-redundant proteins (Letunic et al., 
2002; Schultz et al., 1998). ANK repeats are present in a diverse set of proteins involved 
in transcription, cell cycle regulation, cell signaling, cytoskeleton integrity, endocytosis, 
inflammatory response, and various transport phenomena. Each ankyrin repeat folds into 
two antiparallel α-helices that are connected by an exposed loop or a β-hairpin (Mosavi et 
al., 2004). Exposed loops contain non-conserved residues, which are likely to be involved 
in the recognition of specific proteins.  Ankyrin repeats stack together to form an L-
shaped structure known as Ankyrin Repeat Domains (ANKRD). Examples of ANKRD-
binding proteins include Cdk4/6 cell cycle regulators, signaling protein Notch, Nf-κB 
inhibitor IκB, TRP cation channels, megalin (Mosavi et al., 2004). ANKRD proteins 
mediate specific protein–protein interactions and do not appear to have an enzymatic 
function. ANKRD can be present as a domain in complex multi-domain proteins or exist   
Ankyrin repeat domain-containing protein 9 (ANKRD9) was identified as a potential 
regulator of copper homeostasis through a genome-wide high-throughput 
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siRNA/ionomics screen (Malinouski et al., 2014). Information about properties and 
cellular/molecular function of ANKRD9 is very limited.  Expression of hepatic ANKRD9 
mRNA is increased 30-40 fold in chicken with hepatic accumulation of lipids caused by 
riboflavin deficiency and fatty acid oxidation. Fasting and thyroid hormone (which 
reduces hepatic triglyceride content) decrease hepatic mRNA levels of ANKRD9, 
whereas re-feeding increases its levels (Wang et al., 2009). Unpublished data shows that 
ANKRD9 knock-out mice (Ankrd9
tm1(KOMP)Wtsi
) have a decreased amount of total body 
fat, increased lean body mass, and increased bone mineral content 
(https://www.mousephenotype.org/data/genes/MGI:1921501).  These data suggest the 
role for ANKRD9 in lipid homeostasis 
 
ANKRD9 levels are changed upon cell damage or in apoptosis in chicken, human HepG2 
cells, and Hek293 cells (Wang et al., 2009). A microarray analysis revealed that 
ANKRD9 was downregulated in mouse colonic epithelial cells treated with epithelial-
disrupting agent dextransulfate sodium (DSS), which induces tissue damage (Rogier et 
al., 2014).  Another study in zebrafish, determined that ANKRD9 is an estrogen target 
gene, but the mechanism of estrogen-dependent regulation of ANKRD9 expression is 
unknown (Hao et al., 2013). Overall, ANKRD9 levels respond to different apparently 
unrelated stimuli, and the actual function of ANKRD9 remains largely unknown. 
 
In our collaborative study, we found that ANKRD9 downregulation leads to an increase 
of intracellular copper (Malinouski et al., 2014) and the aim of current study was to 
understand the role of ANKRD9 in copper homeostasis.  We found that ANKRD9 
96 
 
downregulation resulted in fragmentation of Golgi apparatus, raising the possibility that 
ANKRD9 might be involved in maintaining Golgi integrity. In addition, the proteins that 
we examined were partially glycosylated in cells with decreased levels of ANKRD9.  It 
has been previously shown that disruption of Golgi structure and defects in glycosylation 
are linked events, (Petrosyan et al., 2012; Pokrovskaya et al., 2011; Shestakova et al., 
2006; Struwe and Reinhold, 2012), however ANKRD9 has not been previously 
implicated in this process. In addition, we found that ANKRD9 downregulation resulted 
in sequestration of intracellular copper and significant upregulation of the copper uptake 
protein Ctr1, presumably as a mechanism to compensate for functional copper deficiency 




Initial characterization of recombinant ANKRD9  
ANKRD9 consists of 317 amino acids and it is conserved among vertebrates (Fig. 4-1a). 
It has a predicted size of 34.3 kDa and based on Pymol model predictions it consists of 
several alpha helices and loops (Fig. 4-1b).   The number of ankyrin repeats in ANKRD9 
is unclear.  Wang et al. predicted that ANKRD9 has three ankyrin repeats at its N-
terminus (ANK1:71-100 aa, ANK2: 112-141 aa, ANK3: 158-187 aa) and a poly-Leu 
motif (Wang et al., 2009). Similarly, three repeats were predicted in ANKRD9 protein in 





 amino acids (http://www.ebi.ac.uk/interpro/protein/ Q96BM1). We 
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performed homology modeling using Phyre2; this program revealed a typical ANKRD 
fold containing 8 repetitive sequences (Fig. 4-1b).     
 
To begin characterization of ANKRD9, we generated a corresponding cDNA by RT-PCR 
using mRNA isolated from HeLa cells.  The sequence encoding Flag-tag was introduced 
at the 5’-end and the final product was cloned into a pcDNA 3.1 (+) vector. HeLa cells 
were then transfected with Flag-ANKRD9 and expression and localization of 
recombinant protein was monitored by immunostaining. Fig. 4-1c illustrates that Flag-
ANKRD9 localizes primarily to cytoplasmic vesicles in agreement with the findings of a 
previous study (Wang et al., 2009). Cell lysates were used for immunoblotting, and Flag-
ANKRD9 was detected as two major bands around 35 kDa (Fig. 4-1d). We confirmed 
that there was a single plasmid species with Flag-ANKRD9/pcDNA 3.1(+) construct, so 
the double bands might be due to posttranslational modifications. Since ANKRD9 is 
predicted to be a soluble protein, yet is is observed targeted to vesicles, it is possible that 
it is palmitoylated at the invariant Cys residue 110. 
 
Down-regulation of ANKRD9 increases intracellular copper levels 
The genome-wide siRNA-mediated screen found that down-regulation of ANKRD9 in 
HeLa cells by transient transfection with a pool of four ANKRD9 siRNAs increases 
copper levels by 1.7 fold (Fig. 4-1e, f, g). The levels of other elements were not altered 
significantly (Fig. 4-1e, f, g). We repeated the down-regulation experiments along with 
the copper content measurements. The efficiency of ANKRD9 was determined using 
qPCR. In our experiments ANKRD9 mRNA was decreased 50% in cells transfected with 
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ANKRD9 siRNA compared to cells transfected with non-targetting siRNA (Fig. 4-2b). 
Atomic absorption spectroscopy of whole cell lysates showed that decrease of ANKRD9 
amount is associated with 1.3 fold higher copper compared to control cells transfected 
with the non-targeting (NT) siRNA (Fig. 4-2a). By comparison, complete knock-down of 
ATP7A, which is the major copper-exporting ATPase in HeLa cells, resulted in a 1.9 fold 
increase of intracellular copper levels (Fig. 4-2a).   
 
ANKRD9 is required for normal Golgi structure 
To explain elevation of cellular copper in cell with lower ANKRD9 levels, we first 
examined the effect of ANKRD9 downregulation on ATP7A, the major copper export 
protein in HeLa cells. Under basal conditions, ATP7A is localized to the trans-Golgi 
network (TGN), where it pumps copper to cuproenzymes located in the lumen.  Upon increase 
of intracellular copper, ATP7A traffics to vesicles and plasma membrane to export excess 
copper (Gupta and Lutsenko, 2009). Since other ankyrin proteins are known to be involved 
in membrane protein trafficking/stabilization (Devarajan et al., 1996; Tamura et al., 
2011), we tested whether down-regulation of ANKRD9 affects ATP7A or its localization 
at the TGN. 
HeLa cells were transfected with the NT siRNA or ANKRD9 siRNA and immunostained 
with the markers of Golgi compartments and anti-ATP7A antibodies. Depletion of 
ANKRD9 resulted in a dispersion of TGN46 (trans Golgi marker) (Fig. 4-2c) and 
Gpp130 (cis-medial Golgi marker) (Fig. 4-2d). ATP7A, which normally localizes to the 
TGN (Fig. 4-2c) and partially to cis-medial Golgi (Fig. 4-2d), also showed a fragmented 
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staining pattern in ANKRD9 depleted cells.  ATP7A still retained its Golgi localization, 
it colocalized with the fragmented TGN (Fig. 4-2c).  
We used electron microscopy to determine the effect of ANKRD9 downregulation on the 
Golgi structure in more detail; we also examined if the structure of other organelles was 
affected by ANKRD9 down-regulation.  Consistent with the immunostaining data, we 
observed that the Golgi increased in size significantly and was fragmented in the 
ANKRD9-depleted cells (Fig. 4-3). The fragmented Golgi vesicles were not dispersed 
throughout the cytoplasm, but were arranged in clusters. No significant changes in the 
structure of other organelles were observed, which point to the Golgi organelle as the 
primary (direct or indirect) target of ANKRD9 downregulation. To verify our electron 
microscopy observations that other organelles were not significantly affected by 
ANKRD9 depletion, we immunostained siRNA-transfected HeLa cells with antibodies 
against calreticulin (endoplasmic reticulum (ER) marker) and Lamp1 (lysosomal marker) 
(Fig. 4-4). No significant difference in the pattern of ER or lysosomes was seen between 
control and ANKRD9-depleted cells.  
 
ANKRD9 depletion results in partial glycosylation of ATP7A 
ATP7A is the major copper exporting protein in HeLa cells. Therefore if ANKRD9 
downregulation decreases ATP7A levels, the intracellular copper levels would increase 
due to inefficient copper export out of the cells.  We measured both the mRNA and 
protein levels of ATP7A in ANKRD9-depleted cells to test this possibility.  The effect of 
ANKRD9 downregulation on the level of ATP7A protein level was determined by 
immunoblotting after SDS-PAGE separation of cell lysates. Quantification of ATP7A 
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protein bands using densitometry showed that the amount of ATP7A was decreased by 
40% in the ANKRD9-depleted cells; however, that might be due to differences in 
comparing a single crisp band (control) versus a diffuse band (ANKRD9 knock down) 
(Fig. 4-5b). In contrast, the qPCR analysis of mRNA levels demonstrated that ATP7A 
mRNA levels were increased 1.8 fold in ANKRD9-downregulated cells (Fig. 4-5c). 
Thus, at present we cannot exclude the possibility that the loss of ANKRD9 was 
associated with enhanced degradation of ATP7A. 
 
Interestingly, we also observed a shift in the electrophoretic mobility of ATP7A in the 
ANKRD9-depleted cells.   ATP7A undergoes N-linked glycosylation (Yamaguchi et al., 
1996), so we hypothesized that the glycosylation of ATP7A was affected as a result of 
ANKRD9 downregulation. Tunicamycin inhibits N-acetylglucosamine transferases 
disrupting glycosylation of newly synthesized proteins (Heifetz et al., 1979). Fig. 4-5a 
shows a fully glycosylated band and a lower unglycosylated band of ATP7A in cells 
treated with tunicamycin. The ATP7A protein band in ANKRD9-downregulated cells 
was more diffuse suggesting presence of partially glycosylated ATP7A intermediates 
(Fig. 4-5a).  
 
ANKRD9-dependent loss of Golgi structure does not appear to affect normal protein 
sorting 
Given significant change in Golgi morphology we tested whether this structural change 
affects the ability of the TGN to retain and/or sort proteins to other compartments.  We 
first examined whether the dispersed structures containing ATP7A in the ANKRD9-
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depleted cells were mistargeted and fused to the lysosomes. No significant colocalization 
was observed between ATP7A in dispersed TGN and lysosomal markers, demonstrating 
that ATP7A was not mislocalized to the lysosomes (Fig. 4-4b). 
We further tested whether the cis-medial Golgi and trans-Golgi compartments mix as a 
result of the fragmentation caused by ANKRD9 depletion.  In control cells, the cis-
medial Golgi (Gpp130) and trans-Golgi (TGN 46) colocalized partially (Fig. 4-6). In 
ANKRD9 depleted cells, two different patterns were observed. In a subset of cells 
Gpp130 and TGN 46 colocalized in the fragmented structures, whereas in another subset 
Gpp130 and TGN 46 did not colocalize significantly (Fig. 4-6). In this second subset of 
cells, the cis-medial Golgi had a more dispersed staining pattern compared to the trans- 
Golgi, suggesting that the dispersion of the cis-medial Golgi may precede the dispersion 
of the trans Golgi. This observation raised the possibility that the ANKRD9 depletion 
may primarily affect the cis-medial Golgi sub-compartment resulting in its dispersion 
followed by the dispersion of the trans Golgi sub-compartment.  
Next we examined whether the fragmented Golgi vesicles colocalize with vesicular 
organelles, which are involved in retrograde/anterograde trafficking and sorting, such as 
early endosomes, late endosomes, and lysosomes. ANKRD9-depleted cells were 
immunostained for both TGN 46 and the lysosomal marker Lamp1, to determine if the 
fragmented Golgi vesicles and lysosomes colocalize. No significant colocalization was 
observed, suggesting that ANKRD9 downregulation did not cause mislocalization of the 
TGN proteins to lysosomes (Fig. 4-7a). We also did not observe a significant difference 
in the pattern of early/late endosomal structures between control and ANKRD9-depleted 
cells. As seen in Fig. 4-7b and Fig. 4-7c, the TGN46 targeted to fragmented trans Golgi 
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compartments did not colocalize with the early or late endosomes, confirming that the 
fragmented Golgi vesicles retained their Golgi identity and were not fused with other 
organelles. 
 
ATP7A traffics to the plasma membrane in response to copper in ANKRD9-depleted cells 
In order to determine whether glycosylation of ATP7A was important for trafficking 
from the TGN to the plasma membrane, cells were treated with 200 µM CuCl2 for 5 h 
and then immunostained for ATP7A and TGN 46. As seen in Fig. 4-8, in control cells 
ATP7A localized to the TGN under basal conditions, and trafficked out of the TGN in 
response to copper treatment. The same phenomenon was observed in ANKRD9-
depleted cells (Fig. 4-8). In high confluency areas, the plasma membrane staining of 
ATP7A in both control cells and ANKRD9-depleted cells was detected (Fig. 4-8c). Thus, 
partially glycosylated ATP7A could traffic to its correct localization (plasma membrane) 
in response to copper treatment in ANKRD9-depleted cells with fragmented Golgi. 
Surface biotinylation was used to confirm that the partially glycosylated ATP7A was 
localized to the plasma membrane under high copper conditions (data not shown).  
 
Effect of ANKRD9 depletion on localization and glycosylation of Na/K ATPase β1-
subunit, Lamp1 and TGN 46 
We wanted to determine whether ANKRD9 depletion affected the localization of other 
membrane glycoproteins known to be targeted to different cellular compartments and 
whether their glycosylation status was altered. We focused on the plasma membrane 
localized Na/K ATPase β1-subunit, lysosomal membrane localized Lamp1, and Golgi-
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localized TGN 46 proteins.  As seen in Fig. 4-9a, depletion of ANKRD9 resulted in a 
shift of Na/K ATPase β1-subunit from a mature form to a high mannose glycosylated 
form (which is the predominant form found in the ER (Tokhtaeva et al., 2009)). Thus, 
ANKRD9 depletion presumably affects glycosylation of proteins after they exit the ER. 
Tunicamycin treatment of cells resulted in a shift towards the unglycosylated form of the 
protein (Fig. 4-9a).  The plasma membrane localization of Na/K ATPase β1-subunit was 
not altered significantly as observed by immunostaining (Fig. 4-9b) or surface 
biotinylation studies (Fig. 4-17).  The Na/K-ATPase consists of one α and one β subunits 
(Kaplan, 2002). To confirm the plasma membrane localization of the fully assembled 
complex at the plasma membrane, cells were immunostained against the Na/K ATPase 
α1-subunit and as expected it was localized to the plasma membrane (Fig. 4-9c). Thus, 
ANKRD9 depletion did not alter the localization of Na/K ATPase to the plasma 
membrane.  
 
Lamp1 is a transmembrane protein that localizes to lysosomes and undergoes N-linked 
glycosylation (Andrejewski et al., 1999).  ANKRD9-downregulation and tunicamycin 
treatment altered the glycosylation pattern of Lamp1, as evidenced by changes in its 
electrophoretic mobility (Fig. 4-10). Lamp 1-immunostained lysosomal structures were 
not altered in ANKRD9-downregulated cells (Fig. 4-4b, Fig. 4-7a). Similar loss of 
glycosylation but targeting fidelity to the compartment was observed for TGN 46, which 
is a glycosylated protein (Prescott et al., 1997). ANKRD9 downregulation or tunicamycin 
treatment both resulted in a shift from the 100 kDa band towards 70 kDa band. Thus, 
ANKRD9 downregulation has a global effect on the glycosylation of proteins located at 
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different regions within the cell and does not appear to alter their targeting/localization 
significantly. 
 
Individual ANKRD9 siRNAs #2 and #3 affect the Golgi structure and protein 
glycosylation similarly to the siRNA pool 
Multiple effects of ANKRD9 depletion (changes in Golgi morphology, loss of complex 
glycosylation and increase of copper levels) suggested that ANKRD9 had either multiple 
roles or more than one protein was affected by siRNA pool directed against ANKRD9 
(off-target effect). In order to determine specificity of siRNA-mediated down-regulation, 
we used individual siRNAs to knock down ANKRD9 in HeLa cells. The degree of 
ANKRD9 depletion and phenotypic consequences were evaluated. The siRNA sequences 
were targeted against different regions of ANKRD9 and had varying effects.  ANKRD9 
siRNA #1 and ANKRD9 siRNA #4 had no apparent effect on Golgi structure (Fig. 4-11). 
By contrast, ANKRD9 siRNA #2 and ANKRD9 siRNA #3 resulted in Golgi 
fragmentation as evidenced by the TGN 46 and ATP7A staining patterns.  Cells 
transfected with ANKRD9 siRNA #2 had more fragmented pattern of Golgi, whereas 
cells transfected with ANKRD9 siRNA #3 had more dispersed pattern of the Golgi. 
ATP7A localized to the TGN under basal conditions (Fig. 4-11) and it trafficked out of 
the TGN in response to copper (Fig. 4-12) in cells transfected with the individual 
ANKRD9 siRNA sequences. 
We then used lysates of ANKRD9 siRNA transfected cells to determine the effect of the 
individual ANKRD9 siRNAs on protein glycosylation (ATP7A, Lamp1 and Na/K 
ATPAse β1-subunit).  ANKRD9 siRNA #1 and ANKRD9 siRNA #4 had no significant 
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effect on ATP7A glycosylation supporting the idea that structure of Golgi and complex 
glycosylation could be linked. In contrast, we observed partially glycosylated 
intermediates of ATP7A with ANKRD9 siRNA #2 and ANKRD9 siRNA #3. ANKRD9 
siRNA #2 resulted in several partially glycosylated intermediates of ATP7A, whereas 
ANKRD9 siRNA #3 yielded one major partially glycosylated intermediate (Fig. 4-13a). 
Similarly, partial glycosylation was observed for Lamp1 and Na/K ATPAse β1-subunit 
with ANKRD9 siRNA #2 and ANKRD9 siRNA #3  (Fig. 4-13b).  
 
To determine whether different effects of individual mRNA correlated with the degree of 
ANKRD9 down-regulation we quantified ANKRD9 mRNA by qPCR after treatment 
with individual siRNAs. Treatment with ANKRD9 siRNA #2, ANKRD9 siRNA #3 and 
ANKRD9 siRNA #4 resulted in a similar 46-56% decrease of ANKRD9 mRNA levels 
(Fig. 4-16a, b). The fact that ANKRD9 siRNA #4 did not affect Golgi structure and 
glycosylation with levels of ANKRD9 depletion comparable to ANKRD9 siRNA #2 and 
#3 suggests the possibility of downregulation of different isoforms of ANKRD9 or off-
target effects. ANKRD9 siRNA #1 did not decrease the ANKRD9 levels significantly, 
and as evidenced from the previous experiments did not have a significant effect on Golgi 
structure and glycosylation. 
ANKRD9 is shown to have five protein coding splice variants (Fig. 4-14).  Multiple 
sequence alignment was performed to compare the sequence similarity between the five 
variants. Only three of the splice variants result in a full length ANKRD9 protein.  Only 
two of the siRNA sequences (ANKRD9 siRNA#1 and ANKRD9 siRNA#3) targeted the 
mRNA sequences encoding all five variants. The primer set used for qPCR detected all 
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five ANKRD9 transcripts (Appendix, Fig. 6-2). Further information regarding the 
ANKRD9 sequences, exons and siRNA target sequences can be found on Fig. 4-14 and 
Appendix, Fig. 6-2. We are currently not sure whether the difference in phenotypes 
observed by different siRNA sequences is due the presence of different isoforms and 
differences in the downregulation efficiency of each isoform. 
 
ANKRD9 depletion results in a significant increase of the copper uptake protein Ctr1 to 
compensate for the “copper-deficient” state of the cells  
The above experiments revealed an interesting link between Golgi structure and protein 
glycosylation, and the possibility that ANKRD9 might be critically involved in these 
processes. Although ATP7A localized to the TGN and trafficked to its correct location in 
ANKRD9-depleted cells, intracellular copper was elevated in these cells.  It is possible 
that the partially glycosylated ATP7A might have lower copper transport activity 
compared to fully glycosylated ATP7A, which would lead to inefficient copper export 
out of the cells. In this part of our study, we focused on the effect of ANKRD9 
downregulation on the copper homeostasis and tried to understand the mechanism 
through which the copper levels are elevated in ANKRD9-depleted cells. 
First, we determined the mRNA levels of proteins known to be involved in copper 
homeostasis in cells transfected with ANKRD9 pool siRNA. We focused on the primary 
high affinity copper uptake protein Ctr1, low affinity copper uptake protein Ctr2, copper 
exporting ATPase ATP7A, and a copper chaperone CCS. A significant 6.5 fold increase 
in the mRNA level of Ctr1 was observed in ANKRD9-depleted cells (Fig. 4-15).  The 
increase in the protein level of Ctr1 was confirmed using individual ANKRD9 siRNA 
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sequences (Fig. 4-17). The mRNA level of Ctr2 was increased 2.2 fold and the mRNA 
level of the copper-exporting ATPase ATP7A was increased 1.8 fold in ANKRD9-
depleted cells (Fig. 4-15). These results demonstrate that the major effect of ANKRD9 
downregulation was on the level of the main copper uptake protein Ctr1.  
Previous studies have demonstrated that Ctr1 mRNA levels are sensitive to treatment 
with high copper or copper chelation. Treating cells with a high copper resulted in a 30-
60% decrease of Ctr1 mRNA levels, whereas copper chelation using BCS resulted in a 
two fold increase of Ctr1 mRNA levels (Song et al., 2008).  Additionally, copper-
independent conditions such as hypoxia and inflammation have been shown to trigger an 
increase in Ctr1 levels (White et al., 2009a; White et al., 2009b; Zheng et al., 2010).  
Therefore the observation that ANKRD9 depletion increases Ctr1 levels by 6.5 fold was 
very interesting. 
It was especially intriguing that the Ctr1 levels were increased when the cells already 
have excess of copper. We hypothesized that the intracellular copper might be 
sequestered and inaccessible, therefore the cells might respond by increasing the level of 
Ctr1. The copper chaperone for superoxide dismutase (CCS) can serve as a marker of 
cellular copper status. Under high copper conditions CCS protein levels are decreased, 
and in response to copper chelation CCS protein levels are increased in cells (Dong et al., 
2014). Similarly, CCS protein levels were increased in rats fed on a copper deficient diet 
(Bertinato et al., 2003; Prohaska et al., 2003). Previous studies found no effect of cellular 
copper status on the mRNA levels of CCS, suggesting that CCS levels in response to 
copper are regulated post-translationally. In order to determine if the ANKRD-depleted 
cells were deprived of available/exchangeable copper despite increase of total copper 
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content, we measured the mRNA level of CCS and we observed 1.8 fold increase in its 
levels (Fig. 4-15). Based on our results, we think that ANKRD9 depletion triggers 
changes within the cells, which result in intracellular sequestration and accumulation of 
copper. The accumulated copper is inaccessible and cells are in a ‘pseudo-copper-
deficient’ state triggering the upregulation of the copper uptake protein Ctr1 as a 
compensatory effect.  
 
ANKRD9 depletion using ANKRD9 siRNA #2, ANKRD9 siRNA #3 or ANKRD9 siRNA #4 
results in increased Ctr1 levels 
We have observed that the individual ANKRD9 siRNA sequences have varying effects 
on Golgi structure and glycosylation of proteins. Therefore, we examined whether the 
mRNA levels of ANKRD9, Ctr1, Ctr2, CCS, and ATP7A are different in response to 
each individual ANKRD9 siRNA (Fig. 4-16).   
Three of the tested siRNA sequences, ANKRD9 siRNA #2, #3 and #4, yielded consistent 
results. All three resulted in significant decrease of ANKRD9 mRNA levels, increase of 
Ctr1 mRNA/protein levels, and increase in CCS mRNA levels (Fig. 4-16). Interestingly, 
ANKRD9 siRNA #4 resulted in decrease of ANKRD9 mRNA levels comparable to 
levels with ANKRD9 siRNA #2 and ANKRD9 siRNA #3, however the increase in Ctr1 
mRNA levels was less significant (2.6 fold increase with ANKRD9 siRNA #4 versus 4 
fold increase with ANKRD9 siRNA #2 and 8 fold increase with ANKRD9 siRNA #3). 
The increase in Ctr1 mRNA and CCS mRNA levels was only observed in cases in which 
the ANKRD9 depletion was significant. It would be interesting to determine whether the 
increase of Ctr1 mRNA/protein levels correlates with the increase of intracellular copper 
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levels and changes in Golgi structure. The levels Ctr2 mRNA were altered depending on 
the siRNA sequence; they increased with ANKRD9 siRNAs #2 and #3 and decreased 
with ANKRD9 siRNA #4. ANKRD9 siRNA #1 did not decrease ANKRD9 mRNA levels 
significantly, and consequently it did not have a significant effect on Ctr1 and CCS 
mRNA levels; however the Ctr2 mRNA levels were decreased by 50%.  We confirmed 
that ANKRD9 downregulation also affected the protein levels of Ctr1. As seen in Fig. 4- 
17, Ctr1 levels were increased in cells transfected with ANKRD9 siRNA #2 (lane 2) and 
ANKRD9 siRNA #3 (lane 4), compared to control cells (lane 1). Similar to the qPCR 
results, ANKRD9 siRNA #3 had more pronounced effect on Ctr1 protein levels.  In 
addition, ANKRD9 depletion resulted in partially glycosylated intermediates of Ctr1.  
The ANKRD9 siRNA #3 had a more pronounced effect on glycosylation than ANKRD9 
siRNA #2. The glycosylation of Ctr1 is normally in a mature form (lane 1), but ANKRD9 
siRNA #3 caused nearly all glycosylation to be a high mannose form (lane 4), as 
demonstrated via EndoH deglycosylation treatment (lane 12). Surface biotinylation was 
used to confirm that Ctr1 was able to traffic to the plasma membrane regardless of its 
immature glycosylation (lanes 6, 8).   Similar results were obtained for Na/K ATPase β 
subunit. Both ANKRD9 siRNA #2 and ANKRD9 siRNA #3 resulted in defects in 
glycosylation of the Na/K ATPase β subunit (Fig. 4-17, lanes 2,4), which was able to 
traffic to the plasma membrane regardless of its glycosylation status (Fig. 4-17, lanes 
6,8). Based on these results both Ctr1 and Na/K ATPase β subunit were able to traffic to 







ANKRD9 was identified as a novel regulator of copper homeostasis thorough a high 
throughput ionomics study and its depletion resulted in increase of intracellular copper 
levels (Malinouski et al., 2014). We characterized the involvement of ANKRD9 in 
copper homeostasis by focusing primarily on the high affinity copper uptake protein Ctr1 
and copper-exporting ATPase ATP7A that are involved in determining copper levels in 
cells. We found that ANKRD9 depletion resulted in significant increase in the levels of 
Ctr1 mRNA and protein, whereas the effect on ATP7A was less significant. Based on 
previous studies, the Ctr1 levels increased in mice fed on copper deficient diet (Nose et 
al., 2010).  Therefore, it was intriguing that in ANKRD9-depleted cells the Ctr1 levels 
were increased despite an increase of intracellular copper. One possible explanation of 
this phenomenon was sequestration of copper in some intracellular “storage” vesicles that 
would render cytosol copper deficient and induce upregulation of Ctr1 to maintain the 
intracellular copper levels.  The levels of the copper chaperone CCS can be used to 
determine the copper content of cells, since CCS protein expression increases in copper 
deficiency (Bertinato et al., 2003). We measured the level of CCS in ANKRD9-depleted 
cells and observed an increase of the CCS mRNA. This result strongly suggests that the 
cells were in a ‘copper-deficient’ state, which explains the increase of Ctr1 mRNA and 
protein levels. This observation also suggests that copper is sequestered within vesicles in 
the ANKRD9-depleted cells. Given the vesicular localization of ANKRD9 (at least for 
the recombinant protein) it is possible that ANKRD9 is involved in the release of copper 
from “copper storage” vesicles. 
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Another interesting finding was that ANKRD9 depletion led to dilation/fragmentation of 
the Golgi cisternae and defects in protein glycosylation.  ANKRD9 depletion primarily 
disrupted the Golgi structure with no detectable effect on the structure of other 
organelles.  We observed dispersed patterns of the cis-medial Golgi and trans-Golgi 
compartments in ANKRD9-depleted cells. The fragmented Golgi compartment appeared 
to retain its Golgi identity as it did not mix with the ER, lysosomes, early endosomes or 
late endosomes. In addition, the glycosylation of proteins such as Ctr1, ATP7A, Na+/K+ 
ATPase, Lamp1 and TGN 46 was impaired, with no significant effect on their 
localization except for the dispersed pattern of TGN 46.   
ATP7A, the major copper-exporting ATPase in HeLa cells was localized to the 
fragmented Golgi compartments.  ATP7A was partially glycosylated and it trafficked in 
response to copper, so the partial glycosylation of ATP7A did not influence its ability to 
traffic from TGN to the plasma membrane in high copper. The effect of partial 
glycosylation on copper export has not been studied yet; therefore no conclusions can be 
made regarding the copper transport activity of ATP7A.  The proposed glycosylation 




RS, localized within the lumenal loops between 
transmembrane segments 1 and 2 and segments 5 and 6, respectively (Liu et al., 2010). 
The partial glycosylation might interfere with the copper transfer from ATP7A to the 
acceptor proteins within the Golgi lumen; copper sequestering vesicles or extracellular 
copper binding proteins.  The lumenal loop M672-P707 was previously shown to be 
involved in transferring copper to an acceptor protein, peptidylglycine monooxygenase 
(Lutsenko et al., 2007; Otoikhian et al., 2012); therefore it is plausible that the partial 
glycosylation might influence the folding of the loops and result in less efficient copper 
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transfer to acceptor proteins. Future studies can use glycosylation-impaired ATP7A and 
measure its copper transport activity to more firmly determine the effect glycosylation on 
ATP7A-mediated copper transport from cells.  A second possibility is that glycosylation 
of ATP7A might protect it from degradation, therefore the partially glycosylated ATP7A 
might have a shorter half life compared to its fully glycosylated version. 
In addition, the glycosylation of the high affinity copper uptake protein Ctr1 was 
impaired by ANKRD9 depletion. Ctr1 undergoes both N-linked and O-linked 
glycosylation (Maryon et al., 2007). The N-linked glycosylation occurs at its N-terminus 
at the Asn15 residue; however impairing N-linked glycosylation has no obvious effect on 
the half life of Ctr1, or cell surface targeting of Ctr1. However, the Asn
15
Gln Ctr1 
mutant, which lacks N-linked glycosylation, has a lower copper transport activity 
(decreased by 25%) in comparison to the wild-type Ctr1 protein (Eisses and Kaplan, 
2002; Klomp et al., 2002; Klomp et al., 2003; Maryon et al., 2007). O-linked 
glycosylation occurs at Thr 27, and it protects Ctr1 from proteolytic degradation. 
Inhibiting O-linked glycosylation of Ctr1 results in a removal of 30 amino acids from its 
N-terminus producing a cleaved form of Ctr1, which has lower copper uptake efficiency 
(about 50%) compared to the full length Ctr1 protein (Maryon et al., 2007). It appears 
that both the N-linked and O-linked glycosylation are required for efficient copper 
transport by Ctr1.  Our data suggests that defects in N-linked glycosylation are 
responsible for the partially glycosylated Ctr1 protein. Since the copper transport activity 
of Ctr1 lacking N-linked glycosylation was decreased, it is possible that the partially 
glycosylated Ctr1 can transport copper less efficiently to meet the cellular needs, which 
might explain the upregulation of Ctr1 levels. Further studies will focus on copper uptake 
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and export out of the cells using radioactive Cu
64
 to determine which step is affected due 
to ANKRD9 downregulation.  
 
We cloned ANKRD9 and observed it to be localized to cytoplasmic vesicles. Ctr1 is 
endocytosed in response to high copper, therefore we would like to compare the 
localization of Ctr1 and ANKRD9 and determine whether under high copper conditions 
they are localized to the same vesicular compartments.  Additionally, we observed that 
Flag-ANKRD9 is a monomeric protein with two major bands, which raises the possibility 
that it might be modified post-translationally, such as palmitoylation which might recruit 
ANKRD9 to the vesicular membranes. 
 
In order to determine the specificity of ANKRD9 downregulation, individual ANKRD9 
siRNAs were used.  ANKRD9 siRNA #2 and ANKRD9 siRNA #3 had an effect on Golgi 
structure and protein glycosylation, whereas ANKRD9 siRNA #4 had no effect although 
it has similar downregulation efficiency. ANKRD9 #2, ANKRD9 #3 and ANKRD9 #4 
resulted in an increase of Ctr1 levels.  Copper levels in cells transfected with ANKRD9 
siRNAs #2, #3 and #4 will be measured to determine whether the increase of Ctr1 
mRNA/protein levels correlates with the increase of intracellular copper levels and 
changes in Golgi structure. Further studies will focus on understanding the mechanisms 
through which the copper uptake is increased in ANKRD9-depleted cells. Specificity of 
the phenotype will be further confirmed by transfecting ANKRD9-depleted cells with 




ANKRD9 depletion resulted in Golgi fragmentation and specific elevation of copper. We 
wanted to determine whether Golgi fragmentation and elevation of copper levels are 
linked events. Based on several studies which have identified proteins important for 
maintaining the Golgi integrity, and comparing the copper levels obtained from our high 
throughput ionomics screen in response to downregulation of these proteins, we observed 
that the Golgi fragmentation not always was associated with increase in copper levels 
(details are listed below).  
Golgi is a complex organelle consisting of stacks of cisternae. It is important for the 
anterograde (and sometimes retrograde) trafficking and sorting of proteins. Glycosylation 
of proteins and lipids in mammalian cells occurs in the Golgi and it is a highly ordered 
process. Therefore the Golgi structure is arranged in cisternae with a particular set of 
glycosyltransferase enzymes residing in each of them, ensuring the sequential processing 
of glycans. The conserved oligomeric Golgi complex (COG complex) is a tethering 
complex, which plays an important role in Golgi glycosylation. It is a hetero-oligomer 
consisting of eight subunits, COG1–COG8. Disruption to the COG complex results in 
mislocalization of the glycosyltransferase enzymes and interferes with normal protein 
glycosylation in the medial and/or trans-Golgi (Pokrovskaya et al., 2011). 
Cells transiently transfected with COG3 siRNA have fragmented Golgi, and defective 
protein glycosylation. The partially glycosylated proteins Lamp2 and CD44 were 
localized to their correct compartments following COG3 knockdown, demonstrating that 
it does not affect anterograde trafficking and protein sorting. In these cells medial-Golgi 
enzymes were severely mislocalized (Shestakova et al., 2006). ICP-MS data shows that 
COG3 knockdown resulted in increase of copper levels (Cu-fold change: 1.369, Cu-z 
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score: 4.328). In contrast, knockdown of the other COG subunits has no effect on copper 
levels. For example, COG7 knockdown results in Golgi fragmentation, mislocalization of 
several glycosyltransferases and defective protein glycosylation of LAMP2 and CD44 
(Shestakova et al., 2006), with no significant effect on the copper levels (Cu-fold change: 
0.996, Cu-z score: -0.078). Other proteins shown to cause Golgi fragmentation are the 
centromere/kinetochore protein ZW10 and a RAD50-interacting protein RINT-1 (Sun et 
al., 2007).  The copper levels in HeLa cells with downregulation of either proteins was as 
follows:  ZW10 siRNA (Cu-fold change: 1.000, Cu-z score: -0.051), RINT-1 siRNA (Cu-
fold change: 0.848, Cu-z score: -2.717). The siRNA transfections need to be repeated to 
confirm that they result in Golgi fragmentation in HeLa cells with no increase in copper 
levels; however it appears that the Golgi fragmentation and increase of copper levels are 
independent events (i.e. Golgi fragmentation can occur without copper increase and vice 
versa). 
The target binding proteins of ANKRD9 and its intracellular localization have not been 
identified; therefore currently we are not sure about the sequence of events causing the 
increase in intracellular copper levels observed by ANKRD9 downregulation: Golgi 
fragmentation, defects in glycosylation of proteins, copper sequestration, and possible 
increase of copper uptake or possible decrease of copper export. The possibilities are that 
copper misbalance induces Golgi fragmentation and defects in glycosylation or vice 
versa. Copper misbalance can be induced if ANKRD9 is involved in targeting and 
trafficking of Ctr1 or ATP7A in cells either directly or indirectly which would result in 
copper accumulation triggering Golgi fragmentation and defects in glycosylation. 
Another possibility is that ANKRD9 is involved in maintaining Golgi structure either 
116 
 
directly by being localized to the Golgi membranes or indirectly by the influencing the 
targeting of another Golgi resident structural protein. The third possibility is that 
ANKRD9 is involved in the targeting of a channel, pump, or glycosyltransferases to the 
Golgi. Further studies will focus on understanding the mechanisms through which the 
copper uptake is increased in ANKRD9-depleted cells. 
 
Materials and Methods 
Cell lines: HeLa cells (obtained from ATCC) were maintained in DMEM supplemented 
with 10 % FBS and 1 % pen/strep at 37 ºC in a 5% CO2 incubator. 
siRNA transfection: Dharmacon’s Wet Reverse Transfection Protocol was used for the 
transfection of HeLa cells. ANKRD9 siRNA was used at final concentration of 5 nM or 
20 nM for individual siRNA sequences or 20 nM for the pool (human siGenome 
ANKRD9 siRNA, M-015551-01, Dharmacon). Dharmafect I was used as a transfection 
reagent. 72 h after transfection cells were harvested or fixed for immunostaining.  
Treatments with tunicamycin, excess copper and copper chelation: Cells were treated 
with 10 µg/ml Tunicamycin overnight. Copper treatment was done with 200 µM CuCl2 
for 5 h and copper chelation was done using 100 µM bathocuproine disulfonate (BCS) 
for 3 h.  
Immunohistochemistry with organellar markers: For the TGN46, Lamp1, Calreticulin, 
Gpp130 and ATP7A immunostaining the following protocol was used. Cells were fixed 
using 3% paraformaldehyde at 37ºC for 12 min. Cells were washed with 1X PBS and 
blocked/permeabilized simultaneously for 12 min using 1% BSA/ 1% saponin in 1X 
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PBS. Cells were washed with 1X PBS and then incubated with appropriate primary and 
secondary antibodies diluted in 0.5 % BSA in 1X PBS. (Primary antibodies: mouse anti-
ATP7A antibody 1:250 (Santa Cruz), rabbit anti-ATP7A antibody 1:300 (Hycult 
Biotech), sheep anti-TGN46 1:300 (Genetex), mouse anti-Lamp1 1:500 (Developmental 
Studies Hybridoma Bank), rabbit anti-Gpp130 1:500 (Covance), rabbit anti-calreticulin 
1:300 (Stressgen) . Secondary antibodies: Alexa Fluor 488 Goat anti mouse antibody 
1:500 (Invitrogen), Alexa Fluor 555 donkey anti sheep 1:500 (Invitrogen), Alexa Fluor 
555 donkey anti mouse 1:500 (Invitrogen), Alexa Fluor 488 donkey anti rabbit 1:500 
(Invitrogen), Alexa Fluor 555 Goat anti rabbit antibody 1:500 (Invitrogen). The glass 
slides were mounted using Fluoromount G w/DAPI (Electron Microscopy Sciences).  
Images were taken using a Zeiss LSM 510 confocal microscope and a 40x oil or 100x oil 
immersion objective. 
Immunohistochemistry with Na/K ATPase antibodies: Cells were washed with 1X PBS 
and fixed/permeabilized using cold (-20°C) acetone for 30 sec. Cells were washed with 
1X PBS and blocked overnight with blocking solution (1% BSA, 2% goat serum in PBS). 
Cells were washed with 1X PBS and then incubated with the appropriate primary and 
secondary antibodies.  The primary antibodies were diluted in 1% BSA, 0.2% saponin in 
1X PBS and cells were immunoprobed for 3 h.  The secondary antibodies were diluted in 
blocking solution and cells were immunoprobed for 1h at 37 °C (Primary antibodies: 
mouse anti-Na/K ATPase β subunit 1:1000 (Affinity Bioreagents), mouse anti-Na/K 
ATPase α1 subunit 1:1000 (Millipore), and sheep anti-TGN46 1:300 (Genetex); 
Secondary antibodies: Alexa Fluor 488 Goat anti mouse antibody 1:500 (Invitrogen) and 
Alexa Fluor 555 donkey anti sheep 1:500 (Invitrogen)).  The glass slides were mounted 
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using Fluoromount G w/DAPI (Electron Microscopy Sciences).  Images were taken using 
a Zeiss LSM 510 confocal microscope and a 40x oil or 100x oil immersion objective. 
Immunohistochemistry with endosomal markers: Cells were washed with 1X cold PBS, 
followed by 2 min incubation on ice with 0.025% saponin in PHEM buffer. Cells were 
incubated twice for 2 min with  0.025% saponin/8% sucrose in PHEM buffer, and fixed 
for 30 min at room temperature with 4% paraformaldehyde in 1X PBS (PHEM buffer: 60 
mM PIPES, 25 mM HEPES, 10 mM EGTA, 2 mM MgCl2). Cells were washed with 1X 
PBS and blocked using blocking buffer (1% BSA, 0.025% saponin in 1X PBS) for 1 h. 
Cells were washed with 1X PBS and then incubated with the appropriate primary and 
secondary antibodies diluted in blocking buffer. (Primary antibodies: sheep anti-TGN46 
1:300 (Genetex), mouse anti EEA1 1:300 (BD Biosciences) and mouse LBPA 1:100 
(Echelon Biosciences). Secondary antibodies: Alexa Fluor 555 donkey anti mouse 
antibody 1:500 (Invitrogen) and Alexa Fluor 488 donkey anti sheep 1:500 (Invitrogen)). 
The glass slides were mounted using Fluoromount G w/DAPI (Electron Microscopy 
Sciences).  Images were taken using a Zeiss LSM 510 confocal microscope and a 40x oil 
or 100x oil immersion objective. 
Western blotting: Cells were harvested, the pellet was resuspended in Laemmli loading 
buffer, sonicated for 30 sec and centrifuged for 15 min at 3000 g at 4 ºC. The supernatant 
was loaded to 8 % or 12% SDS gel. Proteins were transferred to a PVDF membrane 
using CAPS buffer, pH 11.0. The membrane was cut at 130 kDa and probed using mouse 
anti-Na/K ATPase α1 subunit (1:10000, Millipore), mouse anti-ATP7A (1:3000, Santa 
Cruz), mouse anti-Na/K ATPase β subunit (1:10000, Affinity Bioreagents), sheep anti-
TGN 46 (1:3000, Genetex), or mouse anti-Lamp1 (1:5000, Developmental Studies 
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Hybridoma Bank).  Goat anti mouse Igg-HRP (1:10000, Santa Cruz) or donkey anti 
sheep Igg-HRP (1:10000, Santa Cruz) was used as a secondary antibody and the 
membranes were developed using a SuperSignal West Pico Substrate (Thermo 
Scientific). 
Electron microscopy sample preparation: Cells were rinsed using warm 1X PBS, and 
fixed using 2% glutaraldehyde (2% paraformaldehyde, 0.1 M NaCacodylate, 3 mM 
CaCl2 pH 7.2-7.4) for 1 hr at RT. Cells were washed three times for 10 min each using a 
solution containing 0.1 M Na Cacodylate, 3% sucrose, and 3mM CaCl2. Cells were 
incubated on ice for 1 h in dark in a solution containing 1% OsO4, 0.8% KFeCn6, 0.1M 
NaCacodylate, and 3mM CaCl2. Cells were rinsed twice for 5 min using water. Cells 
were incubated for 1 hr in dark in 2% uranyl acetate. Cells were washed for 5 min using 
30% ethanol, 50% ethanol, 70% ethanol, and 90% ethanol, followed by three washes for 
5 min with 100% ethanol. Cells were incubated overnight with 100% embedding resin 
(Epon (1:1 A:B)) (Electron Microscopy Sciences). Next day the resin was changed three 
times with  Epon (1:1 A:B) containing 1.5% DMP-30 catalyst and a 15 psi vacuum step 
for 2 h was included during each incubation. The resin was dried 3 days at 37°C oven for 
three days, followed by and overnight incubation at 60°C. Ultra thin sections were cut, 
placed on grids and imaged using Hitachi 7600 transmission electron microscope. 
Cloning of Flag tagged ANKRD9: ANKRD9 was amplified from cDNA obtained from 
HeLa cells using the following primers: Nhe I restriction site/Flag tag containing Fwd 
primer (CGGCTAGCATGGATTACAAGGATGACGACGATAAGATGCCGTGGG 
ACG) and Hind III restriction site containing Rev primer (AAAAGCTTCTAG 
CCTTTGCCAGTGAGG). The amplified fragment was digested using Nhe I and Hind III 
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restriction enzymes and ligated into an expression vector pcDNA 3.1(+) (Invitrogen) 
digested with the same enzymes. The vector was sequenced and mutations were not 
detected.  
Transient transfection of HeLa cells with Flag-ANKRD9: HeLa cells were grown on 
coverslips and transfected with 2 µg of Flag-ANKRD9 using Lipofectamine-2000 
(Invitrogen) according to manufacturer’s instructions.  16 h after transfection cells were 
either harvested for western blotting or fixed for immunostaining. Cells were rinsed with 
1X PBS and fixed in cold acetone-methanol mixture (1:1) for 30 sec. The cells were 
blocked in blocking buffer (1 % gelatin, 1 % BSA in PBS) and then incubated with 
appropriate primary and secondary antibodies diluted in blocking buffer. (Primary 
antibody: mouse anti-Flag antibody 1:300 (Sigma) and rabbit anti-Gpp130 1:500 
(Covance). Secondary antibody: Alexa Fluor 488 Goat anti mouse antibody 1:500 
(Invitrogen) and Alexa Fluor 555 goat anti rabbit 1:500 (Invitrogen)).  The glass slides 
were mounted using Fluoromount G w/DAPI (Electron Microscopy Sciences).  Images 
were taken using a Zeiss LSM 510 confocal microscope and a 100x oil immersion 
objective. For Western blotting, cells were harvested, the pellet was resuspended in 30 µl 
of Laemmli loading buffer, sonicated for 30 sec and centrifuged for 15 min at 3000 g at 
4 ºC. The supernatant was loaded to 8 % SDS gel. Proteins were transferred to a PVDF 
membrane using CAPS buffer, pH 11.0. The membrane was probed for Flag-ANKRD9 
using Flag antibody (1:5000, Sigma). Goat anti mouse Igg-HRP (1:10000, Santa Cruz) 
was used as a secondary antibody and the membranes were developed using a 
SuperSignal West Pico Substrate (Thermo Scientific). 
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Measurement of copper levels using atomic absorption spectroscopy: Cells transfected 
with siRNAs were counted and 1x10
6
 cells were pelleted in an Eppendorf tube. 100 µl of 
concentrated HNO3 was added to the pellet and the tubes were incubated at 50°C for 30 
min. 25 µl of the solution was mixed with 115 µl water and copper content was measured 
using SHIMADZU AA - 6650 Atomic Absorption Spectrophotometer. 
Biotinylation of Surface CTR1. All biotinylation procedures were carried out at 4ºC or on 
ice. Cell surface proteins in siRNA-transfected cells were labeled with cell-impermeable 
Sulfo-NHS-SS-biotin (Pierce) reagent. Plates were placed on ice and cells were washed 
with cold 1X PBS. EZ-Link Sulfo-NHS-biotin was diluted in biotinylation buffer (10 
mM trithanolamine, pH 7.5,    2 mM CaCl2, and 150 mM NaCl) at a final concentration 
of 0.5 mg/ml and added to the cells. Cells were incubated on ice for 30 min with a slow 
rocking motion. Cells were rinsed twice with quench buffer (100 mM glycine in 1X PBS) 
for 20 min. The buffer was aspirated, cells were harvested and incubated in lysis buffer 
(1% Triton-X-100, 150 mM NaCl, 5  mM EDTA, and 50 mM Tris-HCl, pH 7.5) for 1h. 
Cells were centrifuged at 10000g for 10 min, and an aliquot was taken. The remaining 
supernatant was incubated with streptavidin-agarose beads (Pierce) in a centrifuge spin-
column (Pierce) overnight at 4ºC. The column was centrifuged at 500g for 3 min at 4ºC 
to remove the buffer. The beads were washed three times with lysis buffer, twice with 
salt wash buffer ( 500 mM EDTA, 0.1% Triton-X-100 and 50 mM Tris, pH 7.5) followed 
by a single wash with 10 mM Tris, pH 7.5 solution. The column was centrifuged at 
10000g for 10 min at 4ºC. The protein elution was done by adding 100 µL of 2X-SDS 
PAGE sample buffer containing 150 mM dithiothreitol and incubating the column 
overnight. The sample was centrifuged at 3000g for 5 min to elute the biotinylated 
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protein from the beads. Samples were separated by SDS-PAGE, and Ctr1 and Na/ K 
ATPase β 1 subunit was detected using Western blot analysis. 
 
RNA isolation and quantitative PCR: HeLa cells were transiently transfected with the 
indicated siRNA or NT RNA control and cells were harvested. RNA was isolated using 
RNeasy Mini Kit (Qiagen) and cDNA was prepared using Transcriptor First Strand 
cDNA Synthesis Kit (Roche). RNA or cDNA was used as a template and real-time PCR 
was performed using Power SYBR Green master mix (Applied Biosystems). The 
following primer sequences were used: Ctr1-Fwd (GACCAAATGGAACCATCCTT), 
Ctr1-Rev (ATGACCACCTGGATGATGTG), Ctr2-Fwd (TCAGATTCATTCCCTGT 
TGG), Ctr2-Rev (GCATGATGAAGTAGCCGATG), ANKRD9-Fwd (ACATCCC CGG 
AACTAGGTGA), ANKRD9-Rev (GTAGAAGGCGAACGACGACT), GAPDH-Fwd 
(CATCAATGGAAATCCCATCA), GAPDH-Rev (GACTCCACGACGTACTCAGC), 
ATP7A-Fwd (TGGTTCAAATTGATGCCAGT), ATP7A-Rev (CCGGTTACCAATGA 
GGACTT), CCS-Fwd (CAACAGCTGTGGGAATCACT), CCS-Rev (AGCTGCTCA 










Figure 4-1. Flag-ANKRD9 localizes mainly to cytoplasmic vesicles and ANKRD9 knockdown results 
in increased copper levels. (a) Multiple sequence alignment of ANKRD9 protein sequences. (b) Pymol 
model of ANKRD9. ANKRD9 consists of several alpha helices and loops. Alpha helices are shown in blue 
color and loops are shown in pink color. A single ankyrin repeat sequence (amino acids 158-190) is shown 
in green color.  (c) HeLa cells were transiently transfected with Flag-ANKRD9. Fixed cells were 
immunostained using antibodies against Flag-ANKRD9 and cis- medial Golgi (Gpp130) (Scale bar:10µm)  
(d) Cells lysates from transfected cells were used for immunoblotting against Flag-ANKRD9 using Flag 
antibody. Two major bands around 35kDa were detected corresponding to the monomeric size of 
ANKRD9. (e) Following gene-specific knockdowns, metal contents were measured using ICP-MS 
(Inductively coupled plasma mass spectrometry). Shown is the effect of ANKRD9 downregulation on 
intracellular metal content of cells. (f) Fold change of different metals in ANKRD9 downregulated cells. 






Figure 4-2. ANKRD9 knockdown results in increased copper levels and changes in Golgi structure 
and ATP7A localization.  HeLa cells were transfected with 20 nM NT (non-targeting), ANKRD9 pool 
siRNA or ATP7A pool siRNA, and harvested for copper content measurement/qPCR or fixed for 
immunostaining. (a) Copper levels in ANKRD9-siRNA and ATP7A-siRNA transfected cells are increased, 
as measured using AAS (atomic absorption spectrophotometer). (b) ANKRD9 mRNA levels are decreased 
in ANKRD9-siRNA transfected cells as determined by qPCR. (c) ANKRD9 downregulation causes 
dispersion of trans-Golgi network (TGN 46) (red, middle panel) and ATP7A (green, left panel)  (Scale bar: 
10µm). (d) ANKRD9 downregulation causes dispersion of Gpp130 cis-medial Golgi (Gpp130) (red, middle 














Figure 4-3. ANKRD9 downregulation results in Golgi dilation and fragmentation. Electron 
microscopy analysis of HeLa cells transiently transfected with non-targeting (NT) siRNA or ANKRD9 
pool siRNA. Different magnifications are shown. Asterics mark the Golgi region. In NT siRNA-transfected 
cells Golgi structure is characterized by ribbons (left panels), whereas in ANKRD9-downregulated cells 
(middle and right panels) Golgi is fragmented and enlarged (phenotype depends on downregulation 






Figure 4-4. ANKRD9 depletion does not affect the structure of endoplasmic reticulum (ER) and 
lysosomes, and dispersed ATP7A does not mis-localize to lysosomes. Following siRNA transfection 
with non-targeting (NT) siRNA or ANKRD9 pool siRNA cells were fixed, immunostained and analyzed by 
confocal microscopy.  (a) ATP7A and ER (calreticulin) immunostaining or (b) ATP7A and lysosomes 























Figure 4-5.  ANKRD9 downregulation results in changes in electrophoretic mobility of ATP7A, 
decreased ATP7A protein and increased ATP7A mRNA levels. HeLa cells were transfected with NT 
(non-targeting) or ANKRD9 pool siRNA. Cells lysates were used for immunoblotting against ATP7A and 
Na/K ATPase. (a) ATP7A glycosylation was affected as a result of ANKRD9 downregulation. A 
representative blot is shown. Tunicamycin treatment was used to inhibit N-linked glycosylation resulting in 
a lower molecular weight band which is the unglycosylated ATP7A. (b) Quantification of western blot data 
by densitometry. The ATP7A protein levels were normalized to Na/K-ATPase protein levels and the values 
were compared with the intensity of ATP7A in cells transfected with a non-targeting siRNA (NT siRNA). 
The error bars correspond to s.d. values from four independent experiments. (c) ATP7A mRNA levels in 
NT (non-targeting) or ANKRD9 pool siRNA-transfected HeLa cells. GAPDH mRNA levels were used as 









Figure 4-6. ANKRD9 depletion results in partial overlap or no overlap between cis-medial Golgi and 
trans-Golgi compartments. HeLa cells transiently transfected with non-targeting (NT) siRNA or 
ANKRD9 pool siRNA were immunostained using antibodies against cis-medial Golgi (Gpp130) (left 
panel, green) and trans-Golgi (TGN46) (middle panel, red). Partial overlap is observed in control cells 
transfected with NT siRNA and some cells transfected with ANKRD9 siRNA. In some cases no significant 
















Figure 4-7.  Trans-Golgi organelles do not localize to lysosomes, early endosomes or late endosomes 
in ANKRD9-depleted cells. HeLa cells were transiently transfected with non-targeting (NT) siRNA or 
ANKRD9 pool siRNA and immunostained using antibodies against Trans-Golgi network (TGN 46) and (a) 
lysosomes-Lamp1, (b) early endosomes-EEA1 (c) and late endosomes-LBPA and analyzed by confocal 
microscopy (Scale bar:10µm).(Intensity of red signal in ANKRD9-depleted cells was increased to match 







Figure 4-8. ATP7A traffics out of the Golgi and to the plasma membrane in response to copper in 
ANKRD9-donwregulated cells. Following siRNA-mediated knockdown with non-targeting (NT) siRNA 
or ANKRD9 pool siRNA, HeLa cells were kept under basal conditions or treated with 200 µM CuCl2 for 5 
h, and immmunostained with antibodies for ATP7A (green) and TGN46 (red) (Scale bar:10µm). ATP7A 
traffics out of the TGN in response to copper in both NT siRNA (panel a) and ANKRD9 siRNA (panel b) 
transfected cells. ATP7A also localizes to the plasma membrane in copper treated cells (panel c, asterisk 
mark the cells with plasma membrane staining of ATP7A, intensity of green signal was increased to show 







Figure 4-9. ANKRD9 downregulation influences glycosylation of Na/K ATPase (β subunit), but its 
plasma membrane localization is not altered significantly. (a) Following siRNA-mediated knockdown 
with non-targeting (NT) siRNA or ANKRD9 pool siRNA, HeLa cell lysates were used for immunoblotting 
against Na/K ATPase (β subunit). Glycosylation of Na/K ATPase (β subunit) was affected as a result of 
ANKRD9 downregulation resulting in a high mannose glycosylated form. Tunicamycin treatment was used 
to inhibit N-linked glycosylation resulting in a proportion of unglycosylated Na/K ATPase (β subunit). A 
representative blot is shown. (b) Cells were fixed, immmunostained with antibodies against Na/K ATPase 
(β and α1 subunits) (green) and TGN46 (red) and analyzed by confocal microscopy (left panels (40x 
images)-scale bar:25µm, right panels (100x images)-scale bar:10µm). Na/K ATPase localized to the plasma 







Figure 4-10. ANKRD9 depletion influences glycosylation of Lamp1 and TGN46. Following siRNA-
mediated knockdown with non-targeting (NT) siRNA or ANKRD9 pool siRNA, and treatment with 
tunicamycin, HeLa cell lysates were used for immunoblotting against Lamp1 (a) or TGN 46 (b). 
Representative blots are shown. (a) ANKRD9 downregulation results in changes in glycosylation pattern of 
Lamp1, resulting in 2 bands. (b) ANKRD9 downregulation results in changes in glycosylation pattern of 
TGN 46, resulting in a shift of TGN 46 protein bands from 100 kDa towards 70 kDa. Tunicamyin treatment 




Figure 4-11. ANKRD9 siRNAs #2 and #3 affect ATP7A localization and Golgi structure, whereas 
ANKRD9 siRNAs #1 and #4 have no significant effect on ATP7A localization and Golgi structure. 
HeLa cells were transfected with 5 nM NT (non-targeting), individual ANKRD9 siRNAs (numbered 1-4) 
or 20 nM ANKRD9 pool siRNA. Cells were immunostained using antibodies against ATP7A (green, left 
panel) and trans-Golgi network (TGN 46) (red, middle panel).  Shown are 100x images, (Scale bar: 10µm) 
(a) and 40x images (Scale bar: 25µm) (b).  ANKRD9 downregulation using ANKRD9 siRNA #2, 
ANKRD9 siRNA #3 and ANKRD9 pool siRNA causes dispersion of TGN 46 and ATP7A. ANKRD9 










Figure 4-12. ATP7A traffics out of the Golgi in response to copper in ANKRD9-depleted cells. HeLa 
cells were transfected with 5 nM NT (non-targeting), individual ANKRD9 siRNAs (numbered 1-4) or 
20 nM ANKRD9 pool siRNA. 72 h after transfection cells were treated with 200 µM CuCl2 for 5 h and 
fixed for immunostaining. Cells were immunostained using antibodies against ATP7A (green, left panel) 
and trans-Golgi network (TGN 46) (red, middle panel). Shown are 100x images (Scale bar:10µm) (a) and 





Figure 4-13. Depletion of ANKRD9 using individual ANKRD9 siRNA sequences results in shifts of 
electrophoretic mobility of ATP7A, Lamp1 and Na/K ATPase (β subunit). Following siRNA-mediated 
knockdown with 20nM of non-targeting (NT) siRNA, ANKRD9 individual siRNAs  or ANKRD9 pool 
siRNA, HeLa cell lysates were used for immunoblotting for ATP7A, Na/K ATPase (α1 subunit), Lamp1 
and  Na/K ATPase (β subunit). A representative blot is shown. (a) ANKRD9 siRNA #2 and ANKRD9 
siRNA #3 result in changes of glycosylation of ATP7A, and ANKRD9 siRNA #1 and ANKRD9 siRNA #4 
have no effect.  (b) ANKRD9 siRNA #2 and ANKRD9 siRNA #3 result in changes of glycosylation of 
Lamp1 (upper panel) and Na/K ATPase (β subunit) (lower panel), and ANKRD9 siRNA #1 and ANKRD9 





Figure 4-14. Information about ANKRD9 transcripts and siRNA targeting regions. (a)ANKRD9 has 
five protein coding splice variants (transcripts). (b) Clustal W multiple sequence alignment of the 
ANKRD9 splice variants and targeting sites of the ANKRD9 siRNA sequences. (c) ANKRD9 








Figure 4-15. Depletion of ANKRD9 affects copper homeostasis genes.  Following siRNA-mediated 
knockdown with 20nM of non-targeting (NT) siRNA, or ANKRD9 pool siRNA, HeLa cell lysates were 
used for RNA isolation. mRNA levels of ANKRD9, ATP7A, Ctr1, Ctr2 and CCS were determined using 
qPCR. GAPDH mRNA levels were used as internal control. (a) Bar graph demonstrating mRNA levels in 
ANKRD9 downregulated cells. ANKRD9 downregulation results in increase of ATP7A, Ctr1, Ctr2 and 
CCS mRNA levels. The error bars correspond to s.d. values from three independent experiments. (b) Table 





Figure 4-16. Effect of individual ANKRD9 siRNA sequences on copper homeostasis. Following 
siRNA-mediated knockdown with 20nM of non-targeting (NT) siRNA, or ANKRD9 individual siRNAs 
(labeled 1-4), HeLa cell lysates were used for RNA isolation. mRNA levels of ANKRD9, ATP7A, Ctr1, 
Ctr2 and CCS were determined using qPCR. GAPDH mRNA levels were used as internal control. (a) Bar 
graph demonstrating mRNA levels in ANKRD9 downregulated cells. The error bars correspond to s.d. 










Figure 4-17. ANKRD9 depletion results in increased protein amount of high mannose Ctr1 that can 
traffic to the plasma membrane regardless of its immature glycosylation. Following siRNA-mediated 
knockdown with 5nM of non-targeting (NT) siRNA, Ctr1 siRNA, ANKRD9 siRNA #2 or ANKRD9 
siRNA #3, cell surface proteins were biotinylated, cells were lysed and biotinylated cell surface proteins 
were isolated.  Endoglycosidase H  (EndoH) was used to remove high mannose N-glycans.  Shown is a 
western blot of total cell lysate (input) or eluted cell surface  protein samples (biotinylated) probed with an 
antibody to Ctr1 or Na/K ATPase (β1 subunit). Ctr1 siRNA was used as a control to verify Ctr1 bands in 
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The studies described in this thesis were focused on understanding different modes of 
regulation of copper homeostasis in human cells. Our experiments determined the role of 
a kinase mediated phosphorylation in trafficking of the copper-transporting ATPase 
ATP7B (Chapter 2), identified and provided initial characterization of novel regulators of 
copper homeostasis (Chapter 3), and investigated the cellular function of the adaptor 
protein ANKRD9, especially its role in copper homeostasis (Chapter 4). 
Prior to this work, it was known that kinase mediated phosphorylation and trafficking of 
the copper exporting ATPases ATP7A and ATP7B to vesicles might be linked events 
(Vanderwerf et al., 2001), however the exact role of kinase mediated phosphorylation in 
trafficking had not been determined. We characterized the role of the predicted 
phosphorylation sites Ser340 and Ser341 residues in the kinase-mediated 
phosphorylation, subcellular localization, structure and activity of ATP7B. We 
determined that Ser340 and Ser341 are involved in the exit of ATP7B from the trans-
Golgi network (TGN) and identified the mechanism through which this event occurs.  
Both serine residues are important for copper-dependent kinase-mediated 
phosphorylation and modification of these residues minimizes interactions between the 
N-terminal domain and the nucleotide binding domain. We conclude that the role of a 
kinase-mediated phosphorylation is to maintain an “open” conformation of ATP7B and 
that stabilization of this state is the key trigger of ATP7B trafficking to vesicles. We 
propose that trafficking of ATP7B in response to elevated copper is initiated by structural 
changes, induced by copper binding to the regulatory N-terminal domain.  These 
structural changes disrupt interdomain contacts allowing access to a kinase and 
phosphorylation of residues 340/341. Phosphorylation at these (and possibly other) 
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residues stabilizes and maintains the “trafficking-compatible” state  in which ATP7B is 
sorted to exit sites for further relocation to vesicles. 
Information about proteins regulating trafficking of Cu-ATPases is very limited.  The 
role of AP1 protein complex  and CD42 kinase in trafficking of ATP7A has been directly 
demonstrated  (Holloway et al., 2013) and ATP7A was found among proteins associated 
with WASH trafficking complex (Ryder et al., 2013). The studies on ATP7B point to the 
role of glutaredoxin, protein kinase D is trafficking of this Cu-ATPases. Our data from 
the ionomic screen suggest that copper homeostasis is maintained mostly by trafficking 
and post-translational modifications. Knockdown of IBTK, CAMK2N2, DNAJC5, 
DNAJC17, ABCC3, ANKRD9, and SLC6A4 resulted in elevation of intracellular copper 
levels. Our initial studies revealed that out of seven tested targets, down-regulation of five 
had a significant effect on ATP7A. This result emphasizes that ATP7A is primarily responsible 
for maintaining cellular copper balance in HeLa cells. Novel regulators of ATP7A, which alter 
its post-translational modification status (phosphorylation and glycosylation), were 
characterized. The depletion of the kinase inhibitors IBTK (inhibitor of Bruton tyrosine 
kinase) and CAMK2N2 (calcium/calmodulin-dependent protein kinase II inhibitor 2) 
resulted in a significant decrease in ATP7A protein levels. The involvement of these 
kinase inhibitors in phosphorylation of ATP7A have not been previously known or 
considered, and controlling the ATP7A levels through kinase mediated phosphorylation 
is a novel possible mechanism of maintaining copper homeostasis.  Further studies will 




Finally, we found that in HeLa cells ANKRD9 (ankyrin repeat domain-containing protein 
9) plays a role in maintenance of Golgi flat stacks and/or proper glycosylation of 
proteins, and contributes to cellular copper homeostasis. ANKRD9 depletion resulted in 
partial glycosylation of ATP7A and decreased protein levels; raising the possibility that 
proper glycosylation is needed for the stability of ATP7A. Since ATP7A trafficked in 
response to copper (i.e. copper export was normal) but total levels of copper in a cell 
were nevertheless increased we examined other copper homeostasis related proteins in 
ANKRD9-depleted cells. Unexpectedly, ANKRD9 depletion led to a significant increase 
in the levels of the copper uptake protein, Ctr1 and the copper chaperone CCS mRNA 
levels.  Both these proteins are known to be regulated by copper deficiency suggesting 
that the cells were in ‘copper-deficient’ state, and that excess copper was sequestered 
(possibly in vesicles) and not available. Given the vesicular localization of recombinant 
ANKRD9 it is possible that ANKRD9 is involved in the release of copper from “copper 
storage” vesicles and that upon its depletion copper is trapped and unavailable.  
It is also possible that the effect of ANKRD9 on copper transport is indirect. The 
glycosylation of Ctr1 is affected by ANKRD9 depletion The loss of complex 
glycosylation may decrease the transport rate decreasing copper uptake, which might 
explain the upregulation of Ctr1 levels. Another important aspect is that Ctr1 is involved 
in the uptake of the anticancer-drug cisplatin (Ishida et al., 2002), therefore increasing 
Ctr1 levels through ANKRD9 depletion might lead to an increased uptake of cisplatin to 
cancer cells. Further studies will be done to better understand the mechanism through 
which ANKRD9 regutlates CTR1 and to measure cisplatin uptake in ANKRD9-depleted 
cells    
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The results in chapter three, demonstrating the negative effect of ABCC3 (ATP-binding 
cassette, subfamily C (CFTR/MRP), member 3) down-regulation on ATP7A trafficking 
are equally novel ABCC3 is an organic anion and bile acid transporter. Previously, 
treating hepatocytes (HepG2) with copper resulted in upregulation of ABCC3 (Song and 
Freedman, 2005).  In the liver, excess copper is excreted from hepatocytes into the bile, 
therefore bile acid transport and copper metabolism might be linked events.  This 
hypothesis awaits further experimental testing. 
Taken together our studies have pointed to the existence of novel regulatory pathways in 
copper homeostasis. We have determined that structural changes initiate the exit of 
ATP7B from the Golgi in response to copper, and kinase mediated phosphorylation 
might be needed to keep the domains apart. The initial characterization of novel proteins 
involved in maintaining copper homeostasis was done, and yielded interesting results 
linking kinase inhibitors, and an anion transporter in regulation of copper levels through 
ATP7A. The role of the anion transporter ABCC3 in regulating copper-responsive 
trafficking of ATP7A is a novel regulatory pathway, and further studies will be needed to 
characterize its mechanism. It was a very intriguing finding that ANKRD9 depletion led 
to ‘copper-deficient’ state of cells and upregulation of the copper uptake protein, Ctr1. So 
far, no other protein has been linked to increasing Ctr1 levels and we are still working on 
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Glycosylation is not required for ATP7A trafficking to the plasma membrane in 
tunicamycin-treated cells  
The ability of partially glycosylated ATP7A to traffic to the plasma membrane in 
response to copper, suggested that complex sugars were not required for trafficking (Fig 
4-8, Fig 4-12).  Consequently, we were interested whether complete removal of sugars 
would disrupt ATP7A trafficking. Cells were treated with tunicamycin to inhibit the 
glycosylation of newly synthesized proteins and ATP7A localization was determined in 
basal and high copper conditions. The loss of glycosylation of ATP7A was verified using 
Western blotting.   
As seen in Fig 6-1, ATP7A localized to the TGN under basal conditions in both control 
and tunicamycin-treated cells. In cells treated with excess copper, ATP7A trafficked out 
of the TGN and upon removal of excess copper and treatment with the copper chelator 
BCS, ATP7A returned to the TGN. Surface biotinylation experiments confirmed that the 
unglycosylated ATP7A could traffic to the plasma membrane in response to copper (data 
not shown). Altogether our results indicate that N-linked glycosylation of ATP7A was 
not important for its trafficking in response to copper overload or copper chelation.  
Future studies will include measuring the copper content of tunicamycin-treated cells, to 





Effect of downregulation of other ankyrin proteins and glycosyltransferases on copper 
levels 
ANKRD9 is a member of a large family of structurally similar proteins.  We were 
interested whether down-regulation of other ANKRD proteins would alter the cellular 
copper levels or the effects of ANKRD9 were unique. In order to determine the 
specificity of ANKRD9, we compared the effect of downregulation of other ankyrin 
repeat or ankyrin proteins using the data generated by siRNA ionomic screen (Malinouski 
et al., 2014). The analyzed proteins are listed in Table 6-1. Most of the listed 
ankyrin/ankyrin repeat proteins have no significant effect on copper levels as evidenced 
by the low z-scores (z-score<2) (Table 6-1). Several downregulated proteins have a high 
z-score (ranging from 4 to 7), which coincides with significant changes in copper levels.  
These proteins included an adaptor protein AGAP2 that was shown to be involved in the 
retrograde trafficking from endosome to the TGN (Wu et al., 2013), protein ANKS3 that 
is a polymeric scaffolding protein (Leettola et al., 2014), and ASB13 the function of 
which is currently unknown.  These proteins are interesting potential regulator of copper 
metabolism and their role in regulation of copper uptake or export should be investigated 
further. 
  
In our analysis of ANKRD9 we found that loss of this protein is associated with 
decreased complex glycosylation and increased levels of CTR1; there was also a 
reciprocal relationship between these two phenomena.  Consequently, we were interested 
whether downregulation of glycosyltransferases has an effect on the copper levels.  We 
hypothesized that a missing glycosyltransferases would result in defects in glycosylation, 
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and possible changes in copper contents of cells. Majority of known glycosylation 
enzymes had no significant effect on copper levels (z-score<2) (Table 6-2). In Table 6-3, 
the glycosyltransferases enzymes which have an effect on copper levels are listed (z-

















Figure 6-1. ATP7A traffics in response to copper treatment and copper chelation in tunicamycin-
treated cells. In response to excess copper ATP7A traffics out of the TGN, and removal of excess copper 
using BCS triggers the trafficking of ATP7A to TGN. No significant difference was observed in the 
trafficking pattern of ATP7A control (a) and in tunicamycin-treated (b) cells which have a mixture of both 



















ANKRD9 splice variants and siRNA targeting regions 
ANKRD9-transcript4      ------------------------------------------------------------ 
ANKRD9-transcript5      ------------------------------------------------------------ 
ANKRD9-transcript2      CGGCGGCGGACGGTCCCGCTGTCCTGCCTGGCCGGGGCCGCACTGCGCCGCCCGCCGCCC 60 
ANKRD9-transcript1      --------GACGGTCCCGCTGTCCTGCCTGGCCGGGGCCGCACTGCGCCGCCCGCCGCCC 52 
ANKRD9-transcript3      ------------------------------------------------------------ 
                                                                                     
ANKRD9-transcript4      ------------------------------------------------------------ 
ANKRD9-transcript5      ------------------------------------------------------------ 
ANKRD9-transcript2      GCCGCCCGCCGCCCGCCGCCGGCGACGGCACCGCCGCCCTGCGATCCGGCCGCGGCGGCT 120 
ANKRD9-transcript1      GCCGCCCGCCGCCCGCCGCCGGCGACGGCACCGCCGCCCTGCGATCCGGCCGCGGCGGCT 112 
ANKRD9-transcript3      ------------------------------------------------------------ 
                                                                                     
ANKRD9-transcript4      ------------------------------------------------------------ 
ANKRD9-transcript5      ------------------------------------------------------------ 
ANKRD9-transcript2      CAGAGCGCGGCTGCGGCGGGCGCGGGCGGCGGTGGCTCCCTCCCGTGCGTCCGTCGTGGG 180 
ANKRD9-transcript1      CAGAGCGCGGCTGCGGCGGGCGCGGGCGGCGGTGGCTCCCTCCCGTGCGTCCGTCGTGGG 172 
ANKRD9-transcript3      ------------------------------------------------------------ 
                                                                                     
ANKRD9-transcript4      ------------------------------------------------------------ 
ANKRD9-transcript5      ------------------------------------------------------------ 
ANKRD9-transcript2      ACCTTTGCCCGCTCGCCCGCGGGGGACAGCGCGCGCTCCGGTCCGCGGCAGGGGCGGGGA 240 
ANKRD9-transcript1      ACCTTTGCCCGCTCGCCCGCGGGGGACAGCGCGCGCTCCGGTCCGCGGCAGGGGCGGGGA 232 
ANKRD9-transcript3      ------------------------------------------------------------ 
                                                                                     
ANKRD9-transcript4      ------------------------------------------------------------ 
ANKRD9-transcript5      ------------------------------------------------------------ 
ANKRD9-transcript2      CGCCCGGCCTGTGGCCCCCGCGCCCCCCATGGTGAGTCCCCGTCCCCCGCGCCGCGCCCG 300 
ANKRD9-transcript1      CGCCCGGCCTGTGGCCCCCGCGCCCCCCATGGTGAGTCCCCGTCCCCCGCGCCGCGCCCG 292 
ANKRD9-transcript3      ------------------------------------------------------------ 
                                                                                     
ANKRD9-transcript4      ------------------------------------------------------------ 
ANKRD9-transcript5      ------------------------------------------------------------ 
ANKRD9-transcript2      CGGCCGCCGCCCCCTCCTCCTCCGGCACACGCGCACGCAGGTGCAGCCCTCGCTGCGCCG 360 
ANKRD9-transcript1      CGGCCGCCGCCCCCTCCTCCTCCGGCACACGCGCACGCAGGTGCAGCCCTCGCTGCGCCG 352 
ANKRD9-transcript3      ------------------------------------------------------------ 
                                                                                     
ANKRD9-transcript4      ------------------------------------------------------------ 
ANKRD9-transcript5      ------------------------------------------------------------ 
ANKRD9-transcript2      GCCACCTGCGCGCGGACGCCCCGCTCGGCCCCGCGACCCTCCGCCGCCCGACGTCTGGCC 420 
ANKRD9-transcript1      GCCACCTGCGCGCGGACGCCCCGCTCGGCCCCGCGACCCTCCGCCGCCCGACGTCTGGCC 412 
ANKRD9-transcript3      ------------------------------------------------------------ 
                                                                                     
ANKRD9-transcript4      ------------------------------------------------------------ 
ANKRD9-transcript5      ------------------------------------------------------------ 
ANKRD9-transcript2      GTGCAGGCCGGGAGGGGACGGGTAGGAGGTGGCGGGTGGCCCCGGGCGCGGCGCTGCCTT 480 
ANKRD9-transcript1      GTGCAGGCCGGGAGGGGACGGGTAGGAGGTGGCGGGTGGCCCCGGGCGCGGCGCTGCCTT 472 
ANKRD9-transcript3      ------------------------------------------------------------ 
                                                                                     
ANKRD9-transcript4      ------------------------------------------------------------ 
ANKRD9-transcript5      ------------------------------------------------------------ 
ANKRD9-transcript2      CGATGGCCCAACCCCCTTATTCACGAGCCGCGGCCGTGACTCTGCCCGGTGACGTGGGGA 540 
ANKRD9-transcript1      CGATGGCCCAACCCCCTTATTCACGAGCCGCGGCCGTGACTCTGCCCGGTGACGTGGGGA 532 
ANKRD9-transcript3      ------------------------------------------------------------ 
                                                                                     
ANKRD9-transcript4      ------------------------GGCGCCCCACGCGTGCCGGCACAGGGCATATCTGGG 36 
ANKRD9-transcript5      ------------------------------------------------------------ 
ANKRD9-transcript2      GGCCGAACTTTACGTAACCCGCCCGGCGCCCCACGCGTGCCGGCACAGGGCATATCTGGG 600 
ANKRD9-transcript1      GGCCGAACTTTACGTAACCCGCCCGGCGCCCCACGCGTGCCGGCACAGGGCATATCTGGG 592 
ANKRD9-transcript3      ------------------------------------------------------------ 
                                                                                     
ANKRD9-transcript4      GCCCGGAGGCCCAGGCTTGGGGAAGGGGCTCCAGTCACGGTGTTGCCCACGGGCCACAGC 96 
ANKRD9-transcript5      ------------------------------------------------------------ 
ANKRD9-transcript2      GCCCGGAGGCCCAGGCTTGGGGAAGGGGCTCCAGTCACGGTGTTGCCCACGGGCCACAGC 660 
ANKRD9-transcript1      GCCCGGAGGCCCAGGCTTGGGGAAGGGGCTCCAGTCACGGTGTTGCCCACGGGCCACAGC 652 
ANKRD9-transcript3      ------------------------------------------------------------ 






ANKRD9-transcript4      CTACCCGCACCGCGCCGCTCTCTTTAACTCAGTTACTGCCAGTGATAGTGACCCAGTCAG 156 
ANKRD9-transcript5      ------------------------------------------------------------ 
ANKRD9-transcript2      CTACCCGCACCGCGCCGCTCTCTTTAACTCAGTTACTGCCAGTGATAGTGACCCAGTCAG 720 
ANKRD9-transcript1      CTACCCGCACCGCGCCGCTCTCTTTAACTCAGTTACTGCCAGTGATAGTGACCCAGTCAG 712 
ANKRD9-transcript3      ------------------------------------------------------------ 
                                                                                     
ANKRD9-transcript4      TGTGTGTGGACGCGGCCTGCCTTCTGTCCCAGGCCCCTTGTGACCAAGGGCTTACCCTTG 216 
ANKRD9-transcript5      ------------------------------------------------------------ 
ANKRD9-transcript2      TGTGTGTGGACGCGGCCTGCCTTCTGTCCCAGGCCCCTTGTGACCAAGGGCTTACCCTTG 780 
ANKRD9-transcript1      TGTGTGTGGACGCGGCCTGCCTTCTGTCCCAGGCCCCTTGTGACCAAGGGCTTACCCTTG 772 
ANKRD9-transcript3      ------------------------------------------------------------ 
                                                                                     
ANKRD9-transcript4      AAAGAAGGCAGTAGGGAGGTTGGGACGGAGCCAGAGGTCAGACGCCTAGGCTCAGGTCGG 276 
ANKRD9-transcript5      ------------------------------------------------------------ 
ANKRD9-transcript2      AAAGAAGGCAGTAGGGAGGTTGGGACGGAGCCAGAGGTCAGACGCCTAGGCTCAGGTCGG 840 
ANKRD9-transcript1      AAAGAAGGCAGTAGGGAGGTTGGGACGGAGCCAGAGGTCAGACGCCTAGGCTCAGGTCGG 832 
ANKRD9-transcript3      ------------------------------------------------------------ 
                                                                                     
ANKRD9-transcript4      GGCTGGGGACTCAGAGGGCAGGGTCAGGGCCTAAGCTCGATTGCCTGTGGGTTGGGGGTC 336 
ANKRD9-transcript5      ------------------------------------------------GGGTTGGGGGTC 12 
ANKRD9-transcript2      GGCTGGGGACTCAGAGGGCAGGGTCAGGGCCTAAGCTCGATTGCCTGTGGGTTGGGGGTC 900 
ANKRD9-transcript1      GGCTGGGGACTCAGAGGGCAGGGTCAGGGCCTAAGCTCGATTGCCTGTGGGTTGGGGGTC 892 
ANKRD9-transcript3      ------------------------------------------------------------ 
                                                                                     
ANKRD9-transcript4      CCCACCAATTCTGGAATGAGCCCAAACTGAGACGCAGGGGACCTGAGTTCTAGGCCTGGC 396 
ANKRD9-transcript5      CCCACCAATTCTGGAATGAGCCCAAACTGAGACGCAGGGGACCTGAGTTCTAGGCCTGGC 72 
ANKRD9-transcript2      CCCACCAATTCTGGAATGAGCCCAAACTGAGACGCAGGGGACCTGAGTTCTAGGCCTGGC 960 
ANKRD9-transcript1      CCCACCAATTCTGGAATGAGCCCAAACTGAGACGCAGGGGACCTGAGTTCTAGGCCTGGC 952 
ANKRD9-transcript3      ------------------------------------------------------------ 
                                                                                     
ANKRD9-transcript4      TCTGCCGTGGCTTGCTGACCTTGGAGAATTGGAGAAGCTTGTGCCCTGCTGGAAAGTGGG 456 
ANKRD9-transcript5      TCTGCCGTGGCTTGCTGACCTTGGAGAATTGGAGAAGCTTGTGCCCTGCTGGAAAGTGGG 132 
ANKRD9-transcript2      TCTGCCGTGGCTTGCTGACCTTGGAGAATTGGAGAAGCTTGTGCCCTGCTGGAAAGTGGG 1020 
ANKRD9-transcript1      TCTGCCGTGGCTTGCTGACCTTGGAGAATTGGAGAAGCTTGTGCCCTGCTGGAAAGTGGG 1012 
ANKRD9-transcript3      ----------------------GGAGAATTGGAGAAGCTTGTGCCCTGCTGGAAAGTGGG 38 
                                              ************************************** 
ANKRD9-transcript4      ATGGCAGTACCCGCTTCATCTAGTAGTCGGGGAGATCAAGAGAGGTATGGGACCTGAAGA 516 
ANKRD9-transcript5      ATGGCAGTACCCGCTTCATCTAGTAGTCGGGGAGATCAAGAGAGGTATGGGACCTGAAGA 192 
ANKRD9-transcript2      ATGGCAGTACCCGCTTCATCTAGTAGTCGGGGAGATCAAGAGAGGTATGGGACCTGAAGA 1080 
ANKRD9-transcript1      ATGGCAGTACCCGCTTCATCTAGTAGTCGGGGAGATCAAGAGAGGTATGGGACCTGAAGA 1072 
ANKRD9-transcript3      ATGGCAGTACCCGCTTCATCTAGTAGTCGGGGAGATCAAGAGAGGTATGGGACCTGAAGA 98 
                        ************************************************************ 
ANKRD9-transcript4      GGATGGCAGACTGTGCAGTGCGGTGCACACCGGTCTCCAGGTTGTTTTCACCCTCCTATC 576 
ANKRD9-transcript5      GGATGGCAGACTGTGCAGTGCGGTGCACACCGGTCTCCAGGTTGTTTTCACCCTCCTATC 252 
ANKRD9-transcript2      GGATGGCAGACTGTGCAGTGCGGTGCACACCGGTCTCCAGGTTGTTTTCACCCTCCTATC 1140 
ANKRD9-transcript1      GGATGGCAGACTGTGCAGTGCGGTGCACACCGGTCTCCAGGTTGTTTTCACCCTCCTATC 1132 
ANKRD9-transcript3      GGATGGCAGACTGTGCAGTGCGGTGCACACCGGTCTCCAGGTTGTTTTCACCCTCCTATC 158 
                        ************************************************************ 
ANKRD9-transcript4      TCCTCCCAGGAGCTAACGTGTAAGCAAACATGTTTGGATAGAGGGCTGGTGCCACGCCCC 636 
ANKRD9-transcript5      TCCTCCCAGGAGCTAACGTGTAAGCAAACATGTTTGGATAGAGGGCTGGTGCCACGCCCC 312 
ANKRD9-transcript2      TCCTCCCAGGAGCTAACGTGTAAGCAAACATGTTTGGATAGAGGGCTGGTGCCACGCCCC 1200 
ANKRD9-transcript1      TCCTCCCAGGAGCTAACGTGTAAGCAAACATGTTTGGATAGAGGGCTGGTGCCACGCCCC 1192 
ANKRD9-transcript3      TCCTCCCAGGAGCTAACGTGTAAGCAAACATGTTTGGATAGAGGGCTGGTGCCACGCCCC 218 
                        ************************************************************ 
ANKRD9-transcript4      AGGCTCACCCCGCCCGCACAGCCGTCGTCCACCCCTCCCCTTTCTTACAGATAAAGCTGA 696 
ANKRD9-transcript5      AGGCTCACCCCGCCCGCACAGCCGTCGTCCACCCCTCCCCTTTCTTACAGATAAAGCTGA 372 
ANKRD9-transcript2      AGGCTCACCCCGCCCGCACAGCCGTCGTCCACCCCTCCCCTTTCTTACAGATAAAGCTGA 1260 
ANKRD9-transcript1      AGGCTCACCCCGCCCGCACAGCCGTCGTCCACCCCTCCCCTTTCTTACAGATAAAGCTGA 1252 
ANKRD9-transcript3      AGGCTCACCCCGCCCGCACAGCCGTCGTCCACCCCTCCCCTTTCTTACAGATAAAGCTGA 278 
                        ************************************************************ 
ANKRD9-transcript4      GGCTCGGCCAGGGACTGTGATATACCCACATCCCCGGAACTAGGTGATCGCGGTGCAGGA 756 
ANKRD9-transcript5      GGCTCGGCCAGGGACTGTGATATACCCACATCCCCGGAACTAGGTGATCGCGGTGCAGGA 432 
ANKRD9-transcript2      GGCTCGGCCAGGGACTGTGATATACCCACATCCCCGGAACTAGGTGATCGCGGTGCAGGA 1320 
ANKRD9-transcript1      GGCTCGGCCAGGGACTGTGATATACCCACATCCCCGGAACTAGGTGATCGCGGTGCAGGA 1312 
ANKRD9-transcript3      GGCTCGGCCAGGGACTGTGATATACCCACATCCCCGGAACTAGGTGATCGCGGTGCAGGA 338 
                        ************************************************************ 
ANKRD9-transcript4      ACCAGGTAGGTCTGAGTCTGGATCATGCCTCTGAACAGCCCAGGAAGAGGCTCCAGGGGC 816 
ANKRD9-transcript5      ACCAGGTAGGTCTGAGTCTGGATCATGCCTCTGAACAGCCCAGGAAGAGGCTCCAGGGGC 492 
ANKRD9-transcript2      ACCAGGTAGGTCTGAGTCTGGATCATGCCTCTGAACAGCCCAGGAAGAGGCTCCAGGGGC 1380 
ANKRD9-transcript1      ACCAGGTAGGTCTGAGTCTGGATCATGCCTCTGAACAGCCCAGGAAGAGGCTCCAGGGGC 1372 
ANKRD9-transcript3      ACCAGGTAGGTCTGAGTCTGGATCATGCCTCTGAACAGCCCAGGAAGAGGCTCCAGGGGC 398 
160 
 
                        ************************************************************ 
 
ANKRD9-transcript4      CTCCAAGTGGTCTGGGGTCGGAGATCAGGGTCAGGGTTGCGCTTGGGCTGGAGAGTGGAT 876 
ANKRD9-transcript5      CTCCAAGTGGTCTGGGGTCGGAGATCAGGGTCAGGGTTGCGCTTGGGCTGGAGAGTGGAT 552 
ANKRD9-transcript2      CTCCAAGTGGTCTGGGGTCGGAGATCAGGGTCAGGGTTGCGCTTGGGCTGGAGAGTGGAT 1440 
ANKRD9-transcript1      CTCCAAGTGGTCTGGGGTCGGAGATCAGGGTCAGGGTTGCGCTTGGGCTGGAGAGTGGAT 1432 
ANKRD9-transcript3      CTCCAAGTGGTCTGGGGTCGGAGATCAGGGTCAGGGTTGCGCTTGGGCTGGAGAGTGGAT 458 
                        ************************************************************ 
 
ANKRD9-transcript4      TTGCCTCAGCTTGAGATGTGGGCCCAAGCTTTCTCATCCCCTCCCTGGCCTTTTCTTTAT 936 
ANKRD9-transcript5      TTGCCTCAGCTTGAGATGTGGGCCCAAGCTTTCTCATCCCCTCCCTGGCCTTTTCTTTAT 612 
ANKRD9-transcript2      TTGCCTCAGCTTGAGATGTGGGCCCAAGCTTTCTCATCCCCTCCCTGGCCTTTTCTTTAT 1500 
ANKRD9-transcript1      TTGCCTCAGCTTGAGATGTGGGCCCAAGCTTTCTCATCCCCTCCCTGGCCTTTTCTTTAT 1492 
ANKRD9-transcript3      TTGCCTCAGCTTGAGATGTGGGCCCAAGCTTTCTCATCCCCTCCCTGGCCTTTTCTTTAT 518 
                        ************************************************************ 
ANKRD9-transcript4      TTGGGGTCGTATGAACCTGGCTTAGGTGGGAACAGAAGCTCTTCCAGTGGGTCCCTGGGT 996 
ANKRD9-transcript5      TTGGGGTCGTATGAACCTGGCTTAGGTGGGAACAGAAGCTCTTCCAGTGGGTCCCTGGGT 672 
ANKRD9-transcript2      TTGGGGTCGTATGAACCTGGCTTAGGTGGGAACAGAAGCTCTTCCAGTGGGTCCCTGGGT 1560 
ANKRD9-transcript1      TTGGGGTCGTATGAACCTGGCTTAGGTGGGAACAGAAGCTCTTCCAGTGGGTCCCTGGGT 1552 
ANKRD9-transcript3      TTGGGGTCGTATGAACCTGGCTTAGGTGGGAACAGAAGCTCTTCCAGTGGGTCCCTGGGT 578 
                        ************************************************************ 
ANKRD9-transcript4      TGGAGAGGGGAGGGGAGATTTGAGGGCATGGGCAGCAAGGGCATTTCCAGCAGAGGTGCC 1056 
ANKRD9-transcript5      TGGAGAGGGGAGGGGAGATTTGAGGGCATGGGCAGCAAGGGCATTTCCAGCAGAGGTGCC 732 
ANKRD9-transcript2      TGGAGAGGGGAGGGGAGATTTGAGGGCATGGGCAGCAAGGGCATTTCCAGCAGAGGTGCC 1620 
ANKRD9-transcript1      TGGAGAGGGGAGGGGAGATTTGAGGGCATGGGCAGCAAGGGCATTTCCAGCAGAGGTGCC 1612 
ANKRD9-transcript3      TGGAGAGGGGAGGGGAGATTTGAGGGCATGGGCAGCAAGGGCATTTCCAGCAGAGGTGCC 638 
                        ************************************************************ 
ANKRD9-transcript4      AGAGAGCAAGTCAGTTTCAAGGAGGGAGAACAGGTACAGCTAGATCAAGGATGGAGGCGG 1116 
ANKRD9-transcript5      AGAGAGCAAGTCAGTTTCAAGGAGGGAGAACAGGTACAGCTAGATCAAGGATGGAGGCGG 792 
ANKRD9-transcript2      AGAGAGCAAGTCAGTTTCAAGGAGGGAGAACAGGTACAGCTAGATCAAGGATGGAGGCGG 1680 
ANKRD9-transcript1      AGAGAGCAAGTCAGTTTCAAGGAGGGAGAACAGGTACAGCTAGATCAAGGATGGAGGCGG 1672 
ANKRD9-transcript3      AGAGAGCAAGTCAGTTTCAAGGAGGGAGAACAGGTACAGCTAGATCAAGGATGGAGGCGG 698 
                        ************************************************************ 
ANKRD9-transcript4      TGGTTCTGGGCGTCGGAGAGATGGAGCTGTAGGGTGACTGGAAGGGCCTGGCCGAGGCTG 1176 
ANKRD9-transcript5      TGGTTCTGGGCGTCGGAGAGATGGAGCTGTAGGGTGACTGGAAGGGCCTGGCCGAGGCTG 852 
ANKRD9-transcript2      TGGTTCTGGGCGTCGGAGAGATGGAGCTGTAGGGTGACTGGAAGGGCCTGGCCGAGGCTG 1740 
ANKRD9-transcript1      TGGTTCTGGGCGTCGGAGAGATGGAGCTGTAGGGTGACTGGAAGGGCCTGGCCGAGGCTG 1732 
ANKRD9-transcript3      TGGTTCTGGGCGTCGGAGAGATGGAGCTGTAGGGTGACTGGAAGGGCCTGGCCGAGGCTG 758 
                        ************************************************************ 
ANKRD9-transcript4      GAGGTAGGTACAGGCCTGGTGGGCCAGGACCGGAGGGGCTGTGTGAGGGGCAGAGGGGAG 1236 
ANKRD9-transcript5      GAGGTAGGTACAGGCCTGGTGGGCCAGGACCGGAGGGGCTGTGTGAGGGGCAGAGGGGAG 912 
ANKRD9-transcript2      GAGGTAGGTACAGGCCTGGTGGGCCAGGACCGGAGGGGCTGTGTGAGGGGCAGAGGGGAG 1800 
ANKRD9-transcript1      GAGGTAGGTACAGGCCTGGTGGGCCAGGACCGGAGGGGCTGTGTGAGGGGCAGAGGGGAG 1792 
ANKRD9-transcript3      GAGGTAGGTACAGGCCTGGTGGGCCAGGACCGGAGGGGCTGTGTGAGGGGCAGAGGGGAG 818 
                        ************************************************************ 
ANKRD9-transcript4      TCCCCGGGCCTCCCCAGTTTCCCCGCGCCTCACCGTGGCCTCTTCCTTTCCCCGCAGGTG 1296 
ANKRD9-transcript5      TCCCCGGGCCTCCCCAGTTTCCCCGCGCCTCACCGTGGCCTCTTCCTTTCCCCGCAGGTG 972 
ANKRD9-transcript2      TCCCCGGGCCTCCCCAGTTTCCCCGCGCCTCACCGTGGCCTCTTCCTTTCCCCGCAGGTG 1860 
ANKRD9-transcript1      TCCCCGGGCCTCCCCAGTTTCCCCGCGCCTCACCGTGGCCTCTTCCTTTCCCCGCAGGTG 1852 
ANKRD9-transcript3      TCCCCGGGCCTCCCCAGTTTCCCCGCGCCTCACCGTGGCCTCTTCCTTTCCCCGCAGGTG 878 
                        ************************************************************ 
ANKRD9-transcript4      TGCCTTCGCGGGATCCATGCCTTGAGGCCCAGGAACGCCCCGCCGCCAGCATGCCGTGGG 1356 
ANKRD9-transcript5      TGCCTTCGCGGGATCCATGCCTTGAGGCCCAGGAACGCCCCGCCGCCAGCATGCCGTGGG 1032 
ANKRD9-transcript2      TGCCTTCGCGGGATCCATGCCTTGAGGCCCAGGAACGCCCCGCCGCCAGCATGCCGTGGG 1920 
ANKRD9-transcript1      TGCCTTCGCGGGATCCATGCCTTGAGGCCCAGGAACGCCCCGCCGCCAGCATGCCGTGGG 1912 
ANKRD9-transcript3      TGCCTTCGCGGGATCCATGCCTTGAGGCCCAGGAACGCCCCGCCGCCAGCATGCCGTGGG 938 
                        ************************************************************ 
ANKRD9-transcript4      ACGCGCGGCGGCCTGGGGGTGGCGCGGACGGCGGGCCCGAGGCCTCGGGCGCGGCGCGCT 1416 
ANKRD9-transcript5      ACGCGCGGCGGCCTGGGGGTGGCGCGGACGGCGGGCCCGAGGCCTCGGGCGCGGCGCGCT 1092 
ANKRD9-transcript2      ACGCGCGGCGGCCTGGGGGTGGCGCGGACGGCGGGCCCGAGGCCTCGGGCGCGGCGCGCT 1980 
ANKRD9-transcript1      ACGCGCGGCGGCCTGGGGGTGGCGCGGACGGCGGGCCCGAGGCCTCGGGCGCGGCGCGCT 1972 
ANKRD9-transcript3      ACGCGCGGCGGCCTGGGGGTGGCGCGGACGGCGGGCCCGAGGCCTCGGGCGCGGCGCGCT 998 
                        ************************************************************ 
ANKRD9-transcript4      CGCGAGCGCAGAAGCAGTGCCGCAAGTCGTCGTTCGCCTTCTACCAGGCGGTGCGCGACC 1476 
ANKRD9-transcript5      CGCGAGCGCAGAAGCAGTGCCGCAAGTCGTCGTTCGCCTTCTACCAGGCGGTGCGCGACC 1152 
ANKRD9-transcript2      CGCGAGCGCAGAAGCAGTGCCGCAAGTCGTCGTTCGCCTTCTACCAGGCGGTGCGCGACC 2040 
ANKRD9-transcript1      CGCGAGCGCAGAAGCAGTGCCGCAAGTCGTCGTTCGCCTTCTACCAGGCGGTGCGCGACC 2032 
ANKRD9-transcript3      CGCGAGCGCAGAAGCAGTGCCGCAAGTCGTCGTTCGCCTTCTACCAGGCGGTGCGCGACC 1058 






ANKRD9-transcript4      TGCTACCCGTGTGGCTGCTGGAGGATATGCGCGCCAGCGAGGCCTTCCACTGGGACGAGC 1536 
ANKRD9-transcript5      TGCTACCCGTGTGGCTGCTGGAGGATATGCGCGCCAGCGAGGCCTTCCACTGGGACGAGC 1212 
ANKRD9-transcript2      TGCTACCCGTGTGGCTGCTGGAGGATATGCGCGCCAGCGAGGCCTTCCACTGGGACGAGC 2100 
ANKRD9-transcript1      TGCTACCCGTGTGGCTGCTGGAGGATATGCGCGCCAGCGAGGCCTTCCACTGGGACGAGC 2092 
ANKRD9-transcript3      TGCTACCCGTGTGGCTGCTGGAGGATATGCGCGCCAGCGAGGCCTTCCACTGGGACGAGC 1118 
                        ************************************************************ 
ANKRD9-transcript4      GCGGGCGCGCCGCCGCCTACTCGCCCTCTGAGGCGCTGCTCTACGCGCTCGTGCACGACC 1596 
ANKRD9-transcript5      GCGGGCGCGCCGCCGCCTACTCGCCCTCTGAGGCGCTGCTCTACGCGCTCGTGCACGACC 1272 
ANKRD9-transcript2      GCGGGCGCGCCGCCGCCTACTCGCCCTCTGAGGCGCTGCTCTACGCGCTCGTGCACGACC 2160 
ANKRD9-transcript1      GCGGGCGCGCCGCCGCCTACTCGCCCTCTGAGGCGCTGCTCTACGCGCTCGTGCACGACC 2152 
ANKRD9-transcript3      GCGGGCGCGCCGCCGCCTACTCGCCCTCTGAGGCGCTGCTCTACGCGCTCGTGCACGACC 1178 
                        ************************************************************ 
ANKRD9-transcript4      ACCAAGCGTACGCGCATTACCTGCTGGCCACGTTCCCGCGGCGCGCGCTCGCACCGCCCA 1656 
ANKRD9-transcript5      ACCAAGCGTACGCGCATTACCTGCTGGCCACGTTCCCGCGGCGCGCGCTCGCACCGCCCA 1332 
ANKRD9-transcript2      ACCAAGCGTACGCGCATTACCTGCTGGCCACGTTCCCGCGGCGCGCGCTCGCACCGCCCA 2220 
ANKRD9-transcript1      ACCAAGCGTACGCGCATTACCTGCTGGCCACGTTCCCGCGGCGCGCGCTCGCACCGCCCA 2212 
ANKRD9-transcript3      ACCAAGCGTACGCGCATTACCTGCTGGCCACGTTCCCGCGGCGCGCGCTCGCACCGCCCA 1238 
                        ************************************************************ 
ANKRD9-transcript4      GTGCCGGCTTCCGCTGCTGCGCGGCTCCCGGGCCGCACGTGGCGCTGGCAGTGCGCTACA 1716 
ANKRD9-transcript5      GTGCCG------------------------------------------------------ 1338 
ANKRD9-transcript2      GTGCCGGCTTCCGCTGCTGCGCGGCTCCCGGGCCGCACGTGGCGCTGGCAGTGCGCTACA 2280 
ANKRD9-transcript1      GTGCCGGCTTCCGCTGCTGCGCGGCTCCCGGGCCGCACGTGGCGCTGGCAGTGCGCTACA 2272 
ANKRD9-transcript3      GTGCCGGCTTCCGCTGCTGCGCGGCTCCCGGGCCGCACGTGGCGCTGGCAGTGCGCTACA 1298 
                        ******                                                       
ANKRD9-transcript4      ACCGCGTGGGCATTCTGCGCCGCATCCTGCGCACCTTGCGCGACTTCCCGGCCGAGGAGC 1776 
ANKRD9-transcript5      ------------------------------------------------------------ 
ANKRD9-transcript2      ACCGCGTGGGCATTCTGCGCCGCATCCTGCGCACCTTGCGCGACTTCCCGGCCGAGGAGC 2340 
ANKRD9-transcript1      ACCGCGTGGGCATTCTGCGCCGCATCCTGCGCACCTTGCGCGACTTCCCGGCCGAGGAGC 2332 
ANKRD9-transcript3      ACCGCGTGGGCATTCTGCGCCGCATCCTGCGCACCTTGCGCGACTTCCCGGCCGAGGAGC 1358 
                                                                                     
ANKRD9-transcript4      GGGCGCGCGTGCTGGACCGGCGTGGCTGCAGCCGCGTGGAGGGCGGTGGCACGTCGCTGC 1836 
ANKRD9-transcript5      ------------------------------------------------------------ 
ANKRD9-transcript2      GGGCGCGCGTGCTGGACCGGCGTGGCTGCAGCCGCGTGGAGGGCGGTGGCACGTCGCTGC 2400 
ANKRD9-transcript1      GGGCGCGCGTGCTGGACCGGCGTGGCTGCAGCCGCGTGGAGGGCGGTGGCACGTCGCTGC 2392 
ANKRD9-transcript3      GGGCGCGCGTGCTGGACCGGCGTGGCTGCAGCCGCGTGGAGGGCGGTGGCACGTCGCTGC 1418 
 
                                                                                     
ANKRD9-transcript4      ACGTGGCCTGTGAGCTGGCGCGCCCCGAGTGCCTCTTCCTGCTGCTGGGCCACGGCGCCT 1896 
ANKRD9-transcript5      ------------------------------------------------------------ 
ANKRD9-transcript2      ACGTGGCCTGTGAGCTGGCGCGCCCCGAGTGCCTCTTCCTGCTGCTGGGCCACGGCGCCT 2460 
ANKRD9-transcript1      ACGTGGCCTGTGAGCTGGCGCGCCCCGAGTGCCTCTTCCTGCTGCTGGGCCACGGCGCCT 2452 
ANKRD9-transcript3      ACGTGGCCTGTGAGCTGGCGCGCCCCGAGTGCCTCTTCCTGCTGCTGGGCCACGGCGCCT 1478 
                                                                                     
ANKRD9-transcript4      CGCCCGGTCTGCGGGACGGCGGCGGCCTCACGCCTCTCGAGCTGCTGCTGCGCCAGCTGG 1956 
ANKRD9-transcript5      ------------------------------------------------------------ 
ANKRD9-transcript2      CGCCCGGTCTGCGGGACGGCGGCGGCCTCACGCCTCTCGAGCTGCTGCTGCGCCAGCTGG 2520 
ANKRD9-transcript1      CGCCCGGTCTGCGGGACGGCGGCGGCCTCACGCCTCTCGAGCTGCTGCTGCGCCAGCTGG 2512 
ANKRD9-transcript3      CGCCCGGTCTGCGGGACGGCGGCGGCCTCACGCCTCTCGAGCTGCTGCTGCGCCAGCTGG 1538 
                                                                                     
ANKRD9-transcript4      GCCGCGACGCCGGGGCCACTCCCTCCGCCGCCGGAGCCCCCGCCTCAGCTCCCGGGGAGC 2016 
ANKRD9-transcript5      ------------------------------------------------------------ 
ANKRD9-transcript2      GCCGCGACGCCGGGGCCACTCCCTCCGCCGCCGGAGCCCCCGCCTCAGCTCCCGGGGAGC 2580 
ANKRD9-transcript1      GCCGCGACGCCGGGGCCACTCCCTCCGCCGCCGGAGCCCCCGCCTCAGCTCCCGGGGAGC 2572 
ANKRD9-transcript3      GCCGCGACGCCGGGGCCACTCCCTCCGCCGCCGGAGCCCCCGCCTCAGCTCCCGGGGAGC 1598 
                                                                                     
ANKRD9-transcript4      CGCGCCAGCGCCGCCTGCTGCTGCTGGACCTCCTGGCGCTGTACACCCCCGTGGGTGCCG 2076 
ANKRD9-transcript5      ------------------------------------------------------------ 
ANKRD9-transcript2      CGCGCCAGCGCCGCCTGCTGCTGCTGGACCTCCTGGCGCTGTACACCCCCGTGGGTGCCG 2640 
ANKRD9-transcript1      CGCGCCAGCGCCGCCTGCTGCTGCTGGACCTCCTGGCGCTGTACACCCCCGTGGGTGCCG 2632 
ANKRD9-transcript3      CGCGCCAGCGCCGCCTGCTGCTGCTGGACCTCCTGGCGCTGTACACCCCCGTGGGTGCCG 1658 
                                                                                     
ANKRD9-transcript4      CCGGCTCGGCCCGCCAGGAGCTGCTGGGCGACCGGCCGCGCTGGCAGCG----------- 2125 
ANKRD9-transcript5      ------------------------------------------------------------ 
ANKRD9-transcript2      CCGGCTCGGCCCGCCAGGAGCTGCTGGGCGACCGGCCGCGCTGGCAGCGGCTGCTGGGTG 2700 
ANKRD9-transcript1      CCGGCTCGGCCCGCCAGGAGCTGCTGGGCGACCGGCCGCGCTGGCAGCGGCTGCTGGGTG 2692 
ANKRD9-transcript3      CCGGCTCGGCCCGCCAGGAGCTGCTGGGCGACCGGCCGCGCTGGCAGCGGCTGCTGGGTG 1718 







ANKRD9-transcript4      ------------------------------------------------------------ 
ANKRD9-transcript5      ------------------------------------------------------------ 
ANKRD9-transcript2      AGGACAAGTTCCAGTGGCTGGCGGGCCTGGCGCCGCCCTCGCTCTTCGCGCGCGCCATGC 2760 
ANKRD9-transcript1      AGGACAAGTTCCAGTGGCTGGCGGGCCTGGCGCCGCCCTCGCTCTTCGCGCGCGCCATGC 2752 
ANKRD9-transcript3      AGGACAAGTTCCAGTGGCTGGCGGGCCTGGCGCCGCCCTCGCTCTTCGCGCGCGCCATGC 1778 
                                                                                     
ANKRD9-transcript4      ------------------------------------------------------------ 
ANKRD9-transcript5      ------------------------------------------------------------ 
ANKRD9-transcript2      AGGTGCTGGTCACCGCCATCTCTCCAGGCCGCTTCCCCGAGGCCCTGGACGAGCTGCCGC 2820 
ANKRD9-transcript1      AGGTGCTGGTCACCGCCATCTCTCCAGGCCGCTTCCCCGAGGCCCTGGACGAGCTGCCGC 2812 
ANKRD9-transcript3      AGGTGCTGGTCACCGCCATCTCTCCAGGCCGCTTCCCCGAGGCCCTGGACGAGCTGCCGC 1838 
                                                                                     
ANKRD9-transcript4      ------------------------------------------------------------ 
ANKRD9-transcript5      ------------------------------------------------------------ 
ANKRD9-transcript2      TGCCCCCATTCCTGCAGCCGTTGGACCTCACTGGCAAAGGCTAGGCCCGGAGCACCCTAG 2880 
ANKRD9-transcript1      TGCCCCCATTCCTGCAGCCGTTGGACCTCACTGGCAAAGGCTAGGCCCGGAGCACCCTAG 2872 
ANKRD9-transcript3      TGCCCCCATTCCTGCAGCCGTTGGACCTCACTGGCAAAGGCTAGGCCCGGAGCACCCTAG 1898 
                                                                                     
ANKRD9-transcript4      ------------------------------------------------------------ 
ANKRD9-transcript5      ------------------------------------------------------------ 
ANKRD9-transcript2      GCGCTGGATTTTGGGACAAAACTATTTTTCAGAGCGTTGTACCG---------------- 2924 
ANKRD9-transcript1      GCGCTGGATTTTGGGACAAAACTATTTTTCAGAGCGTTGTACCGGCACTTTATATATATT 2932 
ANKRD9-transcript3      GCGCTGGATTTTGGGACAAAACTATTTTTCAGAGCGTTGTACCGGCACTTTATATATATT 1958 
                                                                                     
ANKRD9-transcript4      ------------------ 
ANKRD9-transcript5      ------------------ 
ANKRD9-transcript2      ------------------ 
ANKRD9-transcript1      GATCTCTGTACGGCACAA 2950 
ANKRD9-transcript3      GATCTCTGTACGGCACAA 1976 
                                           
 
Figure 6-2. Multiple sequence alignment of ANKRD9 splice variants. Sequences obtained from 
ENSEML database; ankyrin repeat domain 9 [Source:HGNC Symbol;Acc:20096] were aligned using 
Clustal W. Intron sequences are marked with green. Bold corresponds to translated protein coding regions. 
The rest of the sequence is untranslated regions (UTRs). The following colors are used to mark the siRNA 
targeted regions (yellow-ANKRD9 siRNA#1, blue- ANKRD9 siRNA#2, green- ANKRD9 siRNA#3, and 














Table 6-1. Downregulation of most ankyrin repeat proteins has no significant effect on copper levels. 
Shown are ICPMS data from the ionome database (Malinouski et al., 2014), in bold are the genes which 
upon downregulation result in statistically significant increase of copper levels (z-score>4). 




ANKRD9 Ankyrin repeat domain 9 1.703 7.184 
AGAP2 ArfGAP with GTPase domain, ankyrin repeat and PH domain 2 1.425 5.2 
ANKS3 Ankyrin repeat and sterile alpha motif domain containing 3 1.485 4.403 
ASB13 Ankyrin repeat and SOCS box-containing 13 1.412 4.066 
SOWAHC sosondowah ankyrin repeat domain family member C 1.241 3.985 
ASB14 Ankyrin repeat and SOCS box-containing 14 1.299 3.282 
ASB5 Ankyrin repeat and SOCS box-containing 5 1.308 3.016 
ASB9 Ankyrin repeat and SOCS box-containing 9 1.305 2.988 
ASB16 Ankyrin repeat and SOCS box-containing 16 1.195 2.974 
ANKRD11 Ankyrin repeat domain 11 1.148 2.925 
ANKDD1A Ankyrin repeat and death domain containing 1A 1.201 2.878 
ANKS4B Ankyrin repeat and sterile alpha motif domain containing 4B 1.217 2.793 
AGAP3 ArfGAP with GTPase domain, ankyrin repeat and PH domain 3 1.202 2.439 
ANKRD7 Ankyrin repeat domain 7 1.261 2.115 
ANKRD33 Ankyrin repeat domain 33 1.118 1.968 
KANK4 Homo sapiens KN motif and ankyrin repeat domains 4  1.002 0.029 
ASZ1 Ankyrin repeat, SAM and basic leucine zipper domain containing 1 1.012 0.085 
ANKMY1 Ankyrin repeat and MYND domain containing 1 1.07 1.905 
ANKRD23 Ankyrin repeat domain 23 1.005 0.098 
ANKRD44 Ankyrin repeat domain 44 1.02 0.193 
ANKRD46 Ankyrin repeat domain 46 1.024 0.219 
ASAP2 ArfGAP with SH3 domain, ankyrin repeat and PH domain 2 1.018 0.249 
ARAP3 ArfGAP with RhoGAP domain, ankyrin repeat and PH domain 3 1.017 0.327 
ASB17 Ankyrin repeat and SOCS box-containing 17 1.046 0.367 
ANK3 Ankyrin 3, node of Ranvier (ankyrin G) 1.024 0.371 
ASB6 Ankyrin repeat and SOCS box-containing 6 1.048 0.43 
ANKHD1 Ankyrin repeat and KH domain containing 1 1.02 0.461 
ANKRD13D Ankyrin repeat domain 13 family, member D 1.1 1.468 
ANKRD5 Ankyrin repeat domain 5 1.037 0.533 
NRARP NOTCH-regulated ankyrin repeat protein 1.046 0.555 
ABTB1 Ankyrin repeat and BTB (POZ) domain containing 1 1.039 0.564 
BANK1 B-cell scaffold protein with ankyrin repeats 1 1.026 0.591 
ACAP1 ArfGAP with coiled-coil, ankyrin repeat and PH domains 1 1.053 0.618 
ANKS1B Ankyrin repeat and sterile alpha motif domain containing 1B 1.078 1.374 
ANKRD30A Ankyrin repeat domain 30A 1.059 0.662 
ANKRD54 Ankyrin repeat domain 54 1.017 0.679 
ANKRD32 Ankyrin repeat domain 32 1.131 1.305 
ASB10 Ankyrin repeat and SOCS box-containing 10 1.127 1.296 
ANKRD1 Ankyrin repeat domain 1 (cardiac muscle) 1.049 0.71 
ANKS6 Ankyrin repeat and sterile alpha motif domain containing 6 1.065 0.723 
RFXANK Regulatory factor X-associated ankyrin-containing protein 1.045 0.747 
ANKRD13B Ankyrin repeat domain 13B 1.086 0.755 
ASAP3 ArfGAP with SH3 domain, ankyrin repeat and PH domain 3 1.06 1.201 
KANK1 KN motif and ankyrin repeat domains 1 1.049 0.81 
ASB15 Ankyrin repeat and SOCS box-containing 15 1.076 0.816 
ANKRD13A Ankyrin repeat domain 13A 1.087 1.066 
ANKS1A Ankyrin repeat and sterile alpha motif domain containing 1A 1.071 0.935 
AGAP1 ArfGAP with GTPase domain, ankyrin repeat and PH domain 1 1.09 1.049 
ASB3 Ankyrin repeat and SOCS box-containing 3 1.04 1.038 
AGAP4 ArfGAP with GTPase domain, ankyrin repeat and PH domain 4 1.087 1.019 





Table 6-2. Glycosyltransferases which upon downregulation do not alter the copper levels 
significantly. Shown are ICPMS data from the ionome database, (z-score<2) (Malinouski et al., 2014). 
UGT1A1(NM_000463) UGT1A10 (NM_019075), UGT1A3 (NM_019093) UGT1A5 (NM_019078) 
UGT1A6 (NM_001072) UGT1A7  (NM_019077) UGT1A8 (NM_019076) UGT2A1 (NM_006798) 
UGT2A3  (NM_024743) UGT2B10   (NM_001075) UGT2B11 (NM_001073)   UGT2B15 (NM_001076)    
UGT2B17 (NM_001077) UGT2B28 (NM_053039)   UGT2B4 (NM_021139)   UGT2B7 (NM_001074) 
UGT3A2(NM_174914) HAS1 (NM_001523) HAS2 (NM_005328) HAS3 (NM_005329) 
GYS1 (NM_002103) GYS2 (NM_021957) ALG2 (NM_033087) GLT1D1 (NM_144669) 
GTDC1(NM_001006636) PIGA (NM_002641) ABO (NM_020469) GBGT1 (NM_021996) 
B4GALNT4 (NM_178537) B4GALT2 (NM_003780) B4GALT3 (NM_003779) B4GALT4 
(NM_003778) 





XXYLT1 (NM_152531) GLT8D1 (NM_018446 ) 
GLT8D2 (NM_031302) GYG1(NM_004130) GYG2 (NM_003918) GYLTL1B 
(NM_152312) 
FUT4 (NM_002033) FUT5 (NM_002034) FUT6 (NM_000150) FUT7 (NM_004479) 
FUT9(NM_006581) FUT10(NM_032664)  FUT1 (NM_000148)  FUT2 (NM_000511)  
B4GALNT1(NM_001478) B4GALNT2 (NM_153446)  MGAT1 (NM_002406)  POMGNT1 
(NM_017739)  
RTFDC1 (NM_016407 ) GCNT1(NM_001490) GCNT2 (NM_001491) GCNT3 (NM_004751) 
GCNT4 (NM_016591)  GCNT7 (XM_001723344) XYLT1(NM_022166) XYLT2 (NM_022167) 
UGCG (NM_003358) ALG9 (NM_024740) PIGB (NM_004855) PIGZ (NM_025163) 
FUT8 (NM_178154) UGCGL1 (NM_020120) UGCGL2 (NM_020121) GLT25D1 (NM_024656) 
GALNT2 (NM_004481) GALNT3(NM_004482) GALNT5 (NM_014568) GALNT6 (NM_007210) 
GALNT8 (NM_017417) GALNT10 (NM_198321) GALNT11 (NM_022087) GALNT12 
(NM_024642) 
GALNT13 (NM_052917) GALNT14 (NM_024572) GALNTL2 (NM_054110) GALNTL3 
(NM_022479) 
ST3GAL1 (NM_003033) ST3GAL2 (NM_006927) ST3GAL3 (NM_006279) ST3GAL5 (NM_003896) 













ST8SIA2 (NM_006011) ST8SIA3 (NM_015879) ST8SIA4 (NM_005668) ST8SIA5 (NM_013305) 
B3GALNT2 (NM_152490) B3GALT1 (NM_020981) B3GALT2 (NM_003783) B3GALT3 
(NM_003781) 
B3GALT4 (NM_003782) B3GALT6 (NM_080605) B3GNT2 (NM_006577) B3GNT4 (NM_030765) 
B3GNT5 (NM_032047), B3GNT7 (NM_145236) B3GNT8 (NM_198540) B3GNT9 (NM_033309) 
C1GALT1 (NM_020156) C1GALT1C1 
(NM_152692) 
LFNG (NM_001040167) RFNG (NM_002917) 
A4GNT (NM_016161) A4GALT (NM_017436) PYGB (NM_002862) PYGL (NM_002863) 
PYGM (NM_005609) POMT1 (NM_007171) POMT2 (NM_013382) B3GAT1 (NM_018644) 
B3GAT2 (NM_080742) MGAT4A (NM_012214) MGAT4B (NM_014275) MGAT5 (NM_002410) 
ALG6 (NM_013339) ALG8 (NM_024079) ALG3 (NM_005787) ALG10 (NM_032834) 
AER61  (NM_173654) EXT1 (NM_000127) EXT2 (NM_000401) EXTL1 (NM_004455) 
EXTL2 (NM_001439) EXTL3 (NM_001440) POFUT1 (NM_015352) STT3A (NM_152713) 







Table 6-3. Glycosyltransferases which upon downregulation do alter the copper levels. Shown are 
ICPMS data from the ionome database, in bold are the genes which upon downregulation result in 
statistically significant increase of copper levels (z-score>4 or z-score<-4) (Malinouski et al., 2014). 











N-acetylgalactosaminyltransferase 4 1.42 4.867 
GALNT1  
( NM_020474) 
N-acetylgalactosaminyltransferase 1 1.281 4.4 
ALG12  
( NM_024105) 
Alpha-1,6-mannosyltransferase 1.352 4.254 
GALNTL4  
( NM_198516) 
N-acetylgalactosaminyltransferase 18 1.215 3.824 
ST3GAL4 
(NM_006278) 
ST3 beta-galactoside alpha-2,3-sialyltransferase 4 1.303 3.365 
GLT6D1  
( NM_182974) 
Glycosyltransferase 6 domain containing 1 1.186 3.309 
AGO61  
( NM_032806) 





UDP glucuronosyltransferase 1 family, polypeptide A9 1.17 3.083 
PIGV  
( NM_017837) 
Phosphatidylinositol glycan anchor biosynthesis, class V 1.149 3.04 
B3GNT6  
( NM_138706) 





Beta-1,3-glucuronyltransferase 3 (glucuronosyltransferase I) 1.239 2.832 
CERCAM  
( NM_016174) 
Cerebral endothelial cell adhesion molecule 1.356 2.823 
ALG1  
( NM_019109) 
chitobiosyldiphosphodolichol beta-mannosyltransferase 1.166 2.745 
GALNTL5 
(NM_145292) 
N-acetylgalactosaminyltransferase-like 5 1.223 2.636 
GALNT9 
 ( NM_021808) 
N-acetylgalactosaminyltransferase 9 1.101 2.595 
UGT1A4  
( NM_007120) 
UDP glucuronosyltransferase 1 family, polypeptide A4 1.136 2.471 
ALG14  
( NM_144988) 
UDP-N-acetylglucosaminyltransferase subunit 1.189 2.333 
ALG5  
( NM_013338) 
Dolichyl-phosphate beta-glucosyltransferase  1.136 2.267 





OGT                           
( NM_003605) 





UDP glycosyltransferase 8  1.12 2.168 
DPM1  
( NM_003859) 
Dolichyl-phosphate mannosyltransferase polypeptide 1, catalytic subunit 1.135 2.134 
B4GALT5  
( NM_004776) 
UDP-Gal:betaGlcNAc beta 1,4- galactosyltransferase, polypeptide 5 1.204 2.073 
LARGE  
( NM_004737) 
Like-glycosyltransferase 1.12 2.071 
FUT3  
( NM_000149) 
Fucosyltransferase 3 (galactoside 3(4)-L-fucosyltransferase 1.246 2.053 
    
UGT3A1  
( NM_152404) 
UDP glycosyltransferase 3 family, polypeptide A1 0.433 -4.772 





















 ( NM_015101) 
collagen beta(1-O)galactosyltransferase 2 0.753 -3.961 
B3GALTL 
 ( NM_194318) 
beta 1,3-galactosyltransferase-like (B3GALTL) 0.665 -3.502 
B3GNT3  
( NM_014256) 
UDP-GlcNAc:betaGal beta-1,3-N-acetylglucosaminyltransferase 3 0.809 -3.409 
B3GALT5 
 ( NM_006057) 








UDP-Gal:betaGlcNAc beta 1,4- galactosyltransferase, polypeptide 7 0.857 -2.567 
FUT11  
( NM_173540) 
Fucosyltransferase 11 (alpha (1,3) fucosyltransferase) 0.797 -2.455 
ST6GAL1 
(NM_003032) 
ST6 beta-galactosamide alpha-2,6-sialyltranferase 1 0.86 -2.304 
GALNT7  
( NM_017423) 








UDP-Gal:betaGlcNAc beta 1,4- galactosyltransferase, polypeptide 1 0.879 -2.163 
ALG11 
(NM_001004127) 
Alpha-1,2-mannosyltransferase 0.87 -2.155 
ST6GAL2 
(NM_032528) 
ST6 beta-galactosamide alpha-2,6-sialyltranferase 2 0.807 -2.068 
MFNG  
( NM_002405) 





Reference List  
Leettola, C.N., Knight, M.J., Cascio, D., Hoffman, S., and Bowie, J.U. (2014). 
Characterization of the SAM domain of the PKD-related protein ANKS6 and its 
interaction with ANKS3. BMC Struct. Biol. 14, 17-6807-14-17.  
Malinouski, M., Hasan, N.M., Zhang, Y., Seravalli, J., Lin, J., Avanesov, A., Lutsenko, 
S., and Gladyshev, V.N. (2014). Genome-wide RNAi ionomics screen reveals new genes 
and regulation of human trace element metabolism. Nat. Commun. 5, 3301.  
Wu, Y., Zhao, Y., Ma, X., Zhu, Y., Patel, J., and Nie, Z. (2013). The Arf GAP AGAP2 
interacts with beta-arrestin2 and regulates beta2-adrenergic receptor recycling and ERK 


























































ATP7B is a P-type ATPase that uses ATP hydrolysis to transport copper across 
membranes; mutations result in copper accumulation in the body (Wilson’s disease) 
(Gupta et al., 2011). ATP7B has a dual localization in hepatocytes. Under basal 
conditions ATP7B transports copper into the TGN (trans Golgi network) and under 
elevated copper conditions ATP7B traffics from the TGN to endocytic vesicles, which 
accumulate copper and then fuse with the apical plasma membrane to excrete copper out 
of the cell (Roelofsen et al., 2000). Thus, ATP7B trafficking is essential for the regulation 
of intracellular copper levels. The mechanism that controls the copper-dependent exit of 
ATP7B from the TGN is not yet fully characterized. Copper-binding, kinase mediated 
phosphorylation levels, changes in inter-domain interactions, and interactions with 
accessory proteins play a role in facilitating the exit of ATP7B from the TGN; however 
the exact mechanism and sequence of events is not yet fully understood (Guo et al., 2005; 
Lim et al., 2006a; Lim et al., 2006b; Materia et al., 2012; Tao et al., 2003; Tsivkovskii et 
al., 2001; Vanderwerf et al., 2001).  
 
Protein dimerization/oligomerization may enhance recruitment of trafficking machinery 
and be part of the mechanism that governs the TGN exit of ATP7B. A bacterial 
homologue of ATP7B (CopA) forms dimers as demonstrated by cryoelectron microscopy 
and reconstitution (Wu et al., 2008); existence of P-type ATPases (such as Na,K-ATPase 
and H+-ATPase) as oligomeric structures has been actively discussed in the literature. 
Whether mammalian ATP7B can form dimers, and whether these dimers are 
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physiologically relevant was unknown.  This section describes experiments testing 
oligomerization state of ATP7B in mammalian cells.  
 
Results 
ATP7B exists in multimeric complexes in cells 
We hypothesized that dimerization/oligomerization might be a novel mechanism 
regulating ATP7B trafficking. We analyzed the possibility of endogenous ATP7B 
forming higher molecular weight complexes in cells under native conditions.  First we 
determined the apparent molecular mass of ATP7B following solubilization with mild 
detergent that retains tetrameric protein organization. The membranes obtained from 
HepG2 cells were resuspended using n-Dodecyl β-D-maltoside (DDM) and run on blue 
native gels (BN-PAGE). BN-PAGE is an electrophoretic technique that allows separation 
of multiprotein complexes in a native conformation (Schagger and von Jagow, 1991). 
Our results suggested that the endogenous ATP7B exists in at least two forms: a 
monomeric form (around 230kDa) and in a higher molecular weight complex (around 
480kDa), which could be a dimeric form of ATP7B (Fig. 7-1). We used three different 
antibodies of ATP7A to determine the size of ATP7B under native conditions. The 
dimeric structure was recognized primarily by the NBD-antibody, directed against the 
central portion of the molecule (Fig. 7-1b) and anti-C-terminus antibody (Fig. 7-1c). 
Staining of the high-molecular weight band with the anti-N-terminal antibody was weak 
implying that the N-terminus of ATP7B might be at the interface of the dimeric 
structures. We have shown for the first time that ATP7B can exist as multimeric 
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complexes in cells and we are interested in determining the role of the dimeric ATP7B 
complexes in cells. 
 
Transfected wt-ATP7B and mutated-ATP7B can bind to each other and influence their 
localization 
We tested whether the recombinant ATP7B variants that usually localize to different 
parts of the cell can colocalize in the same compartment as a result of interaction during 
co-transfection/co-expression. For these experiments, Hek293T cells were cotransfected 
with WT GFP-ATP7B (normally localized in TGN) (Fig. 7-2a) and Flag-
ATP7B
R875,S340/341G 
(normally localized in vesicles) (Fig. 7-2b) and the localization of 
both proteins was assessed. We observed that in the majority of cotransfected cells, both 
proteins colocalize, strongly suggesting their interaction. The localization pattern showed 
staining of both TGN or to vesicles, implying that two ATP7B variants not only interact 
but alter each other’s localization in cells (Fig. 7-2c). In 30-40% of the cells, no 
significant colocalization was observed, suggesting that the level of expression and ratio 
of the proteins might be important for the multimer formation. To further verify potential 
interaction we performed immunoprecipitation experiments. GFP-ATP7B was co-
immunoprecipitated with Flag-ATP7B in cotransfected cells, suggesting that ATP7B 
proteins do interact with each other.  
 
Discussion 
We have shown for the first time that ATP7B can exist in dimeric forms in cells using 
blue native-PAGE and cotransfection studies. Future studies will be focused on 
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determining whether the dimer formation depends on the copper-dependent trafficking of 
ATP7B to vesicles in cells and to identify the regions involved in dimer formation. 
 
The mechanism of ATP7B trafficking to vesicles in response to copper has not been 
identified yet. We would like to determine if the dimer formation of ATP7B is 
physiologically relevant and how it affects dimer formation of ATP7B affects copper 
homeostasis. The dimer formation of ATP7B can be a novel mechanism, which might be 
involved in regulating the trafficking and/or copper transport function of ATP7B.  
 
 
Materials and Methods 
Cell lines: HepG2 cells (obtained from ATCC) were maintained in DMEM supplemented 
with 10 % FBS and 1 % pen/strep at 37 ºC in a 5% CO2 incubator. Hek293TRex cells 
were maintained in MEM supplemented with 10 % FBS, 1 % pen/strep, 1 % non-
essential amino acids, 12.5 μg/mL blasticidin and 100 μg/mL zeocin. During experiments 
media without blasticidin and zeocin was used. 
 
Analysis of cell lysates using BN-PAGE: Cells were harvested, homogenized in a 
homogenizing buffer (25 mM imidazole, 0.25 M sucrose, 1 mM AEBSF and protease 
inhibitor tablets (Roche)) using a Dounce homogenizer with 40 strokes of a tight-fitting 
pestle. The lysate was centrifuged at 700 g for 10 min at 4°C to pellet cell debri and 
nuclei. The postnuclear supernatant was centrifuged at 3,000 g for 10 min at 4°C to pellet 
mitochondria. The resulting supernatant was then centrifuged at 20,000 g for 30 min at 
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4°C to pellet down the microsomal membranes. Protein concentration of the microsomal 
membranes was determined using a Bradford assay (Pierce). 15 µg of the pellet was 
resuspended in solubilizing buffer (1%DDM, 50mM Bis-Tris, 50mM NaCl, 10% w/v 
glycerol, 0.001% Ponceau S, pH 7.2) in a total volume of 15 µl and incubated for 1 h on 
ice. 1X of 10X loading dye (5% coomassie G250, 500mM aminocaproic acid) was added 
to the mixture, and it was loaded to 4-16% native gradient gel (Invitrogen).  Proteins 
were transferred to a PVDF membrane using CAPS buffer, pH 11.0. The membrane was 
probed using rat anti N-terminus antibody (1:3000), rabbit- anti-NBD (nucleotide binding 
domain) antibody (1:3000) or an guinea pig anti C-terminus antibody (1:3000) of 
ATP7B. Goat anti rat Igg-HRP (1:10000, Santa Cruz), donkey anti rabbit Igg-HRP 
(1:10000, Santa Cruz),  or donkey anti guinea pig Igg-HRP (1:10000, Santa Cruz) was 
used as a secondary antibody and the membranes were developed using a SuperSignal 
West Pico Substrate (Thermo Scientific). 
Immunofluorescence microscopy: Hek293TRex cells on coverslips were transiently 
transfected with the wt GFP-ATP7B  or  mutant Flag-ATP7B
R875,S340/341G 
using 
Turbofect. Protein expression of Flag-ATP7B
R875,S340/341G 
was induced with 40 ng/ml 
DOX for 16 h in basal conditions.  Cells were rinsed with PBS and fixed with in cold 
acetone-methanol mixture (1:1) for 30 sec. The cells were blocked in blocking buffer 
(1 % gelatin, 1 % BSA in PBS) and then incubated with appropriate primary and 
secondary antibodies diluted in blocking buffer. (Primary antibody: mouse anti-Flag 
antibody 1:250 (Sigma) and rabbit anti-TGN 46 1:300 (Genetex). Secondary antibody: 
Alexa Fluor 488 Goat anti mouse antibody 1:500 (Invitrogen) and Alexa Fluor 555 goat 
anti sheep 1:500 (Invitrogen)). Coverslips were mounted onto glass slides using 
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Vectashield w/DAPI (Vector Laboratories).  Images were taken using a Zeiss PALM 
confocal microscope and a 100x oil immersion objective. 
Co-immunuprecipitation of GFP-ATP7B: Hek293Trex cells were transiently transfected 
with the wt GFP-ATP7B  or  mutant Flag-ATP7B
R875,S340/341G 
using Turbofect. Protein 
expression of Flag-ATP7B
R875,S340/341G 
was induced with 40 ng/ml DOX for 16 h in basal 
conditions.  Cells were rinsed with PBS and microsomal membranes were isolated as 
described above. The pellet was resuspended in 100 μl of IP buffer (150 mM NaCl, 
10 mM Tris-HCl, 2 mM EDTA (pH 7.5), 1 % n-Dodecyl β-D-maltoside (DDM) (Sigma), 
protease inhibitor tablets (Roche)). 200 μl of blocking buffer (3 % BSA in PBST) was 
added. After 5 min, 2.5 μl of anti-Flag antibody (Sigma) was added and rotated for 1 h at 
room temperature. 55 μl of pre-equilibrated protein G resin (Thermo Scientific) was 
added and rotated for 1 h at RT. The resin was washed with 20 column volumes of PBS 
and the bound protein was eluted using 60 μl of elution buffer (0.17 M Tris, pH 6.8, 
6.8 % SDS, 2.7 M urea, 1:100 β-mercaptoethanol). 24 μl of the eluted protein was loaded 
to a 4-20% TGX gel (Bio-Rad). The proteins were transferred to PVDF membrane using 
a 10 mM CAPS, pH 11 transfer buffer.  Immunoblotting was done using rabbit anti-GFP 
antibody (1:2000 Invitogen) as primary antibody, and HRP-conjugated goat anti-rabbit 
IgG (1:10,000) (Santa Cruz) as a secondary antibody. The membranes were developed 







Figure 7-1. ATP7B exists in high molecular weight complexes. Membrane preparations from HepG2 
cells were solubilized with 1% DDM and run on a blue native gel. The Western blot was immunoblotted 
using an anti N-terminus antibody (a), anti-NBD (nucleotide binding domain) antibody (b) or an anti C-
















Figure 7-2. ATP7B can form dimers in cells. Hek293Trex cells were transfected or cotransfected with 
WT-GFP ATP7B and Flag-ATP7B
R875,S340/341G
. Cells were fixed and immunostained using anti-Flag and 
anti-TGN46 antibody. (a) WT-GFP ATP7B localizes to TGN. (b) Flag-ATP7B
R875,S340/341G
 localizes to 
vesicles. (c)  Representative images of cells cotransfected with both WT-GFP ATP7B (green) and Flag-
ATP7B
R875,S340/341G
 (red). In most cells both ATP7B constructs colocalize either at the TGN region (upper 










Figure 7-3. A. GFP-ATP7B interacts with Flag-ATP7B. Hek293Trex cells were cotransfected with 
GFP-ATP7B and Flag-ATP7B ATP7B. Membrane preparations were co-immunoprecipitated using anti-
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